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AKT Function and Human Oncogenesis
Sungman Park
ABSTRACT
Accumulated evidence indicates that, by the phosphorylation of its physiological
substrates, Akt promotes cell survival, proliferation and angiogenesis.

While a number

of Akt targets have been identified, the mechanism by which Akt regulates cell survival
and growth and induces malignant transformation still remains elusive. During the last
5 years, I have shown that AKT1 cross-talks with Src/Stat3 pathway.
target gene of Stat3.

AKT1 is a direct

Protein/mRNA levels and promoter activity of AKT1 are

significantly induced by constitutively active Src and Stat3. Knockdown of Stat3 or
dominant-negative Stat3 reduced AKT1 expression induced by constitutively active Src.
Blockage of AKT1 expression largely reduced Stat3 function in cell survival and
angiogenesis.

Furthermore, I have shown that proapoptotic protein 24p3 is a major

target of Akt to mediate IL3 signaling in hematopoietic cells.

Forkhead transcription

factor FOXO3a directly binds to and activates 24p3 promoter leading to expression of
24p3 in response to IL3 withdrawal.
action toward 24p3.

Akt phosphorylates FOXO3a and inhibits its

Finally, I have identified a novel transcription factor TZP that

interacts with Akt and p53.

Expression of TZP inhibits cell growth and survival and

induces both G1 and G2/M cell cycle arrest.

TZP directly binds to the p53 promoter and

induces p53 transcription. In addition, TZP interacts with p53 and prevents p53 from
Mdm2-mediated degradation. In response to genotoxic stress, both TZP and p53 were
upregulated and knockdown of TZP reduced p53 expression. Akt phosphorylated TZP
resulting in its translocation from the nucleus into the cytoplasm, and thus inhibits TZP
function. These data indicate that Akt induced by STAT3 confers oncogenesis through
inhibition of the transcription factors.
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CHAPTER 1

Review of Role of PI3K/AKT Pathway in Oncogenesis
The maintenance of normal cell function and tissue homeostasis is dependent on
the precise regulation of multiple signaling pathways that regulate cellular determination
such as proliferation, differentiation, cell growth arrest, or programmed cell death
(apoptosis and autophagy).
this

balance

and

Cancer arises from clones of mutated cells that break out

proliferate

inappropriately

without

compensatory

apoptosis.

Uncontrolled cell growth occurs as a result of disturbed signal transduction that
modulates or alters cellular behavior or function to keep the critical balance between the
rate of cell-cycle progression (cell division) and cell growth (cell mass) on one hand, and
programmed cell death (apoptosis and autophagy) on the other (1, 2).
The PI3K/Akt pathway regulates a variety of cellular processes including nutrient
metabolism, cell growth, proliferation, cell cycle control, survival, differentiation,
migration, and angiogenesis (3).

Deregulation of the PI3K/Akt pathway has been

related to the development of diseases such as diabetes, autoimmunity, and cancer (4-7).
The link between activation of the PI3K/Akt pathway and cancer makes this pathway an
attractive target for therapeutic strategies. Accumulated reports show that activation of
receptor protein-tyrosine kinases (RTK) and cytokine receptor is one of the major
resources for activating PI3K/Akt pathway.

Protein Tyrosine Kinases (PTKs)
Protein tyrosine kinases (PTKs) are enzymes that catalyze the phosphorylation of
tyrosine residues.
receptor PTKs.

There are two classes of PTKs: receptor PTKs and cellular non-

Of the 91 protein tyrosine kinases identified thus far, 59 are receptor
1

tyrosine kinases and 32 are non-receptor tyrosine kinases (Fig. 1).

These enzymes are

involved in cellular signaling pathways and regulate key cell functions such as

Figure 1. Human receptor protein-tyrosine kinases. The prototypic receptor for each
family and the known members are indicated below the receptor. (A) The first six RTK
receptors classes among the 19 human RTK classes. We can observe that the extracellular
region is very different between all the RTKs, and, on the other hand, that the intracellular
region is very conserved. (B) The new domain prediction of RTK. It shows some
classification modifications and updated domain prediction from the latest domain
databases SMART and Pfam. Abbreviation of the prototypic receptors: EGFR,
epidermal growth factor receptor; InsR, Insulin receptor; PDGFR, platelet-derived growth
factor receptor; FGFR, fibroblast growth factor receptor; EphR, ephrin receptor. (Referred
to Grassort J et al. (2003) Nucleic Acids Research 31, 353–358)
proliferation, differentiation and cell survival. Deregulation of these enzymes, through
mechanisms such as point mutations or overexpression, can lead to various forms of
cancer as well as benign proliferative conditions.

Indeed, more than 70% of the known

oncogenes and proto-oncogenes involved in cancer code for PTKs.
2

Receptor PTKs possess an extracellular ligand binding domain, a transmembrane
domain and an intracellular catalytic domain.

The transmembrane domain anchors the

receptor in the plasma membrane, while the extracellular domains bind growth factors.
Characteristically, the extracellular domains are comprised of one or more identifiable
structural motifs, including a cysteine-rich region, fibronectin III-like domain,
immunoglobulin-like domains, EGF-like domain, cadherin-like domain, kringle-like
domain, factor VIII-like domain, glycine-rich region, leucine-rich region, acidic region
and discoidin-like domain (Fig. 1).

Figure 2. Activation of receptor protein tyrosine kinase. (Copyright © 2005
Pearson Education, Inc., publishing as Benjamin Cummings)
The intracellular kinase domain of receptor PTKs can be divided into two classes: those
containing a stretch of amino acids separating the kinase domain and those in which the
kinase domain is continuous. Activation of the kinase is achieved by ligand binding to
the extracellular domain, which induces dimerization of the receptor. Receptors thus
3

activated are able to autophosphorylate tyrosine residues outside the catalytic domain via
cross-phosphorylation. The results of this auto-phosphorylation are stabilization of the
active receptor conformation and the creation of phosphotyrosine docking sites for
proteins which transduce signals within the cell (Fig. 2).

Signaling proteins which bind

to the intracellular domain of receptor tyrosine kinases in a phosphotyrosine-dependent
manner include RasGAP, PI3-kinase, phospholipase Cγ, phosphotyrosine phosphatase
SHP and adaptor proteins such as Shc, Grb2 and Crk (8, 9).
In contrast to receptor PTKs, cellular non-receptor PTKs are located in the
cytoplasm, nucleus or anchored to the inner leaflet of the plasma membrane.

They are

grouped into eight families: SRC, JAK, ABL, FAK, FPS, CSK, SYK and BTK (reviewed
in 10).

Each family consists of several members.

With the exception of homologous

kinase domains (Src Homology 1, or SH1 domains), and some protein- protein
interaction domains (SH2 and SH3 domains), they have little in common structurally.
Of those cellular PTKs whose functions are known, many, such as SRC, are involved in
cell growth.

In contrast, FPS PTKs are involved in differentiation (11), ABL PTKs are

involved in growth inhibition (12), and FAK is associated with cell adhesion (13).
Some members of the cytokine receptor pathway interact with JAKs, which
phosphorylate the transcription factors, STATs (14, 15).

Still other PTKs activate

pathways whose components and functions remain to be determined.
There are four main mechanisms of oncogenic transformation by PTKs.

First, retroviral

transduction of a proto-oncogene corresponding to a PTK is a common transforming
mechanism in rodents and chickens.

Second, genomic rearrangements, such as

chromosomal translocations resulting in formation of oncogenic fusion proteins
containing a PTK catalytic domain and an unrelated protein that provides a dimerization
function.

Third, gain-of-function mutations or small deletions are associated with

several malignancies.

Finally, PTK overexpression is a major mechanism in PTK-

induced transformation. In general, the transforming effect can be ascribed to enhanced
constitutive kinase activity with quantitatively or qualitatively altered downstream
signaling (16).
4

Cytokine Receptors
Cytokines act on their target cells by binding specific membrane receptors.

The

receptors and their corresponding cytokines have been divided into several families based
on their structure and activities. Hematopoietin family receptors are dimers or trimers
with conserved cysteines in their extracellular domains and a conserved Trp-Ser-X-TrpSer sequence (17).

Examples are receptors for IL-2 through IL-7 and GM-CSF.

Interferon family receptors have the conserved cysteine residues, but not the Trp-Ser-XTrp-Ser sequence, and include the receptors for IFNα, IFNβ, and IFNγ.

Tumor necrosis

factor family receptors have four extracellular domains; they include receptors for soluble
TNFα and TNFβ as well as membrane-bound CD40 (important for B cell and
macrophage activation) and Fas (which signals the cell to undergo apoptosis).

Figure 3. Human cytokine receptor superfamily. (Copyright © 2005
Pearson Education, Inc., publishing as Benjamin Cummings)
5

Chemokine family receptors have seven transmembrane helices and interact with G
protein.

This family includes receptors for IL-8, MIP-1 and RANTES (reviewed in 18)

(Fig. 3).

Figure 4. Interaction of cytokine and cytokine receptors. (Referred to Oppenheim JJ et
al. Cytokine Reference. Academic Press (2001))
Hematopoietin cytokine receptors are the best characterized.
have two subunits, one cytokine-specific and one signal transducing.

They generally

An example is the

GM-CSF subfamily, where a unique “α” subunit specifically binds GM-CSF, IL3, or IL-5
with low affinity and a shared “β” subunit signal transducer also increases cytokine6

binding affinity.

Cytokine binding promotes dimerization of the α and β subunits,

which then associate with cytoplasmic tyrosine kinases to phosphorylate proteins which
activate mRNA transcription. GM-CSF and IL3 act on hematopoietic stem cells and
progenitor cells and activate monocytes.

With IL-5, they also stimulate eosinophil

proliferation and basophil degranulation.

All three receptors phosphorylate the same

cytoplasmic protein.

Antagonistic GM-CSF and IL3 activities can be explained by their

competition for limited amounts of β subunit (reviewed in 19).

The IL-2R subfamily of

receptors for IL-2, IL-4, IL-7, IL-9, and IL-15 have a common signal-transducing γ chain.
Each has a unique cytokine-specific chain. IL-2 and IL-15 are trimers, and share
an IL-2R β chain.

Monomeric IL-2R α has low affinity for IL-2, dimeric IL-2R βγ has

intermediate affinity, and trimeric IL-2R αβγ binds IL-2 with high affinity.
chain (Tac) is expressed by activated but not resting T cells.
cells constitutively express low number of IL-2R βγ.

IL-2R α

Resting T cells and NK

Antigen activation stimulates T

cell expression of high affinity IL-2R trimers as well as secretion of IL-2, allowing
autocrine stimulation of T cell proliferation in an antigen-specific manner. Antigen
specificity of the immune response is also maintained by the close proximity of antigenpresenting B cells and macrophages with their helper T cells, so that cytokines are
secreted in the direction of and close to the membrane of the target cell. X-linked severe
combined immunodeficiency (X-scid) is caused by a defect in IL-2R family chain, which
results in loss of activity from this family of cytokines (reviewed in 20).
The TNF receptor family molecules CD40 and Fas bind to cell surface ligands on
effector T cells: CD40L and FasL.

CD40 is expressed on B cell and macrophage plasma

membrane. T cell CD40L binding to B cell CD40 stimulates B cell proliferation and
isotype switching.

T cell CD40L binding to macrophage CD40 stimulates macrophages

to secrete TNFα and become much more sensitive to IFNγ. T cell FasL binding to Fas
leads to the activation of caspases that initiate apoptosis of the cell expressing membrane
Fas.

Activated lymphocytes express Fas, so that FasL-positive Tc cells can regulate the

immune response by eliminating activated cells. An immune deficiency disease linked
to expression of a mutant Fas is characterized by over-proliferation of lymphocytes (21).
7

PI-3 Kinases

PI-3 Kinase family
Based on substrate preference and sequence homology, PI3Ks are divided into
three

classes

(Fig.

5).

In

vivo,

class

I

PI3Ks

primarily

generate

phosphatidylinositol(PtdIns)-3,4,5-trisphosphate from PtdIns(4,5)P2, whereas class III
PI3Ks generate PtdIns(3)P from PtdIns.

Class II PI3Ks preferentially generate

PtdIns(3)P and PtdIns(3,4)P2 in vitro, and might generate PtdIns(3)P, PtdIns(3,4)P2 and
possibly PtdInsP3 in vivo (22).
The domain structures of various PI3K isoforms are illustrated in figure 5.
mammals, numerous genes encode different isoforms of PI3Ks (23).

In

All PI3K isoforms

are widely expressed, with the exception of the class IA p55γ subunit, which is enriched
in the brain and the testes, and the p110δ subunit, which is predominantly expressed in
lymphocytes.
Class IA PI3K is a heterodimer that consists of a p85 regulatory subunit and a
p110 catalytic subunit. Three genes, PIK3R1, PIK3R2 and PIK3R3, encode the p85α,
p85β and p55γ isoforms of the p85 regulatory subunit, respectively.

The PIK3R1 gene

also gives rise to two shorter isoforms, p55α and p50α, through alternative transcriptioninitiation sites.

The class IA p85 regulatory isoforms have a common core structure

consisting of a p110-binding domain flanked by two Src-homology 2 (SH2) domains.
The two longer isoforms, p85α and p85β, also have an extended N-terminal region
containing a Src-homology 3 (SH3) domain and a BCR homology (BH) domain flanked
by two proline-rich (P) regions (23).
The p85 regulatory subunit is crucial in mediating the activation of class IA PI3K
by receptor tyrosine kinases (RTKs).

The SH2 domains of p85 bind to phospho-tyrosine

residues in the sequence context pYxxM on activated RTKs or adaptor molecules (such
as IRS1) (24).

This binding relieves the basal inhibition of p110 by p85 and recruits the

p85–p110 heterodimer to its substrate (PtdIns(4,5)P2) at the plasma membrane (25, 26).
8

Figure 5. Mammalian PI 3-kinase family and their domain structures. (Referred to
Engelman JA et al. (2006) Nature Review Genetics. 7, 606-619)
Three genes — PIK3CA, PIK3CB and PIK3CD — encode the highly
homologous p110 catalytic subunit isoforms p110α, p110β and p110δ, respectively (23).
They possess an N-terminal p85-binding domain that interacts with the p85 regulatory
subunit, a Ras-binding domain (RBD) that mediates activation by the small GTPase Ras,
a C2 domain, a phosphatidylinositol kinase homology (PIK) domain and a C-terminal
catalytic domain.

The PIK and catalytic domains of p110 are homologous to domains

found in a family of protein kinases that includes mTOR (mammalian target of
rapamycin), ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia Rad3
related) and DNA-PK (DNA-dependent serine/threonine protein kinase), indicating that
these proteins share an ancient evolutionary origin.
9

Class IB PI3K is a heterodimer consisting of a p101 regulatory subunit and a
p110γ catalytic subunit. Although p110γ shares extensive homology with the class IA
p110 proteins, p101 is distinct from p85 proteins.

Two other regulatory subunits, p84

and p87PIKAP, have been described recently (27, 28).
Members of class II PI3Ks consist of only a p110-like catalytic subunit.

The

three isoforms of class II PI3Ks — PIK3C2α, PIK3C2β and PIK3C2γ — are encoded
by distinct genes.

All three isoforms share significant sequence homology with the class

I p110 subunits. In addition, class II PI3Ks have an extended divergent N terminus, and
additional PX and C2 domains at the C terminus.

A remarkable feature of this class

PI3Ks is that they can utilize Ca++/ATP for their in vivo lipid kinase activity through the
binding between C2 domain and Ca++ (29).
Class III PI3Ks have a substrate specificity restricted to PtdIns and generate PtdIns(3)P.
These PI3Ks are homologous to Vps34 (vacuolar protein-sorting defective 34), the only
PI3K in yeast, which plays a very important role in protein trafficking from Golgi to the
vacuole and autophagy (30).

Signaling by PI3Ks
The effects of polyphosphoinositides in cells are mediated through the specific
binding to at least two lipid-binding protein domains, the FYVE and pleckstrin-homology
(PH) domains. (Fig. 6).
Class IA PI3Ks are activated by growth factor receptor tyrosine kinases (RTKs;
left).

Both insulin and insulin growth factor 1 (IGF1) receptors use the insulin receptor

substrate (IRS) family of adaptor molecules (shown to the right of the RTK) to engage
class IA PI3Ks, whereas other receptors, such as the platelet-derived growth factor
(PDGF) receptor, recruit class IA PI3Ks directly (shown to the left of the RTK).
By contrast, class IB PI3Ks are activated by G-protein-coupled receptors
(GPCRs) by binding to Gβγ (right).
dephosphorylates

PTEN (phosphatase and tensin homologue)

phosphatidylinositol-3,4,5-trisphosphate

terminates PI3K signaling.

(PIP3)

and

therefore

The 5′-phosphatase SHIP converts PIP3 to phosphatidyl10

inositol-3,4-bisphosphate (PI-3,4-P2).

Figure 6. Mechanism of class I phosphatidylinositol 3-kinase (PI3K) activation. Class IA PI3Ks
are activated by growth factor receptor tyrosine kinases (RTKs; left). Both insulin and insulin
growth factor 1 (IGF1) receptors use the insulin receptor substrate (IRS) family of adaptor
molecules (shown on the right of the RTK) to engage class IA PI3Ks, whereas other receptors,
such as the platelet-derived growth factor (PDGF) receptor, recruit class IA PI3Ks directly (shown
to the left of the RTK). By contrast, class IB PI3Ks are activated by G-protein-coupled receptors
(GPCRs) by binding to Gβγ (right). PTEN (phosphatase and tensin homologue) dephosphorylates
phosphatidylinositol-3,4,5-trisphosphate (PIP3) and therefore terminates PI3K signalling. The 5′phosphatase SHIP converts PIP3 to phosphatidylinositol-3,4-bisphosphate (PI-3,4-P2) (REF. 1).
Gα, guanine nucleotide binding protein (G protein), α; Gβγ, guanine nucleotide binding protein (G
protein), βγ; p110 and p110γ, catalytic subunits of PI3K; p85 and p101, regulatory subunits of
PI3K; SHIP, SH2-domain-containing inositol-5-phosphatase. (Referred to Engelman JA et al.
(2006) Nature Review Genetics. 7, 606-619)

The FYVE domain, named after the first four proteins (Fab1, YOTB, Vac1, and
EEA1) that contain this motif, is an ~80-amino acid sequence containing four conserved
cysteine residues that coordinate two Zn++ ions (31). The structure data clearly show
that FYVE domains only bind to PtdIns(3)P, but not the other lipids (32).
domains appear to be less widespread than PH domain.

FYVE

To date, 22 different FYVE

domain-containing proteins have been found in mammals, and the majority of FYVE
domain-containing proteins have been implicated in membrane trafficking.
PH (Pleckstrin homology) domains are globular protein domains of about 100
amino acids found in over 150 proteins to date. Some PH domains bind phospholipids
with high affinity.

Residues in PH domains essential for high-affinity binding to PIs

have recently been identified (33, 34).
13R/KXRHyd

(30).

These residues lie at the N-terminus, in a KX7-

motif, where X is any amino acid and Hyd is a hydrophobic amino acid

A subset of PH domains preferentially bind to PtdIns(3,4)P2, and PtdIns(3,4,5)P3
11

(30, 35).
Signaling by class I PI3Ks, especially IA PI3Ks, has been extensively studied.
PtdIns(3,4)P2/PtdIns(3,4,5)P3-binding PH domains are found in diverse array of proteins
including protein kinases (e.g. PKB, PDK1, Btk), nucleotide-exchange factors (e. g. Vav,
GRP1, ARNO, Sos1, Tiam1), GTP-activating factors (e. g. GAP1m, centaurins),
phospholipases (e. g. PLCγ2) and adaptor proteins (35, 36).
Signaling by class II PI3Ks has not been widely studied due to their specific
structures, however, the association of class II PI3Ks with cellular membrane
compartments indicates that they might be involved in sorting events or vesicle formation.
Signaling by class III PI3Ks has been mainly placed on membrane trafficking events
because they share high homology with Vps34, which is clearly found to be involved in
yeast membrane trafficking.

For example, PtdIns(3)P-mediated recruitment of the

SARA (Smad anchor for receptor activation) protein to TGF-β receptor is crucial for this
pathway (37, 38).

EE1A is an effector of Rab5 which itself also binds to human Vps34

and p85α/p110β and EE1A has been found to be essential for the trafficking of protein
from Golgi complex to the lysosome (39).

Regulation of PI3Ks
PtdIns(3,4,5)P3, a product of PI3-kinase, plays a regulatory role in a vast array of
biological responses to extracellular signals, including proliferation, differentiation,
apoptosis, vesicle trafficking, cell morphology and cell migration.

The level of this

phospholipid is low in resting cells but increases rapidly in response to growth
factor/cytokine-stimulated plasma membrane recruitment and activation of PI3-kinase,
therefore, the negative regulation becomes important.

So far, three enzymes, SHIP,

SHIP2 and PTEN, have been shown to play key roles in regulating the level of PI-3,4,5P3.
PTEN was first identified in 1997 by three independent groups, so it is also
known as MMAC or TEP1, and PTEN is found to be the major 3-phosphatase of
phosphoinositol-(3,4,5)-triphosphate, and signals down to regulate PI3K/Akt pathway.
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Consistent with the role of PTEN in PI3K/Akt signaling, PTEN negatively regulates cell
survival by causing apoptosis and/or G1 cell cycle arrest. Dysfunctional/absent PTEN
leads to high levels of Akt phosphorylation, and germline mutations of PTEN tumorsuppressor gene have been found to result in a wide spectrum of phenotypes including
Cowden syndrome (40, 41).

PTEN has also been shown to bind FAK (Focal Adhesion

Kinase) and inhibit FAK kinase activity via dephosphorylation (42).
An SH2-containing inositol 5’ phosphatase protein, SHIP, has received
considerable attention because it functions as a negative regulator for PI3K pathway.
Based on current knowledge of PTEN and SHIP, SHIP mainly converts PI-3,4,5-P3 to PI3,4-P2. However, PTEN can convert PI-3,4,5-P3 to PI-4,5-P2.

PTEN-/- cells exhibits

high basal level of Akt activation while only slightly elevated level of Akt
phosphorylation has been observed in SHIP-/- cells (40).

So the exact difference

between PTEN and SHIP is still under investigation even though they share similar
biological function.

Akt/PKB

Origins and Cloning of Akt
Akt, also named protein kinase B (PKB) and RAC, is a serine/threonine protein
kinase with homology to protein kinases A and C (43–46).

The AKT oncogene was

isolated from the directly transforming murine retrovirus AKT8, which was isolated from
an AKR mouse thymoma cell line (43) and spontaneous lymphoma (43).

This virus,

termed AKT8, produced foci of malignant transformation in the mink lung epithelial cell
line CCL-64 (44). A unique feature of AKT8 was its inability to induce focus formation
in other cell lines such as NIH3T3 fibroblasts, which suggested that the virus contained a
previously unidentified oncogene. Sequencing the defective retrovirus from mink lung
epithelial cells infected with AKT8 revealed that it encodes a serine/threonine protein
kinase, namely Akt1 (45). Subsequently, Akt2 was cloned and shown to encode a
closely related kinase that is frequently amplified in human ovarian cancer (46).
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They

contain consensus sequences characteristic of a protein kinase catalytic domain and share
more than 68% similarity to protein kinase C and cAMP-dependent protein kinase.
Moreover, Akt1 and Akt2 have a unique N-terminal region originally designed as Akt
homology (AH) domain (45, 46). Thus, Akt family of serine/threonine kinases was
identified.

Akt gene family
Hitherto, three members of Akt encoded by three separate genes have been identified in
mammalian cells.

All three genes have more than 85% sequence identity and their

protein products share the same structural organization (Fig. 7).

The first amino-

terminal 100 amino acids are a pleckstrin homology (PH) domain that binds to
phospholipids.

A short glycine-rich region locates between PH and catalytic domains,

and links the PH motif to the catalytic domain.
identical or similar substrate specificity.

All Akt members are assumed to have

The last 70 amino acids of the carboxyl

terminal tail contain a putative regulatory domain. In v-Akt, a truncated viral groupspecific antigen, gag, is fused in frame to the full-length Akt1 coding region through a
short 5’ untranslated region of Akt1 (47).
All three Akt members are ubiquitously expressed in mammals, although the
levels of expression vary among the tissues (47).
tissues.

Akt1 is evenly expressed in most

The uppermost expression of Akt2 was observed in the insulin-responsive

tissues such as skeletal muscle, heart, liver, and kidney, suggesting that this isoform is of
important to insulin signaling.

This is further substantiated by the observation that Akt2

expression in developing embryos is also highest in the insulin-responsive tissues,
including liver, brown fat, and skeletal muscle.

A peculiar pattern of Akt1 expression

was detected in brain, where it is markedly increased in regenerating neurons. Unlike
the two other members, Akt3 shows a more limited pattern of expression.

Higher levels

of Akt3 were detected in testis and brain and low levels in the adult pancreas, heart, and
kidney (48, 49, 50). The expression pattern of the three members may not always
reflect their activities.
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Different kinase activity levels of the different members have been observed in
certain tissues and during differentiation, which is not necessarily correlated with their
level of expression (51, 52).

Biochemical features of Akt
Activation of Akt depends on the integrity of the PH domain, which binds to PI3K
product PtdIns-3,4,5-P3, and on the phosphorylation of Thr308 (Thr309 in Akt2 and
Thr305 in Akt3) in the activation loop and Ser473 (Ser474 in Akt2 and Ser472 in Akt3) in
the C-terminal activation domain.

Yang et al provided a molecular explanation for

regulation of Akt activation through Ser474 phosphorylation by analyzing the crystal

Figure 7. Structural organization of the three major Akt/PKB isoforms is shown in comparison
to virally encoded v-Akt Akt/PKB variants contain a plecsktrin homology domain (PH), a
catalytic domain, and a putative regulatory fragment at the C-terminus (RD). v-Akt is an inframe fusion of Akt-1 with a portion of retroviral group-specific antigen (gag). Amino acid
positions are shown for mouse proteins. Threonine and serine residues whose phosphorylation
is required to induce activities of the enzymes are indicated. See text for details (Referred to
Kim D et al. (2005) Front Biosci. 10, 975-987.)
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structures of the unphosphorylated and Thr309-phosphorylated states of the Akt2 kinase
domain (53).

Activation by Ser474 phosphorylation occurs via a disorder-to-order

transition of the alpha-C helix with concomitant restructuring of the activation segment
and reconfiguration of the kinase bilobal structure. These conformational changes are
mediated by a phosphorylation-promoted interaction of the hydrophobic motif with a
channel on the N-terminal lobe induced by the ordered alpha-C helix and are mimicked
by peptides corresponding to the hydrophobic motif of Akt.

Figure 8. Proposed model for Akt/PKB regulation by receptor tyrosine kinases.
Activation of receptor tyrosine kinases by ligands such as epidermal growth factor and platelet-derived
growth factor leads to autophosphorylation of specific tyrosine residues on the intracellular portion of the
receptor. Recruitment of phosphoinositol 3-kinase (PI3K) then occurs, via binding of the SH2 domains of
the regulatory subunit p85 to the phosphotyrosine residues on the receptor, which leads to a
conformational change in the kinase, and consequently to activation. 3'-phosphoinositides generated by
activated PI3K (black circles) then mediate the membrane recruitment Akt/PKB from the cytosol to the
plasma membrane via its PH domains, and change the kinase from an inactive to an active state. A change
in the conformation of Akt/PKB upon lipid binding has been predicted based on biochemical data.
Akt/PKB is then phosphorylated on Thr308 and/or Ser473 by PDK1, and by an as yet unidentified Ser473
kinase. Activated Akt/PKB mediates its intracellular effects, and then becomes inactivated by the action of
phosphatases such as PP2A, which dephosphorylate pThr308 and pSer473 and return Akt/PKB to its
inactive conformation in the cytosol. PTEN or SHIP, which are two known phosphatases, act to
downregulate Akt/PKB activation by dephosphorylating PtdIns(3,4,5)P3 (Referred to Kim D et al. (2005)
Front Biosci. 10, 975-987.).

Activation of Akt
Akt exists in the cytosol of unstimulated cells in a low-activity conformation.
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Upon activation of PI3K, PtdIns(3,4,5)P3/PtdIns(3,4)P2 are synthesized at the plasma
membrane and then Akt interacts through its PH domain with these lipids. This causes
the translocation of Akt from the cytosol to the inner leaflet of the plasma membrane and
leads to a conformational change, which converts Akt into a substrate for PDK1, perhaps
by exposing the Thr308 and Ser473 phosphorylation sites. PDK1 then phosphorylates
Thr308.

PDK1 in this location of the cell also forms a complex with

PtdIns(3,4,5)P3/PtdIns(3,4)P2. Although the role of PDK1 in Thr308 phosphorylation is
well established, the mechanism of Ser473 phosphorylation is controversial.

A number

of candidate enzymes responsible for this modification have been put forward, including
integrin-linked kinase, PDK1 when in a complex with the kinase PRK2, Akt itself,
through autophosphorylation, PKCα, PKCβII, DNA-dependent kinase, and the rictormTOR complex (Fig. 8).
Several reports have indicated that Akt can be activated in cells by a mechanism
independent of PI3K activation, for example in response to heat shock, or increases in
intracellular Ca2+ or cAMP.

Akt is activated by heat shock in NIH3T3 fibroblasts and

this response was not inhibited by wortmannin (50).

However, we and others showed

that Akt1 and Akt2, activated by heat shock as well as oxidative stress are completely
suppressed by the PI3K inhibitors wortmannin and LY294002 (54, 55). Agonists that
increase Ca2+ levels in cells have been reported to activate Akt in a PI3K-independent
manner through the Ca2+/calmodulin-dependent protein kinase kinase (CAMKK) (55).
The stimuli of Akt activation from extensive studies in different fields are summarized in
the Table 1.

PI3k/Akt pathway in human cancer

Akt amplification
Akt was first identified as a component of a fusion product of the retroviral
oncogene v-akt that causes leukaemia in mice (45).
discovered Akt gene amplifications in human cancers.
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A number of studies have

The work that originally

identified Akt as a potential human oncogene detected amplification of Akt1 in a single
gastric carcinoma (44). Akt2 gene amplification has been found in ovarian, pancreatic,
gastric, and breast tumors (44, 45).

Akt2 amplification was mostly associated with

high-grade aggressive ovarian tumors and appears to occur as part of the frequent
amplification of the 19q13.1–q13.2 chromosomal region (46).

One study documented

Akt3 mRNA overexpression and selective activation of the protein by growth factors in
hormone-independent breast and prostate cancer cell lines (56).

Overall, these studies

indicate that Akt gene amplification, especially Akt2, may be a frequent occurrence in
several human cancers (57).

PI3K gene amplification
The PIK3CA gene, which encodes the p110α catalytic subunit of PI3K, is located
on chromosome 3q26, a region that is frequently amplified in a number of human cancers.
Recent studies have revealed amplification of PIK3CA in ovarian (58) and cervical (59)
tumors.

Furthermore, corresponding cell lines harboring this alteration display

enhanced PI3K catalytic activity and growth that is strongly suppressed by PI3K
inhibitors, suggesting that PI3K has oncogenic property at least in these tumor types.

Activation of upstream regulators of PI3K
PI3K is activated as a result of the ligand-dependent activation of tyrosine kinase
receptors, G-protein-coupled receptors, or integrins.

Receptor-independent activation

can also occur, for example, in cells expressing constitutively active Ras proteins (60, 61).
As cell surface receptors are frequently overexpressed and/or activated in many human
cancers (62), downstream signaling pathways are often activated. One of the most
extensively studied examples is the erbB2 tyrosine kinase receptor, which is
overexpressed in a large number of breast and other cancers (63).

ErbB2 is an orphan

receptor with no defined ligand, which acts as a dimerization partner for other members
of the erbB family. ErbB2-containing heterodimers are potent activators of multiple
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signaling pathways involved in proliferation, invasion, and survival (64).

Studies in

breast cancer cells, primary breast tumors, and transgenic mice, all indicate that erbB2,
when overexpressed, is constitutively associated with erbB3 (65).

Because erbB3

possesses seven phosphorylatable tyrosine residues that act as binding sites for the SH2
domains of the p85 regulatory subunit of PI-3K (64), erbB2–erbB3 dimerization robustly
activate the PI3K/Akt pathway. This provides a basis for data showing that tumor cells
overexpressing erbB2 display constitutive Akt activity (66).

PTEN mutation
PTEN (Phosphatase and Tensin homolog deleted on Chromosome 10) is a dualfunction lipid and protein phosphatase that was originally identified as a tumor
suppressor gene frequently mutated in the advanced stages of a number of human cancers,
particularly glioblastoma, endometrial, and prostate cancers.

Additionally, germline

mutations in PTEN induce the rare autosomal dominant inherited human cancer
syndrome known as Cowden's disease, which is associated with increased risk of
developing breast and other cancers (67).

The results of studies in which PTEN has

been overexpressed in various cell lines suggest that PTEN acts as a tumor suppressor by
inhibiting cell growth (68) and increasing susceptibility to apoptosis and anoikis (69).
The main physiological lipid substrate for PTEN is phosphatidyl-inositol
triphosphate (PIP3), the product of PI3K.

PTEN-null embryonic fibroblasts show

elevated PIP3 levels and constitutive Akt activity, indicating that PTEN acts to restrain the
pathway in the unstimulated cells.

Absence of PTEN also strongly correlates with

activation of Akt in tumor cell lines.

Conversely, reintroduction of PTEN in cells

lacking PTEN down-regulates Akt phosphorylation as well as reversing the
phosphorylation of Akt cellular substrates such as BAD (68, 69, 72).

PTEN and

phosphorylated AKT levels were inversely correlated in a large majority of samples with
primary acute leukemias and non-Hodgkin lymphomas as well as in cell lines from these
malignancies (70, 71).

In addition, frequent overexpression of Akt has also been

detected in human malignancies (72).

Mutation of Akt2 has also been found in
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List of stimuli that activate Akt.
Stimuli that regulate G
Tyrosine Kinase
protein coupled receptor
Angiopoietin-1
Bradykinin
C5a
α-CD28 antibodies
Epidermal growth factor
Carbachol
Basic fibroblast growth Growth-related oncogene α
factor
(GROα)
Fibronectin
Endothelin
Gas6
FMet-Leu-Phe
α-integrin antibodies
µ-Opioids
RANTES (regulated on
Interleukins 3
activation, normal T cell
expressed and secreted)
Insulin
Platelet activating factor
Insulin-like growth factor
α-killer cell inhibitory
Phosphatase inhibitors
receptor antibodies
Leukaemia
inhibitory
Vanadate
factor
Nerve growth factor
Okadaic acid
N-methyl-D-aspartate
(NMDA)
Platelet-derived
growth
factor
Stem cell factor
Vascular
endothelial
growth factor
Table 1.

Other activiators
Pertussis toxin
Zinc
Cadmium
Hypoxia
Sodium nitroprusside
Exercise
H2O2
Heat shock
Fluid shear
Tumor necrosis factor α

colorectal cancer (73).

Substrates of Akt
To understand the physiological functions of Akt, it is important to identify its
substrates. It was originally established that the minimum motif in a peptide enabling
Akt

phosphorylation

is

Arginie-Xaa-Arginie-Yaa-Zaa-Serine/Threonine-

Hyd(RXRXXS/T), where Xaa is any amino acid, Yaa and Zaa are preferably small
residues other than glycine, and Hyd is a bulky hydrophobic residue (phenylalanine or
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leucine) (74).
A couple of dozen proteins have been identified as Akt substrates (Table 3),
which include BAD (Ser136) (75), glycogen synthase kinase 3 (GSK3) (76), 6phosphofructo-2-kinase (77), caspase-9 (78), endothelial nitric-oxide synthase (79, 80),
IκB kinase (81, 82), phosphodiesterase 3B (83), rac1 (84), raf-1 protein kinase (85, 86),
mammalian target of rapamycin (mTOR) (87), breast cancer susceptibility gene 1
(BRCA1) (88), insulin receptor substrate 1 (IRS-1) (89), and forkhead transcription
factors (90, 91), cAMP- responsive element binding protein (CREB) (92), human
telomerase reverse transcriptase (hTERT) (93) and MDM2 (94, 95).

Although a number

of physiological substrates of Akt have been reported, the detailed mechanism by which
Akt regulates cell growth and survival has not been well documented, and putative
critical substrates remain to be fully characterized.

Function of Akt

Akt and cell survival
Akt has an anti-apoptotic effect in many cell types.

In the anti-apoptotic

machinery, BAD, Forkhead transcription factor family proteins, human caspase-9 and
IκB kinase have been reported to be the downstream targets of Akt.

BAD can form

heterodimer with anti-apoptotic proteins Bcl-2 or Bcl-XL and therefore, prevent them
from exerting their anti-apoptotic function. Akt can phosphorylate BAD at Ser136 (75),
binds to 14-3-3 scaffold protein and is subjected to degradation, even though and Akt also
induce BAD phosphorylation at Ser112 through PAK1 (p21-activating kinase 1) (96).
After phosphorylation at Ser112 and Ser136, phosphorylated BAD phosphorylation at Ser
155 has been reported to be important for binding to 14-3-3 (97).
Caspase-9 is a protease that is essential in the initiation and possibly later stages
of apoptosis, by forming apoptosomes with Apaf-1 and cytochrome c.

Human

procaspase-9 has been reported to be phosphorylated and inhibited by Akt (98).
still unclear how important and/or general event is for Akt-mediated regulation of
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It is

Table 2. Frequency of mutations in the PI3K-AKT pathway in cancers
Genetic mutations
PIK3CA (p110α)
Mutations

Amplification

PTEN
Loss of Heterozygosity

Mutations

AKT
Amplifications

PIK3RI (p85α)
Mutations

Cancer type

Percentage frequency

Breast
Colon
Glioma
Hepatocellular
Ovarian
Lung
Gastric
Head and neck
Thyroid
Lung:
Squamous cell
Adenocarcinoma

26% (176/684)
26% (88/337)
8% (14/182)
36% (26/73)
10% (35/365)
2% (4/253)
7% (24/338)
42% (54/128)
9% (12/128)

Breast
Gastric
Oesophageal adenocacinoma
Cervical

9% (8/92)
36% (20/55)
6% (5/87)
69% (11/16)

Glioblastoma
Prostate
Breast
Melanoma
Gastric
Glioblastoma
Prostate
Breast
Melanoma
Gastric

54% (98/180)
35% (88/250)
23% (37/164)
37% (53/143)
47% (14/30)
28% (122/432)
12% (26/218)
0% (0/164)
8% (15/185)
0% (0/30)

Ovarian
Pancreatic
Breast
Gastric
Head and neck

12% (18/147)
20% (7/35)
3% (3/106)
20% (1/5)
30% (12/40)

Ovarian
Colon

4% (3/80)
2% (1/60)
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66% (46/70)
5% (4/86)

apoptosis, because the site in which Akt phosphorylates human caspase-9 is not
conserved in the mouse, rat and monkey homologues (99).

Akt and mTOR signaling
PI3K/Akt has recently emerged as an important mediator to regulate nutrientsand growth factor-induced targeting of the rapamycin (TOR) pathway.

TOR (mTOR in

mammals, also known as FRAP, RAFT, or RAPT) is an evolutionarily conserved
serine/threonine kinase that regulates both cell growth and cell cycle progression by
integrating signals from nutrients (amino acids and energy) and growth factors (100-104).
The best-known biochemical function of mTOR is to regulate protein translation by
initiation of mRNA translation and ribosome synthesis leading to an increased rate of cell
mass and size, which is required to support the rapid proliferation.

If the rate of cell

growth is unable to keep up with a rapid rate of cell division, then cell proliferation
cannot be continued, since cells would gradually lose cellular mass and cellular size with
each cell division cycle, resulting in inevitable cell death. Studies in several organisms
with rapamycin, which directly binds to and inhibits TOR function, have shown that
inhibition of TOR pathway limits the rate of cell growth and induces cell cycle arrest in
G1 phase and cell death. Therefore, mTOR and its downstream targets have recently
been appreciated as an important cascade for tumorigenesis and novel therapeutic targets
for cancer (103, 104). Using a murine lymphoma model, Akt promotes tumorigenesis
and drug resistance by disrupting apoptosis, and disruption of Akt signaling using the
mTOR inhibitor rapamycin reverses chemoresistance in lymphomas expressing Akt, but
not in those with other apoptotic defects (105).

eIF4E (Human eukaryotic translation

initiation factor 4E), a translational regulator that acts downstream of Akt and mTOR,
recapitulated Akt's action in tumorigenesis and drug resistance but was unable to confer
sensitivity to rapamycin and chemotherapy. Akt signals through mTOR and eIF4E as an
important mechanism of oncogenesis and drug resistance in vivo and reveals how
targeting apoptotic programs can restore drug sensitivity in a genotype-dependent manner.
It has been shown that mTOR feedback regulates Akt.
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In Drosophila and

mammalian cells, TOR and its associated protein rictor are necessary for serine-473
phosphorylation of Akt, and a reduction in rictor or mTOR expression inhibited an Akt
effector.

The rictor-mTOR complex directly phosphorylated Akt/PKB on serine-473 in

vitro and facilitated threonine-308 phosphorylation by PDK1 (106).

Akt and transcription factors
A recent study has shown that Akt regulates cellular processes through
phosphorylation of transcription factors.

The role of Akt in regulation of the

Forkhead(FH or FoxO) transcription factors was first identified by findings from the
genetic analysis of C. elegans (90, 107).

Phosphorylation sites for Akt are highly

conserved among Forkhead isoforms and species.

So far, three isoforms of Forkhead

proteins (FKHR/FoxO1, FKHRL1/FoxO3 and AFX/FoxO4) are directly phosphorylated
by Akt (91, 108-111).

Phosphorylation of Forkhead by Akt results in the nuclear

exclusion of Forkhead, leading to decreased transcriptional activity that is required for
promoting apoptosis.

The target genes for the Forkhead family are thought to be

extracellular ligands, including the Fas ligand, TRAIL (TNF-related apoptosis-inducing
ligand) and TRADD (TNF receptor type 1 associated death domain), and intracellular
components for apoptosis such as Bim (bcl-2 interacting mediator of cell death), Bcl-6,
and p27 (112).
The transcription factor nuclear factor-κB (NFκB)/Rel family is a key regulator of
the immune response, and deregulation of its activity is implicated in the development of
diseases such as autoimmune disease and cancer (113).

In most cases, activation of

NFκB is dependent on the phosphorylation and degradation of IκB, an inhibitor of NFκB,
by IκB kinase (IKK) complex.
direct and indirect manner.

Akt has been shown to regulate IKK activity in both

Akt interacts with and phosphorylates IKKα on Thr23 in a

PI3K-dependent manner that is required for NFκB activation in response to TNFα
stimulation (81).

Another study has shown that Akt phosphorylates Ser/Thr kinase Tpl-

2 (or Cot) on Ser 400, resulting in IKK complex activation (114). This NFκB activation
by Akt might result in the inhibition of apoptosis by induction of cell survival genes that
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are transcriptionally activated by NFκB (113).
Hu et al. investigated the pathologic relationship between phosphorylated Akt and
FOXO3A in primary tumors (115).

FOXO3A was excluded from the nuclei of some

tumors lacking phosphorylated Akt, suggesting an Akt-independent mechanism of
regulating FOXO3A localization. This phenomenon is due to IKK physical interaction
with, phosphorylation, and inhibition of FOXO3A, which leads to proteolysis of
FOXO3A via the ubiquitin-dependent proteasome pathway.

Cytoplasmic FOXO3A

correlated with expression of IKKβ or phosphorylated Akt in many tumors and was
associated with poor survival in breast cancer.
A transcription factor, CREB (cyclic AMP response element (CRE)-binding
protein), is phosphorylated by Akt1 on Ser133. This process results in increased affinity
of CREB to its co-activator CRB, and transcriptional activation of CREB (92, 116).
CREB is one of the targets of Akt in cell survival signaling, but a detailed mechanism
remains to be elucidated.
The orphan nuclear receptor Nurr77 is required for T-cell antigen receptormediated cell death (117).

This transcription factor is phosphorylated by Akt on Ser 350

(118). Phosphorylation of Nurr77 by Akt causes suppression of Nurr77 activity and
partial inhibition of apoptosis induced by PMA and calcium. These observations suggest
that Akt is implicated in early T-cell development.
Androgen receptor (AR) and estrogen receptor (ER)α, the members of the nuclear
receptor transcription factor group, play an important role in cell growth and survival
(119, 120). Akt phosphorylates AR on Ser 210 and Ser 790 and ERα on Ser 167, which
regulate their transactivational activity (120, 121).
Akt phosphorylates EZH2 (enhancer of zeste homolog 2) at serine-21 and suppresses its
methyltransferase activity by impeding EZH2 binding to histone H3, which results in a
decrease of lysine-27 trimethylation and derepression of silenced genes. These results
imply that AKT regulates the Histone methylation, through phosphorylation of EZH2,
which may contribute to oncogenesis (122).
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Table 3. List of substrates of active Akt.
Substrates

Sites

Reference

AHNAK

Ser5535

Sussmann et al., 2001 JCB

Arfaptin 2

Ser260

Rangone et al., 2005 JBC

ArgBP2γ

Ser232, Thr234, Thr379

Yuan et al., JBC 2005

ARK5

Ser600

Suzuki et al.,2003 JBC

ASK1 (MAP3K5)

Ser83

Kim et al., 2001 MCB

AS160

Ser588, Thr642

Kane et al., 2002 JBC

ATP citrate lyase

Ser455

Bad

Ser75, Ser99

Caspase 9 alpha

Ser196

Berwick et al., 2002 JBC
del Peso at al., 1997 Science
D tt t l 1997 C ll
Cardone et al., 1998 Science

CRHSP24

Ser52

Auld et al., Biochem J. 2005

Ezrin, Cytovillin, Villin 2

Thr567

Shiue et al., 2004 JBC

Filamin C)

Ser2213

Forkhead

Thr24, Ser256, Ser319

GABA (A) receptor*

Ser410

Murray et al., 2004 Biochem J.
Brunet et al., 1999 Cell
R
t l 1999 JBC
Wang et al., 2003 Neuron

GSK3α

Ser19

Cross et al., 1995 Nature

GSK3β

Ser9

Cross et al., 1995 Nature

HAND2, dHAND

Ser114 ?

Murakami et al., 2004 Eur J. Biochem

HO-1 heme oxygenase 1

Ser188

Salinas et al., 2004 FEBS Lett.

Huntingtin

Ser421

Humbert et al.,2002 Dev Cell

Iκ-B kinase α

Thr23

Ozes et al., 1999 Nature

IRS-1

Ser270, Ser307, Ser330, Ser527

Paz et al., 1999 JBC

mTor

Ser2448

Nave et al., 1999 Biochem. J.

PAK1

Ser21

Zhou et al., MCB

p21 WAF

Thr145, Ser 146

Li et al., 2002 JBC 277:11352-11361

p27 Kip1
PIPPin
RNA
t i
PTP-1B

Thr157

Shin et al., 2005 JBC

Ser58

Auld et al., 2005 Biochem. J

Ser50

Ravichandran et al.,2001 Mol. Endocrinol.

Ser466, Ser483

Deprez et al., 1997 JBC

PRAS40

Thr246

Kovacina et al., 2003 JBC

p47phox

Ser304, Ser328

Chen et al., 2003 J. Immunol.

14-3-3-zeta

Ser58

Powell et al., 2002 JBC

Raf-1 = c-Raf

Ser259

Zimmermann and Moelling 1999 Science

MKK4 = SEK1

Ser78

Park et al., 2002 JBC

METTL1 tRNA methylase

Ser27

Cartlidge et al., 2005 EMBO J.

Synip (only by AKT2 )

Ser99

Yamada et al., 2005 J. Cell. Biol.

binding

PFK-2

Tau

Thr212, Ser214

Ksiezak-Reding et al., 2003 BBA

Tuberin = TSC2

Ser939

Manning et al., 2002 Mol. Cell

WNK1

Thr60

Vitari et al., 2003 Biochem J.

YAP1 Yes ass. protein
YB-1
Y-box
binding
protein 1

Ser127

Basu et al.,2005 Mol. Cell.

Ser102

Sutherland et al., 2005 Oncogene
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Akt and cell cycle
p21cip1/waf1 is a cyclin/CDK (cyclin-dependent kinase) inhibitor which plays a
important role in maintaining cell cycle progression, and its impaired function is one of
the major abnormalities in human cancer (123). p21 is reported to be a direct target of
Akt, and phosphorylation of this protein by Akt results in the inhibition of its function to
arrest the cell cycle.

Zhou et al. were the first to describe Akt-mediated phosphorylation

and regulation of p21 (95). They reported that phosphorylation of p21 on Thr145 by
Akt inhibits nuclear localization of p21, leading to activation of cyclin/CDK required for
HER-2/neu-dependent tumor cell growth.

Other groups have suggested different

mechanisms for the regulation of p21 by phosphorylation.

Rossig et al. reported that

phosphorylation of the Thr145 of p21 prevents formation of the complex between p21
and proliferating cell nuclear antigen (PCNA) that causes DNA replication and cell
proliferation (124). Phosphorylation of p21 on Thr145 also decreases the affinity of
Cdk2 and Cdk4 to p21, which causes enzymatic activation of these Cdks. They showed
no significant effect of p21 phosphorylation on its subcellular localization. Another
report showed that p21 could be phosphorylated on Ser146 as well as Thr145 (125).
Phosphorylation of Thr145 reduces affinity to PCNA, whereas phosphorylation of Ser146
enhances protein stability of p21.

Phosphorylation of these sites shows little effect of

p21 on complex formation and inhibition of the cyclin/CDK complex.

The authors also

suggested the possibility that p21 is a chemoresistance target of Akt-overexpressing
cancer cells.

These observations indicate that some experimental conditions or the

genetic background of cells, such as erbB2 overexpression, might affect the regulation of
p21 by Akt.
p27kip1, another major cyclin/CDK inhibitor, is also regulated by Akt-dependent
phosphorylation. In 2002, three reports described direct phosphorylation of p27 by Akt
in breast cancer cells (126-128).

Akt phosphorylates p27 on Thr157, which is located in

its nuclear localization signal (NLS), leading to the nuclear exclusion of p27, activation
of cyclin/Cdk and cell cycle progression. In primary breast cancer cells, cytoplasmic
retention of p27 correlates with prognosis, suggesting that the subcellular localization of
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p27 might be a therapeutic target for breast cancer.
The protein product of the tumor suppressor gene p53 is one of the most
important regulators for cell cycle progression and apoptosis in response to genotoxic
stresses (129).

Murine double minute 2 (MDM2) is an oncogene product and functions

as an ubiquitin E3 ligase of p53 and also is transcriptionally induced by p53 (130). It
directly binds to p53 and targets it for ubiquitination.

In 2001, two groups reported that

Akt-dependent phosphorylation might contribute to nuclear localization of MDM2 (94,
131). Two putative phosphorylation sites, Ser166 and Ser186, were determined by sitedirected mutagenesis. Another group showed that Ser186 was not an Akt site (132).
Ogawara et al. reported that neither Akt nor point mutants for MDM2 on Ser166 and
Ser186 showed any effect on subcellular localization of MDM2, but did show a
PI3K/Akt-dependent increase of p53 ubiquitination (133). The precise effect of Akt on
MDM2 is still controversial.

Taken together, MDM2 should be, at least, an Akt target in

the regulation of cell growth, but the detailed mechanism needs to be further investigated.

Akt and mouse models
Genes encoding activated forms of Akt and Ras were transferred, in a tissuespecific manner, to astrocytes and neural progenitors in mice (134). Although neither
activated Akt nor Ras alone was sufficient to induce glioblastoma multiform (GBM)
formation, the combination of activated Ras and Akt induced high-grade gliomas with the
histological features of human GBMs.

These tumors appeared to arise after gene

transfer to neural progenitors, but not after transfer to differentiated astrocytes.
Increased activity of RAS is found in many human GBMs, and Akt activity is increased
in most of these tumors, implying that combined activation of these 2 pathways
accurately models the biology of this disease.
By targeted disruption of the Akt1 gene, an Akt1-null mouse model was created.
Homozygous mice were viable but smaller than wild type littermates, and they did not
display a diabetic phenotype. Upon exposure to genotoxic stress, their life span was
shorter.

The Akt1-null mice showed increased spontaneous apoptosis in testes and
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thymi.

There was an attenuation of spermatogenesis in the Akt1-null male mice, and

thymocytes were more sensitive to γ-irradiation and dexamethasone-induced apoptosis.
Akt1-null mouse embryo fibroblasts were also more susceptible to apoptosis induced by
TNF, anti-Fas, ultraviolet irradiation, and serum withdrawal (135).
Mice deficient in Akt2 are impaired in the ability of insulin to lower blood
glucose because of defects in the action of the hormone on liver and skeletal muscle.
Ablation of Akt2 in mice resulted in a mild but statistically significant fasting
hyperglycemia due to peripheral insulin resistance and nonsuppressible hepatic glucose
production accompanied by inadequate compensatory hyperinsulinemia (136).

In

addition, Garofalo et al. showed that mice lacking Akt2 exhibited mild growth deficiency
and an age-dependent loss of adipose tissue or lipoatrophy, with all observed adipose
depots dramatically reduced by 22 weeks of age (137). Akt2-deficient mice exhibit
insulin-resistant

with

elevated

plasma

triglycerides,

fasting

hyperglycemia,

hyperinsulinemia, glucose intolerance, and impaired muscle glucose uptake.

In males,

insulin resistance progressed to a severe form of diabetes accompanied by pancreatic β
cell failure; in contrast, female Akt2-deficient mice remained mildly hyperglycemic and
hyperinsulinemic until at least 1 year of age. Thus, Akt2-deficient mice exhibit growth
deficiency similar to that reported for mice lacking Akt1, indicating that both Akt2 and
Akt1 participate in the regulation of growth.

The marked hyperglycemia and loss of

pancreatic β cells and adipose tissue in Akt2-deficient mice suggested that Akt2 plays
critical roles in glucose metabolism and the development or maintenance of proper
adipose tissue and islet mass for which other Akt/PKB isoforms are unable to compensate
fully.
Akt2 is expressed in mouse platelets and is activated by platelet agonists in a PI3
kinase-dependent pathway.

Deletion of the Akt2 gene in mice impaired platelet

aggregation, fibrinogen binding, and granule secretion, especially in response to low
concentrations of agonists that activate the G protein-coupled receptors for thrombin and
thromboxane A2.

Loss of Akt2 also impaired arterial thrombus formation and stability

in vivo, despite having little effect on platelet responses to collagen and ADP (138).
Akt3-knockout mice only exhibit an uniformly reduced brain size, affecting all
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major brain regions, suggesting a central role of Akt3 in postnatal development of the
brain (139).

In addition, although Akt1- and Akt3-deficient brains are reduced in size to

approximately the same degree, the absence of Akt1 reduces cell number, whereas the
lack of Akt3 results in smaller and fewer cells (139). mTOR signaling is attenuated in
the brains of Akt3-/- but not Akt1-/- mice, suggesting that differential regulation of this
pathway contributes to an isoform-specific regulation of cell growth.
Akt1/Akt2 double-knockout (DKO) mice were developed by Peng. et al. DKO
mice showed severe growth deficiency and died shortly after birth.

These mice

displayed impaired skin development due to a proliferation defect, skeletal muscle
atrophy due to marked decrease in individual muscle cell size, and impaired bone
development.

The defects were similar to the phenotype of IGF-1 receptor (IGF1R)-

deficient mice, suggesting that Akt may serve as an important downstream effector of
IGF1R during mouse development.

DKO mice also displayed impeded adipogenesis

through decreased induction of PPARG (peroxisome proliferative activated receptor, γ)
(140).
Loss of Akt1, but not Akt2, resulted in defective ischemia and VEGF-induced
angiogenesis and severe peripheral vascular disease in mice.

Akt1-knockout mice also

had reduced endothelial progenitor cell (EPC) mobilization in response to ischemia.
Introduction of EPCs from wild type mice, but not EPCs from Akt1-/- mice, into wild type
mice improved limb blood flow after ischemia.

Loss of Akt1 reduced basal

phosphorylation of several Akt substrates, migration of fibroblasts and endothelial cells,
and nitric oxide release. This suggested that Akt1 exerts an essential role in blood flow
control, cellular migration, and nitric oxide synthesis during postnatal angiogenesis (141).
In vitro endothelial cells from Akt1-null mice showed impaired migration in
response to VEGF and bound 3 times less fibrinogen than wild type cells.

Akt1-null

mice showed significantly enhanced angiogenesis, which was associated with impaired
blood vessel maturation and increased vascular permeability.

The neovasculature in

Akt1-null mice had decreased basement membrane thickness and decreased laminin
deposition.

These

changes

were

associated

with

reduced

expression

thrombospondin-1 (THBS1) and -2 (THBS2). This result implied that Akt1 is
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of

responsible for the regulation of vascular permeability, angiogenic responses, and
vascular maturation (142).
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Chapter 2
Molecular cloning and characterization of the human AKT1 promoter uncovers its
upregulation by the Src/Stat3 pathway

Abstract
Akt1, also known as protein kinase B α (PKBα), is frequently activated in human
cancers and has been implicated in many cell processes by phosphorylation of
downstream molecules.
documented.

However, transcriptional regulation of the Akt1 has not been

Here, we report the isolation and characterization of the human AKT1

promoter and demonstrate transcriptional upregulation of the AKT1 by the Src/Stat3
pathway.

Protein and mRNA levels of AKT1 are elevated in cells expressing

constitutively active Stat3 as well as in v-Src-transformed NIH3T3 cells.
of Stat3 reduces the AKT1 expression induced by v-Src.

Knockdown

While the 4.2-Kb region

upstream transcription start site of the AKT1 promoter contains five putative Stat3binding motifs, the promoter failed to be induced by Stat3 and/or Src. Further analysis
reveals that major Stat3 response elements are located within exon-1 and intron-1 regions
of the AKT1 gene, which is upstream of AKT1 translation initiation site.

In addition,

ectopic expression of wild type AKT1 in Stat3–/– MEF cells largely rescues serum
starvation-induced cell death.

These findings indicate that the AKT1 promoter

comprises the exon-1 and intron-1 in addition to the sequence upstream of transcriptional
start site. Our data further show that the AKT1 is a direct target gene of Stat3 and
contributes to Stat3 antiapoptotic function.
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Introduction
Akt/PKB represents a subfamily of the serine/threonine protein kinases.

Three

members of this family, Akt1/PKBα, Akt2/PKBβ, and Akt3/PKBγ, have been identified
(1-7). Akt1/PKBα is the most extensively studied member and usually referred to Akt
or PKB in the literature. Akt is activated by extracellular (growth factor, cytokine and
stress) and intracellular (altered receptor tyrosine kinase, Src and Ras) stimuli to regulate
cell growth, survival, differentiation and metabolism (8-11).

Activation of Akt by

growth factor depends on the integrity of the PH domain, which binds to PI3K products
PtdIns-3,4-P2 and PtdIns-3,4,5-P3, and on the phosphorylation of Thr308 (Thr309 in
Akt2 and Thr305 in Akt3) in the activation loop and Ser473 (Ser474 in Akt2 and Ser472
in Akt3) in the C-terminal activation domain by PDK1 and ILK/DNA-PK (12-14). The
activity of Akt is negatively regulated by PTEN, a tumor suppressor gene that is mutated
in a number of human malignancies. PTEN encodes a dual-specificity protein and lipid
phosphatase that reduces intracellular levels of PtdIns-3,4-P2 and PtdIns-3,4,5-P3 in cells
by converting them to PtdIns-4-P1 and PtdIns-4,5-P2, respectively, thereby inhibiting the
PI3K/Akt pathway.
There are no significant differences between three members of Akt in terms of
upstream regulators and downstream targets.

However, several lines of evidence

suggest that the biological/physiological functions of Akt1, Akt2 and Akt3 are different.
First, there are different levels of activation and protein expression in various cell types
between Akt1, Akt2 and Akt3 (5, 15-18).

Second, multimeric complexes formed by

Akt proteins are restricted to individual member, for example, Tcl1b binds to Akt1 and
Akt2 but not Akt3, indicating the need to maintain specificity in interactions with other
signaling proteins (19). Third, although Akt1 and Akt2 proteins require membrane
localization for activity, only Akt2 appears to accumulate in the cytoplasm during mitosis
(20) and in the nucleus during muscle cell differentiation (21).

In addition,

microinjection of anti-Akt1 antibodies blocks cell cycle progression, whereas anti-Akt2
antibodies have no effect on cell cycle but attenuate muscle differentiation (22).
Amplification of the Akt1 gene has been detected in a single gastric carcinoma
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cell line (23), whereas the Akt2 is amplified in different types of human tumor (16-17, 24).
Ectopic expression of wild type Akt2, but not Akt1 and Akt3, results in invasion and
metastasis in human breast and ovarian cancer cells (25) and induces a malignant
phenotype in mouse fibroblasts (20).

Finally, knockout mouse studies demonstrated

distinct phenotype between Akt1, Akt2 and Akt3.

The mice deficient in the Akt2 are

impaired in the ability of insulin to lower blood glucose because of defects in the action
of the hormone on skeletal muscle and liver, similar in some important features to type 2
diabetes in human.

In contrast, Akt1-dificient mice do not display a diabetic phenotype.

The mice are viable but display impairment in organismal growth with smaller organs
than wild type littermates (26-28).

In contrast, a recent report shows that Akt3-/-

knockout mice only exhibit a uniformly reduced brain size, affecting all major brain
regions, suggesting a central role of Akt3 in postnatal development of the brain (29).
While Akt1 signaling has been extensively investigated, its transcriptional
regulation remains largely unknown.

In the present report, we have isolated and

characterized the human AKT1 promoter.

Multiple putative Stat3-binding sites reside

within the promoter and major Stat3 response elements are identified in the exon-1 and
intron-1 regions of the AKT1 gene.
Src.

AKT1 is transcriptionally upregulated by Stat3 and

Elevated expression level of AKT1 induced by Src is inhibited by dominant

negative Stat3.

Stat3–/– MEFs display lower level of Akt1 and reintroduction of the

AKT1 largely rescued cell death in response to serum starvation.

Therefore, our results

provide the first evidence that the AKT1 is a direct Stat3 target and mediates Stat3
survival signal.

Material and methods
Cell Culture, Plasmids, Materials and Transfection - Human epithelial kidney
HEK293, MCF10A, MCF7, mouse fibroblast NIH3T3, Src transformed NIH3T3, and
Stat3−⁄− mouse embryonic fibroblast (MEF) were grown in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine serum.

The plasmids expressing Akt,

Stat3 and Src as well as dominant negative Stat3 have been described previously (30, 34).
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The antibodies to Akt1 and Stat3 were purchased from Cell Signaling and Santa Cruz
Biotechnology, respectively. For transfection, the cells were seeded 18-24 h before
transfection using Lipofectamine plus.

The sequence for Stat3 antisense oligonucleotide

synthesized using phosphorothioate chemistry is 5’-AAAAAGTGCCCAGATTGCCC-3’.
The sequence for control oligonucleotide is identical to the antisense oligonucleotide
except for three mismatched bases (italics), 5’- AAAAAGAGGCCTGATTGCCC-3’.
The sequence of Stat3 siRNA is 5'-AAC AUC UGC CUA GAU CGG CUA dTdT-3'; 3'dTdT GUA GAC GGA UCU AGC CGA U-5'.
Transcription Start Site Mapping of Human AKT1 Gene - For the analysis of the
AKT1 transcription start site, human MCF7 mRNA was reverse transcribed at 55°C
using Supercript reverse transcriptase (Invitrogen) and a primer from the AKT1 exon-1
specific reverse complement oligonucleotide 5'- TGACTTCTTTGACCCAGGCTGG-3'
(31).

Synthesized cDNAs were amplified by polymerase-chain reaction using a series

of forward primers specific for the DNA sequences within the 6,000 bp upstream of the
translation start site and a reverse primer from the non-coding region of exon 1, and the
products of these reactions were resolved by agarose gel electrophoresis.
Cloning and Analysis of Human AKT1 Promoter – To clone the 5'-flanking region
of the human AKT1 gene, 4 cosmid clones were obtained by screening a human placenta
genomic cosmid library (Stratagene) using 5’ non-coding region (a 520-bp fragment from
ATG site) of the AKT1 as a probe. The cosmid clones were sequenced and compared
with human genome database.

Three clones were found to contain 12~28-kb DNA

fragments upstream the translational start site. Two DNA fragments (-4293/+1 and 4293/+1888, Fig. 9C) were amplified with GC-RICH PCR System (Roche) using a
cosmid clone as template. The amplified DNA fragments -4293/+1 and - 4293/+1888
were subcloned into the luciferase reporter vector pGL3 (Promega) at KpnI/BglII site.
Progressive deletion mutants of the pGL3- AKT1 promoter were created by PCR.
integrity of constructs was confirmed by DNA sequencing.

The

The primers were used as

follow: -4293(5’) 5’-CTTCGTGAACATTAACGACAGG GCCTGG-3’; -3392(5’) 5’GTTCAGGCAGAACCTCTGCAGACTCAGG-3’; -3356(5’) 5’-CTGG CCTGGGAGC
TGCCCTGAGG-3’; -2741(5’) 5’- CTCTGCTTCCTCCCTGAATTCCTTCCTCC-3’; 40

1603(5’) 5’-CAGCCTGAAAGTCAACCTAAGC -3’; -1361(5’) 5’-CAGCCCGGCCGC
GCGCTCCCCG-3’; -460(5’) 5’-GGCTAGCCACAAAGGACTGTGACC-3’; -880(3’)
5’- CCAGAATGGAGGAGCGGGAGCAGGAAGT-3’; -732(3’) 5’-GCCCCAGCCTCC
CTCATGACCTT-3’; -305(3’) 5’-GCTTGCCCCTTAGATTGAGTAT-3’; -103(3’) 5’GGAGCTGTGTAGACTTCTCATACA-3’; +159(3’) 5’-GCTCTGGACAG CTGTCTG
ACTCTGT-3’; +595(3’) 5’-GGCTGTGGAAAGACCCATGTTG-3’; +1809(3’) 5’GCTTCCTTTGCTTCTCCCAGAGG-3.
Luciferase Reporter Assay – NIH3T3 or HEK293 cells were cultured in 12-well
plates and transiently transfected with AKT1-Luc, Src and/or Stat3. The amount of
DNA in each transfection was kept constant by the addition of empty vector.

After 36 h

of transfection, luciferase activity was measured using a luciferase assay reagent
(Promega).

Transfection efficiency was normalized by co-transfection with β-

galactosidase expressing vector. The β-galactosidase activity was measured by using
Galato-Light (Tropix). Luciferase activity was expressed as relative luciferase activity.
Northern and Western Blot Analysis – Northern blot analysis of total cellular
RNA was performed according to standard procedures. RNA was extracted using the
RNeasy purification kits (QIAGEN Inc.). Total RNA was electrophoresed in 1.0%
formaldehyde-agarose gels, transferred to Duralon-UVTM membrane (Srtatagene), and
then hybridized with randomly primed α-32P-labeled cDNA probes for AKT1.
Membranes were exposed to autoradiography and the mRNA levels were visualized and
quantified using PhosphorImager analysis (Molecular Dynamics).

Western blot analysis

was performed as described previously (32). Briefly, the cells were lysed with RIPA
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton x-100, 1% Sodium
deoxycholate. 0.1% SDS, 1 mM EDTA. 1 mM PMSF, 5 µg/ml aprotinin and 5 µg/ml
leupeptin), separated in SDS-PAGE and immunoblotted with appropriate antibodies as
indicated in the figure legends.
ChIP and EMSA Assay - ChIP assay was performed essentially as previously
described (33).

Solubilized chromatin was prepared from a total of 2 X 107

asynchronously growing HEK293 cells that were transfected with wild type Stat3 and vSrc.

The chromatin solution was diluted 10-fold with ChIP dilution buffer (1.1% Triton
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–100, 1.2 mM EDTA, 167 mM NaCl, 16.7 mM Tris•HCl, pH 8.1, 0.01% SDS, protease
inhibitors), and precleared with protein-A beads blocked with 2 µg sheared salmon sperm
DNA and pre-immune serum.

The precleared chromatin solution was divided and

utilized in immunoprecipitation assays with either an anti- Stat3 antibody or an anti-actin
antibody. Following wash, the antibody-protein-DNA complex was eluted from the
beads by resuspending the pellets in 1% SDS, 0.1 M NaHCO3 at room temperature for
20 min.

After crosslinking, protein and RNA were removed by incubation with 10 µg

proteinase K and 10 µg RNase A at 42 °C for 3 h. Purified DNA was subjected to PCR
with primers specific for 13 putative Stat3-binding sites within the AKT1 promoter. The
sequences of the PCR primers used are as follows: region 1 forward (-4293): 5’CTTCGTGAACATTAACGACAGGGCC-3’, reverse (-4143): 5’-AATGGCCACCCTG
ACTAAGGAGTGG-3’; region 2 forward (-4221): 5’- AACCCTTCACTGGTTTCTCT
TCATCC-3’, reverse (-4056): 5’-TGCTGGAATATCCCACAATCACAGG-3’; region 3
forward (-4134): 5’- TTCCCTCGCAGTCCCTTCTGCTGC-3’, reverse (-3840): 5’CCCTACTTCCTCTGAAGGTTCAGG-3’; region 4 forward (+233): 5’- ATCCAGAG
GTCTTTGAGTCCAGCC-3’, reverse (+438): 5’-TGCCAGGACAGGGAACACAGG3’; region 5 forward (+413): 5’-AGGTGTGGTCTTCCCTGTCCTGGC-3’, reverse
(+481): 5’-GCTACACTTAGAATGGCAGGAAGG-3’; region 6 forward (+447): 5’AGGCAGTGGGCCTTCCTGCCATTC-3’, reverse (+598): 5’-TCCC AACATGGGTCT
TTCCACAGC-3’; region 7 forward (+831): 5’-GGATAAAGTGTGCTCAGGTGAGG
G-3’, reverse (+1038): 5’-GGCGTCTCAGGTTTTGCCAGGGGG-3’; region 8 forward
(+989): 5’-TCTCTTTGTCTCCAGCGCCCAGG- 3’, reverse (+1200): 5’- ATGAGGAA
GAGAGGACCAGGATGC-3’; region 9 forward (+1262): 5’-GATCCATGGGTAGGA
ACACCATGG-3’;

reverse

(+1419):

5’-TTCCCAGCCTCCCTAACCTGATGC-3’;

region 10 forward (+1440): 5’- AGCCTGGGTCAAAGAAGTCAAAGG-3’, reverse
(+1598): 5’-ATTCTAGGCTTAGAGCCTCCAGCC-3’. Amplified PCR products were
resolved by 1.2% of agarose gel electrophoresis and visualized by BioImage. EMSA was
performed as previously described (35).
MTT Assay - MTT assay was done following the procedure described previously
(36).

Briefly, conditional STAT3 -/- MEF cells (4 x 103 cells/well) were plated in 9642

well microtiter plates and infected with retrovirus expressing Cre for disrupting Stat3.
After infection, wild-type Akt1 was transfected into the cells using LipofectAmine
(Invitrogen).

Cells were serum starved, incubated with MTT (10 µl/well) and

solubilized with 100 µl/well of 20% sodium dodecyl sulphate (SDS) in 50% DMF
(pH4.7) at room temperature for 4 h.
reader at 570 nm.

Absorbance was determined in a Titertek plate

The absorbance is directly related to viable cell number.

The

experiment was repeated three times.

Results
Cloning of the Human AKT1 Promoter Reveals Multiple Putative Stat3 Binding
Sites – To analyze the transcriptional regulation of the serine/threonine kinase AKT1, we
cloned the 5’ flanking region of the human AKT1 gene.

Sequence analyses revealed that

the AKT1 gene consists of 12 exons. The exon-1 is 1.4 kb and locates within the 5’
untranslated region.
(Fig. 9A).

The translation initiation site ATG resides within the exon 2

The transcription start site, which was determined by 5’ race PCR,

lies 1,888-bp upstream of the translation start site.

A putative TATA box was

identified 7-bp upstream of the transcriptional start site.

Transcription element

analyses (http://www.motif.genome.ad.jp) of 6,181 bp of upstream of translation
initiation site of the AKT1 gene revealed multiple binding sites for Stat3, NFκB,
AP1 and GC box within the these regions (Fig. 9B).
has the most

The transcription factor that

binding sites in the AKT1 promoter is Stat3 (twelve putative Stat3

binding sites; -4230/- 4223, -4143/-4136, -4053/-4046, -3287/-3278, - 2851/-2844,
+407/+414, +439/+448, +483/+491, +978/+986, +1047/+1055, +1324/+1331, and
+1443/+1450).

Consensus sequences of Stat3 binding site are TT(N)4-6AA (37).

These observations suggest that the AKT1 gene could be regulated by Stat3 at
transcriptional level.
Stat3 Increases AKT1 Expression at mRNA and Protein Levels – To directly
demonstrate whether the AKT1 is transcriptionally regulated by Stat3, MCF-10A cells
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FIGURE 9. Human AKT1 promoter contains multiple Stat3-binding sites. A, schematic
representation of the human AKT1 genomic locus. The exons are shown as boxes 1–12.
B, the AKT1 promoter sequence. Putative transcription factor binding sites are boxed.
Transcriptional start site and boundaries of exon 1, intron 1, and exon 2 are indicated.
Putative TATA box was boxed within the AP-1-binding site. The translation initiation
site, ATG, was shaded. C, a diagram displays the location of 12 putative Stat3-binding
sites indicated by asterisk within the 6-kb AKT1 promoter.

were infected with adenovirus expressing constitutively active Stat3 (Stat3C) and
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dominant negative Stat3.
control.

The cells infected with adeno-GFP vector were used as

Northern blot analysis showed that constitutively active Stat3C upregulates the

AKT1 (Fig. 10A).

Further, immunoblotting study revealed an elevated protein level of

AKT1 in the cells treated with constitutively active Stat3C (Fig. 10B). Expression of
dominant negative Stat3 slightly inhibited the mRNA and protein levels of AKT1 (Figs.
10A and 10B).

As Stat3 is strongly activated by Src kinase (30), we next examined if

expression level of AKT1 is elevated in v-Src transformed NIH3T3 cells.

As shown in

Figs. 10C and 10D, both protein and mRNA levels of AKT1 were significantly increased
in v-Src transformed NIH3T3 cells.

Further, blockage of Stat3 with antisense RNA

considerably reduced v-Src-induced AKT1. Moreover, upregulation of AKT1 was also
detected in human breast cancer cell line MDAMB-468, which exhibits constitutively
active Src and Stat3, but not in MDA-MB453, which does not.

Inhibition of Src/Stat3

by Src inhibitor (PD180970) or Stat3-SiRNA reduced AKT1 protein level in MDA-MB468 (Figs. 10E and 10F). In addition, conditional knockout of the Stat3 gene decreased
Akt1 expression in mouse embryonic fibroblasts (Fig. 14A).

Based on these data, we

concluded that the Akt1 is a downstream target of Stat3.
Stat3 Transactivates the AKT1 Promoter – We further examined whether the
AKT1 promoter is regulated by Stat3. Luciferase reporter assay revealed that pGL3AKT1-4293/+1, which contains 5 putative Stat3 binding sites, was not stimulated by wild
type or constitutively active Stat3 even when Stat3 was combined with v-Src (Figs. 11A
and 11B).

However, ectopic expression of constitutively active Stat3 significantly

induced the pGL3-Akt1-4293/+1888 activity (Fig. 11C), suggesting that major Stat3
response elements reside in the region of the AKT1 gene between transcription start site
and translation initiation site, which contains exon-1 and intron-1 (Fig. 9B).
Src Induces AKT1 promoter Activity through Stat3 – As v-Src transformed
NIH3T3 cells express high levels of AKT1 that was attenuated by knockdown Stat3 (Fig.
10), we assumed that the AKT1 promoter should be induced by Src through Stat3.
test this hypothesis, luciferase reporter assay was performed with NIH3T3 cells
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To

FIGURE 10. Up-regulation of the
AKT1 by Stat3 and Src. A and B,
constitutively active Stat3 increases
AKT1 expression. MCF10A cells
were infected with adenovirus
expressing
constitutively
active
Stat3C, dominant negative Stat3, and
green fluorescent protein (GFP).
After incubation for 48 h, cells were
subjected to Northern (A) and
Western (B) blot analyses. C, v-Src
transformed NIH3T3 cells express
elevated levels of Akt1. pcDNA3
and v-Src stably transfected NIH3T3
cells were lysed and immunoblotted
with the indicated antibodies. D,
blockage of Stat3 inhibits v-Srcupregulated
Akt1.
v-Srctransformed NIH3T3 cells were
transiently transfected with antisense
oligonucleotides of Stat3 and control
oligonucleotides. Total RNA was
isolated and subjected into Northern
blot analysis with [32P] dCTPlabeled Akt1 (top). The second
panel represents equal loading of
total RNA. Expression of Stat3 was
examined by immunoblotting with
anti-Stat3 antibody (third panel).
Bottom panel shows equal protein
loading. E, the AKT1 protein level is
elevated in human breast cancer
cells with activation of Src and Stat3,
and inhibition of Src reduces AKT1
expression.
MDA-MB-468 cells
expressing constitutively active Src
and Stat3 were treated with or
without a Src inhibitor, PD180970
(250 ng for 24 h), and
immunoblotted with the indicated
antibodies.
MDA-MB-453 cells
with low levels of Src and Stat3
activity were used as control. F,
knockdown of Stat3 reduces AKT1
expression.
MDA-MB-468 cells
were transfected with Stat3-siRNA
(+) or scramble siRNA (-) using
Oligofectamine.
After 48 h of
incubation, cells were lysed and
immunoblotted with the indicated
antibodies.
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transfected with v-Src, pGL3-AKT1-4293/+1888 and wild type Stat3. As shown in Fig.
12A, expression of v-Src alone induces the reporter activity about one-fold, whereas coexpression of v-Src and Stat3 significantly stimulated the AKT1 promoter activity.
Further, wild type Stat3 enhances v-Src induced the AKT1 promoter in a dose dependent
manner (Fig. 12B).

Notably, expression of dominant negative Stat3 considerably

reduces the AKT1 promoter activity induced by v-Src (Fig. 12C). These data indicate
that Stat3 mediates Src stimulated AKT1 promoter activity.

FIGURE 11. Constitutively active Stat3 induces AKT1-4293/+1888, but not AKT1-4293/+1
luciferase activity. NIH3T3 cells were transfected with AKT1-4293/+1-Luc (A and B) and
AKT1-4293/+1888-Luc (C), β-galactosidase and expression constructs are indicated in the
figure. Following a 36-h culture, luciferase activity was measured and normalized to βgalactosidase. Results are the mean ± S.E. of three independent experiments performed in
triplicate.
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Stat3 Response Elements are primarily located within Exon-1/intron-1 Region –
As shown in Fig. 9C, twelve putative Stat3 binding motifs were identified within ~6.0-kb
region upstream translation initiation site of the AKT1 gene.

Src and Stat3 induced

pGL3-AKT1-4293/+1888 but not pGL3-AKT1-4293/+1 activity (Fig. 11), implying that
the Stat3 response elements reside in a region between transcription start site and
translation initiation site.

To test this, we created a series of deletion mutants of the

FIGURE 12. AKT1 promoter is activated by Src through Stat3. A, v-Src, but not wild type
Stat3 stimulates Akt1 promoter activity. NIH3T3 cells were transfected with the indicated
plasmids and subjected to luciferase reporter assay. B and C, v-Src-induced AKT1 promoter
activity was enhanced by coexpression of wild type Stat3 but reduced by dominant negative
Stat3. The transfection and luciferase reporter were performed as described in the legend to
Fig. 5.

AKT1 promoter.

Reporter assay showed that pGL3-AKT1 -325/+1888 was significantly

induced by coexpression of v-Src/Stat3 (Figs. 11C and 13A), whereas deletion of a
region between -4293 and -3172, i.e., pGL3-AKT1 -3172/+1888 considerably reduced
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FIGURE 13. Definition of the
Stat3 response elements. A and
B, major Stat3 response elements
located within the exon 1/intron 1
region of the AKT1 promoter. A
series of deletion mutants of the
AKT1 promoter (left) were
introduced into NIH3T3 cells
together with or without vSrc/Stat3 (A) or constitutively
active Stat3C (B) and then
subjected to luciferase reporter
assay. C, Stat3 binds to 4 sites
of the AKT1 promoter in vivo.
ChIP assay was performed as
described under “Experimental
Procedures.” Triple experiments
showed that Stat3 directly binds
to 4 sites of the AKT1 promoter.
D, mutation of Stat3 DNA-binding
sites within the AKT1 promoter
abrogates
the
Src/Stat3stimulated promoter activity.
Luciferase assay was performed
in NIH3T3 cells transfected with
the AKT1-Luc/-325/-1888 and its
mutants as well as v-Src and
Stat3. E, Stat3 binds to DNA
oligonucleotides corresponding to
Stat3 SIE/GAS binding sites in the
Akt1 promoter.
EMSA of
double-stranded oligonucleotides
containing Stat3-binding sites are
indicated on the top.
Equal
amounts
of
32P-labeled
oligonucleotides were incubated
with nuclear extract prepared
from Stat3C-transfected HEK293
cells in the presence or absence of
a 100 M excess of the unlabeled
oligonucleotides
(competitor).
SIE oligonucleotides were used as
positive control (right panel).
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the promoter activity. Further, pGL3-AKT1-3172/+595 failed to respond to v-Src/Stat3
(Fig. 13A) indicating that the major Stat3 response elements exist in exon-1/intron-1
regions, where there are 7 putative Stat3 binding motifs, as well as in a distal region of
the promoter.

Notably, the results also suggest the presence of a repression factor

binding site(s) within -3172/-325 region because the promoter activity is significantly
increased by deletion of this region as revealed by comparison of the activity between 3172/+1888 and -325/+1888 (Figs. 13A and 13B). To determine if Stat3 could directly
bind to the Stat3-binding site within the AKT1 promoter in vivo and to further define the
Stat3 response elements in the promoter, we carried out chromatin immunoprecipitation
(ChIP) assay, which detects specific genomic DNA sequences that are associated with a
particular transcription factor in intact cells. Human kidney cell line, HEK293, were
transfected with wild-type Stat3 and v-Src and immunoprecipitated with a Stat3 antibody.
The Stat3 bound chromatin was subjected to PCR using oligonucleotide primers that
amplify region spanning each Stat3-binding site within the AKT1 promoter.

As shown

in Fig. 13C, the anti-Stat3 antibody pulled down four Stat3 binding sites (-4230/-4223,
+978/+986, +1324/+1331, and +1443/+1450 (SB1, SB7, SB9 and SB10).

In contrast,

immunoprecipitation with an irrelevant antibody (anti-actin) resulted in the absence of
bands in these sites.
promoter.

These results indicate that Stat3 directly binds to the AKT1

By mutation of Stat3 binding consensus sequences (TT→GG) in AKT1–

325/+1888 that is highly induced by Src/Stat3 and Stat3C (Figs. 13A and 13B), we
further demonstrated that the Stat3 binding sites (SB6, SB9 and SB10) within exon-1 and
intron-1 region are required for Stat3 transactivation of the AKT1 promoter (Fig. 13D).
Moreover, EMSA assay revealed that Stat3 is capable of binding in vitro to DNA
oligonucleotides corresponding to the four Stat3 SIE/GAS binding sites identified in the
Akt1 promoter (Fig. 13E).

Unlike SIE positive control, however, the supershift was not

detected in these four Stat3 binding sites within the promoter (Fig. 13E and data not
shown), which is also observed in other Stat3-induced promoters, such as VEGF, Bcl-xL
and c-Myc (34, 38, 39).
AKT1 Mediates Stat3 Function – Both Stat3 and AKT1 play an essential role in
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cell survival (40- 45). Because AKT1 is a direct target of Stat3, we reasoned that AKT1
could mediate Stat3 function.

To test this hypothesis, conditional knockout of Stat3

MEF cells were infected with Cre and adenovirus expressing wild type AKT1 (Fig. 14A).
Cell survival was evaluated after serum withdrawal for 24 h and 48 h.

Triple

experiments showed that Cre-infected Stat3 MEF increased cell death approximately
30%. Ectopic expression of wild type AKT1 largely rescued knockdown Stat3-induced
cell death (Fig. 14B).

It is noted that Akt1 protein level is considerably decreased in

Stat3-knockout MEFs, further suggesting the critical role of Stat3 in transcriptional
regulation of the AKT1 gene.

To further examine the effects of Akt1 on Stat3 cell

survival signal, constitutively active Stat3-presenting breast cancer cell line MDA- MB468 was treated with Stat3-SiRNA or Akt1-SiRNA as well as the co-transfection of
SiRNA-Stat3 and HA-Akt1 (Fig. 14C).

Tunel assay revealed that knockdown of either

Stat3 or Akt1 induced cell death about 45~50% in response to serum starvation.
However, reintroduction of Akt1 largely inhibits the apoptosis resulting from knockdown
of Stat3 (Fig. 14D).

Disussion
Alterations of the AKT1 at the DNA level have been reported in a single gastric
cancer (23). However, a number of tumors exhibit elevated levels of mRNA, protein
and/or kinase of AKT1 (46), implicating that the AKT1 is regulated at transcriptional,
translational and/or posttranslational levels.
well been documented (47).

Posttranslational regulation of AKT1 has

In this report, we cloned the human AKT1 promoter and

demonstrated a number of transcription factor binding sites within the promoter.
Notably, 12 putative Stat3-binding motifs were identified in the promoter, 4 of which
were shown to directly bind to Stat3 in vivo and in vitro as revealed by ChIP and EMSA
assays. The promoter activity is significantly induced by constitutively active Stat3.
Further, we demonstrated that ectopic expression of constitutively active Stat3 or v-Src
significantly induces mRNA and protein levels of AKT1.

Knockdown Stat3 decreased

Akt1 expression in v-Src transformed cells and mouse embryonic fibroblasts.
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FIGURE 14. Reintroduction of the AKT1 into Stat3-/- MEFs rescues cell death induced by serum
withdraw. A, conditional knock-out of the Stat3 down-regulates Akt1. Stat3 knock-out MEFs were
infected with retrovirus expressing Cre or retrovirus vector alone and immunoblotted with anti-Stat3,
-Akt1, and -actin antibodies (left panels). Right panels show expression of AKT1 by reintroduction
of the AKT1 into Stat3-/- MEFs. B, Stat3- induced cell survival is mediated, at least in part, by
AKT1. Stat3-/- MEFs infected with or without retrovirus-Cre and adeno-AKT1 were assayed for cell
survival after serum withdraw for the indicated times. C and D, knockdown of either Stat3 or Akt1
induces apoptosis and the reintroduction of Akt1 rescues programmed cell death from knockdown of
Stat3. MDA-MB-468 cells were treated with the siRNA of Stat3 (lanes 2 and 3) or Akt1 (lane 5) as
well as scramble siRNA (lanes 1 and 4). HA-Akt1 was simultaneously introduced into the Stat3siRNA cells (lane 3). Following 48 h of transfection and 16 h of serum starvation, apoptotic cells
were assessed by Tunel assay and quantified. Data are representative of three independent
experiments. E, schematic illustration of the regulation of Akt1 by the Src/Stat3 pathway.
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Reintroduction of the AKT1 rescued the cell death in Stat3−⁄− MEFs.

We have

noted that constitutively active, but not wild type Stat3 induces the AKT1 promoter
activity (Fig. 12A).

However, knockout Stat3 in MEFs and breast cancer cells

significantly reduced Akt1 expression (Figs. 14A and 14C).

These data suggest that

basal level of Stat3, which could distribute to the cytoplasm and the nucleus, is required
for expression of normal level of its target genes, such as AKT1.

Ectopic expression of

wild type Stat3 may not increase the nuclear fraction of Stat3 and only constitutively
active Stat3 could translocate into the nucleus and transactivate its target gene(s). This
notion is supported by the observations that Stat3 is persistently activated in many human
cancers and transformed cell lines and that only the activated Stat3 transform cell in cell
culture and induces tumor formation in nude mice (48, 49).

Akt and Stat3 pathways

play an important role in cell processes associated with tumorigenesis such as cell
survival, growth and angiogenesis (50-54).
Cross-talk between these 2 pathways, however, has not been documented.
Therefore, the data presented in this study provide the first evidence of the AKT1 gene as
a direct downstream target of Stat3.

Recently, we have also observed that inhibition of

AKT1 pathway induces hypoxia inducible factor (HIF)- 1α and that knockdown AKT1
largely abrogates the HIF-1α expression stimulated by Stat3 (55).
further support that Stat3 targets Akt to exert its function.
a key molecule for activation of Akt pathway.

These findings

It has been shown that Src is

We and others have previously

demonstrated that constitutively active Src induces Akt kinase activity through PI3K (11,
56).

There is also evidence showing that Src directly binds to Akt and activates Akt

through phosphorylation of Akt at tyrosine-315 (57).
activation by growth factor(s).

Inhibition of Src reduces Akt

In addition, Src mediates estrogen/estrogen receptor and

androgen/androgen receptor activation of Akt (58-61).

In the present report, we present

the evidence of Src regulation of Akt at transcriptional level through activation of Stat3
(Fig. 12E). It is noted that the Akt1 promoter activity induced by src is considerably
lower than that by expression of constitutively active Stat3C (Figs. 11-13), suggesting
that a repressive molecule(s) toward Akt1 promoter is regulated by Src kinase.
In summary, we have isolated and characterized the AKT1 promoter.
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The

promoter sequence analysis demonstrates Stat3 transcriptional regulation of the AKT1.
Further, we have shown that Src/Stat3 induces Akt1 expression through directly binding
to the promoter.

Blocking Stat3 by antisense or genetic knockout significantly

decreases Akt1 expression.

Ectopic expression of AKT1 rescues cell survival

phenotype from Stat3−⁄− MEF cells. These findings are important for several reasons.
First, they provide a mechanistic understanding of regulation of the AKT1 at
transcriptional level. Second, a direct link between AKT1 and Stat3 pathways has now
been established.

Finally, pharmacologicals may have anti-growth effects in the tumor

cells with activation of Stat3 or vice versa.
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Chapter 3
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple
oncogenic growth signaling pathways

Abstract
Vascular endothelial growth factor (VEGF) upregulation is induced by many
receptor and intracellular oncogenic proteins commonly activated in cancer, rendering
molecular targeting of VEGF expression a complex challenge. While VEGF inducers
abound, only two major transcription activators have been identified for its promoter:
hypoxia inducible factor-1 (HIF-1) and signal transducer and activator of transcription
(Stat3). Both HIF-1 expression and Stat3 activity are upregulated in diverse cancers. Here,
we provide evidence that Stat3 is required for both basal and growth signal-induced
expression of HIF-1. Moreover, induction of VEGF by diverse oncogenic growth stimuli,
including IL-6R, c-Src, Her2/Neu, is attenuated in cells without Stat3 signaling. We
further demonstrate that Stat3 regulates expression of Akt, which is required for growth
signal-induced HIF-1 upregulation. Targeting Stat3 with a small-molecule inhibitor
blocks HIF-1 and VEGF expression in vitro and inhibits tumor growth and angiogenesis
in vivo. Furthermore, tumor cells' in vivo angiogenic capacity induced by IL-6R, which
simultaneously activates Jak/STAT and PI3K/Akt pathways, is abrogated when Stat3 is
inhibited. Activation of Stat3 signaling by various growth signaling pathway is prevalent
in diverse cancers. Results presented here demonstrate that Stat3 is an effective target for
inhibiting tumor VEGF expression and angiogenesis.
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Introduction
A crucial role of vascular endothelial growth factor (VEGF) in angiogenesis and
tumor progression in both solid tumors and hematological malignancies has been well
established (1-3).

Inhibiting VEGF and/or VEGF receptor signaling – alone or in

combination with other treatments – has shown promise for tumor antiangiogenesis
therapy in both animal models and cancer patients (4-7)

However, a large array of

oncoproteins overactive in cancer cells act as VEGF inducers, creating a challenge for
blocking tumor VEGF production.

Phosphatidylinosital-3-kinase (PI3K) and Akt

signaling plays an important role in the regulation of VEGF expression (8, 9). Both
PI3K and Akt are frequently activated in a wide range of human cancers by either gainof-function of oncogenic proteins or by loss-of-function of negative regulator,
phosphatase and tensin homologue deleted on chromosome 10 (PTEN) (9, 10).

The

PI3K/Akt signaling pathway upregulates expression of VEGF in both tumor and
endothelial cells, and hypoxia inducible factor-1 (HIF-1) mediates PI3K/Akt-induced
VEGF expression (8, 9, 11). In addition to controlling angiogenesis, HIF-1 regulates
metabolic adaptation to hypoxia and other critical aspects of tumor progression (9).
HIF-1 consists of two subunits: an inducible HIF-1α subunit and a constitutively
expressed HIF-1β subunit (9, 12, 13).

In solid tumors, HIF-1α is frequently upregulated

by intratumoral hypoxia through loss of von Hippel-Lindau (VHL) or p53 function (9).
Deregulation of growth signaling pathways in both solid and hematological malignancies
is common, and upregulation of HIF-1 by abnormal growth signaling has been shown to
be at the protein synthesis level and mediated by PI3K/Akt pathway. It has been
demonstrated that inhibition of mTOR by rapamycin abrogates HIF-1α induction by
growth signaling pathways (9).
Recent studies have also identified Stat3 as a direct transcription activator of the
VEGF gene (14, 15). Activation of Stat3 leads to tumor angiogenesis in vivo (14) and
blocking Stat3 signaling in tumors can reduce tumor angiogenesis (16). A role of Stat3
in upregulating VEGF expression in diverse human cancers has also been demonstrated
(15-17). Importantly, constitutive activation of Stat3 occurs at 50–90% frequency in a
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broad range of human cancers (18 - 22), suggesting that Stat3 activity contributes
significantly to tumor VEGF overproduction.
The Jak/STAT and PI3K/Akt are two parallel pathways mediating functions of
many receptor and nonreceptor tyrosine kinases, including EGFR, Her-2 and c-Src (8, 10,
14, 16, 22 - 24).

IL-6 receptor (IL-6R), which is frequently activated in a wide range of

cancers (25), also signals through both Jak/STAT and PI3K/Akt pathways (19, 26).
Overexpression and/or persistent activation of EGFR/Her-2, Src and IL-6R are known to
promote tumor growth/survival and to induce VEGF expression and angiogenesis (8-10,
12, 16, 20, 22, 23, 27, 28). As IL-6 activates the PI3K/Akt pathway (26), engagement
of IL-6R is predicted to affect HIF-1α expression.

Interestingly, it has been shown that

blocking Stat3, but not PI3K activity, inhibits VEGF expression in tumor cells with
constitutive IL-6R signaling (16), suggesting that Stat3 continues to activate VEGF
expression in the absence of PI3K/Akt signaling.
In this study, we show that Stat3 is obligatory for both basal and growth signalinduced HIF-1α expression.

Moreover, VEGF upregulation by multiple oncogenic

proteins/growth pathways is abrogated in the absence of Stat3 signaling.

We further

demonstrate that Stat3 is required and sufficient for Akt1 expression. Our results also
show that targeting Stat3 by a small-molecule drug inhibits human melanoma growth and
angiogenesis in a xenograft model.

Furthermore, tumor angiogenesis induced by IL-6,

which simultaneously activates Jak/STAT and PI3K/Akt, is attenuated in Stat3
knockdown tumor cells in vivo.

These results demonstrate that Stat3 is a key regulator

of the VEGF gene; in addition to being a direct activator of the VEGF promoter, Stat3 is
required for PI3K-Akt-mediated HIF-1 expression, a key regulator of the VEGF gene.
As such, strategically developing Stat3 antagonists may effectively impair tumor
angiogenesis.

Materials and methods
The following reagents were purchased from various companies as indicated: IL-6
(BD Pharmingen); cycloheximide (Calbiochem); G418 (Cellgro); anti-VEGF monoclonal
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antibody (R&D); anti-HIF-1α polyclonal antibody and anti-β-actin monoclonal antibody
(Santa Cruz Biotechnology); anti-HIF-1α monoclonal antibody (NOVUS Biologicals);
anti-Phospho-Akt (Cell Signaling).
Generation of Stat3 knockdown tumor cell lines and Stat3 knockout mouse
embryonic fibroblasts (MEFs) - MCF-7 breast cancer cells, DU145 prostate cancer cells
and A2058 melanoma cells were cultured in high-glucose RPMI 1640 supplemented with
10% FBS and penicillin–streptomycin.

The Stat3siRNA oligonucleotide, AATTAAAA

AAGTCAGGTTGCTGGTCAAATTCTCTTGAAATTTGACCAGCAACCTGACTTCC,
was inserted into pSilencer 1.0-U6 siRNA expression vector (Ambion).

To generate

siRNA/Stat3 stable tumor cell clones, the siRNAStat3 expression vector was
cotransfected with pcDNA3 into MCF-7 and A2058 cells using Lipofectamine
(Invitrogen), followed by G418 (1 mg/ml) selection. MCF-7 and A2058 clones stably
transfected with the empty vector, pSilencer/pcDNA3, was used as control.

Primary

MEFs were prepared from Stat3flox mice (kindly provided by Drs S Akira and K Takeda
of Osaka University, Japan). To generate Stat3-/- MEFs, MEFs prepared from Stat3flox
mice were transduced with retroviral Cre vector, and selected with puromycin. Deletion
of the Stat3 gene in a majority of the Cre-transduced cells was confirmed by PCR and
Western blot analysis. Control Stat3+/+ MEFs were generated from Stat3flox mice (29),
but the MEFs were transduced with a control empty retroviral vector.
Western blot analysis - MCF-7 cells and MEFs were serum starved for 20 h in
serum-free medium before exposure to IL-6 for 6 h. 50 µg of nuclear or whole-cell
extracts was used for Western blot analysis. HIF-1α rabbit polyclonal antibody (H-206)
(1:500 dilution), HIF-1β mouse monoclonal antibody (1:1500 dilution), Akt1 mouse
monoclonal, anti-phospho-Akt rabbit polyclonal and anti-VEGF monoclonal antibody
(1: 1000 dilutions) were used for the Western blot analyses.

Horseradish peroxidase-

conjugated sheep anti-mouse and donkey anti-rabbit or anti-goat secondary antibodies
were used at 1:2000 and 1:5000 dilutions, respectively.

The signal was developed with

SuperSignal West Pico Chemiluminescent Substrate (PIERCE).
Electrophoretic mobility shift assay (EMSA) - Stat3 DNA-binding assays were
performed as described previously (19)
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Northern blot analysis - TRIzol reagent (Invitrogen) was used to isolate total
RNAs, which were fractionated by 1% agarose–formaldehyde gel electrophoresis,
followed by transferring onto nylon membranes and hybridization with

32

P-labeled

human HIF-1α cDNA.
Pulse-label assays - Pulse-label assays were performed according to previously
described methods (8). Briefly, MCF-7 tumor cells (2 106) were plated in a 10-cm
dish, starved for 20 h and treated with 20 ng/ml IL-6 for 30 min in methionine-free
DMEM.

Before harvesting cells, [35S]Met-Cys was added to final concentration of 0.3

mCi/ml

and

pulse-labeled

for

20–40

min.

Preparation

of

extracts

and

immunoprecipitation with HIF-1α antibody was carried out as described (8).
Cloning and analysis of human Akt1 promoter - To clone the Akt1 promoter, a
DNA fragment containing Akt1 genomic sequences upstream of the translational start site
was obtained by screening a human placenta genomic library (Stratagene) with a 5'
cDNA fragment of the Akt1.

We used the following primers for subcloning of Akt1

promoter region: (5') upstream region 5'-GGCTAGCCACAAAGGACTGTGACC-3'; (3')
downstream region 5'-GCTTCCTTT GCTTCTCCCAGAGG-3'. PCR amplified 2.2-kb
Akt1 promoter fragment was subcloned into the pGL3 vector at BglII-HindIII sites
(Promega).

The construct was confirmed by DNA sequencing. Reporter assays were

performed using the luciferase assay system according to the manufacturer's procedure
(Promega).
Chromatin immunoprecipitation (ChIP) assays - Soluble chromatin was prepared
from a total of 2 107 HEK293 cells that were transiently transfected with v-Src and wtStat3 expression vectors.

Immunoprecipitation was performed with either an anti-

STAT3 antibody or an unrelated antibody (Akt1 antibody).

Following extensive

washing, the immunoprecipitates were crosslinked and treated with proteinase K and
RNase A. Purified DNA was subjected to PCR. The sequences of the PCR primers used
are as follows: region 1 forward (+): 5'-GGATAAAGTGTGCTCAGGTGAGGG-3',
reverse (-) : ATTCTAGGCTTAGAGCCTCCA GCC-3'; region 2 forward (+) : 5'-ACTC
AGCAAGCTCTCAGGCTCTGG-3', reverse (-) : 5'-CATTTACTGAACACC CACTTG
CG-3'. The two fragments from the PCR reactions cover the 2.2 kb Akt1 promoter. PCR
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products were resolved on an agarose gel and visualized by BioImage.
In vivo tumor experiments and matrigel assays - Athymic (nu/nu) 6-week-old
male mice (NCI) were maintained under pathogen-free conditions in accordance with
established institutional guidance and approved protocols. 2 106 A2058 cells were
injected to induce tumors. After tumors reached 3–5 mm in diameter, mice were injected
(i.v.) with either vehicle (10% DMSO/PBS) or 5 mg/kg CPA-7 twice weekly.
assays were performed as described previously (21).

Matrigel

Briefly, 2 106 MCF-7 tumor cells

stably transfected with either an empty control vector or Stat3siRNA expression vector
were suspended in 100 µl PBS and mixed with 0.5 ml Matrigel (Collaborative
Biochemical Products) on ice, followed by subcutaneous injection into the abdominal
midline of nude nice. On day 5, Matrigel plugs were harvested for photography and
hemoglobin content assays.
method.

Hemoglobin quantification was carried out by the Drabkin

Briefly, after dissecting away all the surrounding tissue, Matrigel pellets were

melted at 4 °C and assayed for hemoglobin content (Drabkin's reagent kit, Sigma).
Angiogenesis measurements - Angiogenesis quantification was performed in a
double-blinded fashion by the staff at the Analytic Microscopy Core of Moffitt Cancer
Center and Research Institute.

SPOT Advanced imaging software (v. 3.4.5) was used to

capture bright-field images from two fields for each sample.

Data for these image files

were collected using the Count/Size function of Image-Pro Plus software (v. 5.0).

The

blood vessels (CD31-positive areas) were selected using the histogram and dropper tools.
The Count function was then used to total the number of regions (CD31-positive areas).
Measurement was selected within the Count/Size function and the Area tool was utilized
to calculate the area of CD31-positive blood vessels in each entire field.

Every field in

each of the entire tumor section was examined and included in the analysis.

Results
Activation of IL-6R induces HIF-1α expression - VEGF upregulation in cancer
cells is induced by a large number of receptor and nonreceptor oncoproteins (8, 13, 16, 21,
28, 30, 31).

While many of these oncogenic growth-signaling molecules have been
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shown to induce HIF-1α protein synthesis (9), whether IL-6 could upregulate HIF-1α
expression has not yet been reported.

As IL-6R overactivation has been observed in a

number of human cancers (25), we addressed whether IL-6R engagement activates HIF1α. HIF-1α protein levels in MCF-7 human breast tumor cells were induced by IL-6 in a
dose-dependent manner (Fig. 15a).
It has been well documented that while hypoxia-induced HIF-1α expression is
regulated at the protein stability level, HIF-1α expression induced by oncogenic growth
signaling is regulated at the protein synthesis level (8, 9. 31). An earlier report has also
shown that HIF-1α expression is controlled at the RNA level in rodent cells (32).
therefore determined how IL-6R activation might regulate HIF-1α expression.

We

Northern

Figure 15. Activation of IL-6 receptor
induces HIF-1α expression. (a) MCF-7
breast cancer cells treated with IL-6 for 6 h
at the indicated concentrations had elevated
expression of HIF-1α – but not HIF-1β –
protein. Nuclear proteins were used for the
Western blot analysis. (b) Northern blot
analysis of HIF-1α mRNA levels in MCF-7
tumor cells treated with IL-6 at the indicated
concentrations for 6 h. Ribosomal RNAs
(28S and 18S) are internal controls for RNA
loaded in each lane. (c) Inhibiting protein
synthesis by cycloheximide (CHX)/(100 µm)
indicated a reduction of HIF-1α protein with
time, as shown by Western blot analysis.
Cells were treated by IL-6 (20 ng/ml) for 6 h
before adding CHX. (d) IL-6 at 20 ng/ml
increases levels of both total and activated
Akt proteins in MCF-7 tumor cells as shown
by Western blots. The antibody used for
detecting phospho-Akt (pAkt) recognizes both
Akt1 and Akt2. For the total Akt protein
detection, the antibody is specific for Akt1.
IL-6 treatment also increases Stat3 DNAbinding activity, and expression of VEGF.
This figure worked by Xu, Q.

blot analysis indicates that HIF-1α induction is not regulated at the mRNA level in MCF7 breast cancer cells exposed to IL-6 (Fig. 15b).

Blocking protein synthesis by

cycloheximide (CHX) abrogated the increase in HIF-1α level induced by IL-6 (Fig. 15c).
64

As the half-life of HIF-1α is only approximately 5 min, the disappearance of HIF-1α
protein in the presence of CHX for 15 min or longer suggest that IL-6 signaling affects
HIF-1α expression at the protein synthesis level, consistent with the previously reported
mechanism for growth signaling-induced HIF-1α regulation (8, 31).
It has been also demonstrated that PI3K/Akt pathway is required for growth
signaling-induced HIF-1α upregulation (8, 31). The ability of IL-6 to activate PI3K/Akt
signaling has been reported (26). Activation of IL-6R in MCF-7 cells increased Akt
activity as shown by phosphorylation of AKT, and to a lesser degree, the total protein
level of AKT1 (Fig. 15d).

In addition to PI3K/Akt, the ability of IL-6 signaling to

activate Jak/Stat3 pathway has been documented (19).

Activation of IL-6R in MCF-7

cells, which have little endogenous constitutive Stat3 activity, stimulated Stat3 DNAbinding (Fig. 1d). Activation of Akt and Stat3 by IL-6 was accompanied by an induction
of both HIF-1α and VEGF (Fig. 1c and d).
Stat3 is obligatory for IL-6-induced HIF-1α and VEGF expression - A previous
study showed that in cervical cancer cells with constitutively-activated IL-6R, blocking
Stat3 caused inhibition of VEGF expression (16). In contrast, targeting PI3K, which is
upstream Akt and thereby is expected to inhibit HIF-1α expression, did not interfere with
VEGF expression (16). To investigate whether Stat3 has a regulatory role in HIF-1α
expression, we first determined HIF-1α induction by IL-6R signaling in tumor cells
stably expressing siRNA/Stat3.

MCF-7 tumor cells were transfected with either a

control plasmid vector (pSilencer 1.0-U6) or the same vector encoding siRNA/Stat3.
The effect of the siRNA inhibition of Stat3 in the tumor cells surviving G418 antibiotics
selection was confirmed by Western blot analysis and by EMSA (Fig. 16a, bottom panels).
Furthermore, while control cells exhibit detectable HIF-1α expression, little HIF-1α
protein was detected in MCF-7 cells stably transfected with siRNA/Stat3 with and
without IL-6 stimulation (Fig. 16a).

Moreover, whereas a significant induction of

VEGF by IL-6 stimulation was observed in control MCF-7 cells, no VEGF expression
was detectable in IL-6-treated MCF-7 cells expressing siRNA/Stat3 (Fig. 16a).
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These

data suggest that Stat3 is necessary for both basal and IL-6-induced upregulation of HIF1α and VEGF.
Figure 16. HIF-1α and VEGF
expression induced by both IL-6 receptor
and Src is Stat3 dependent. (a) Both
HIF-1α and VEGF expression is
abrogated in Stat3 knockdown MCF-7
tumor cells. Western blot analysis of
HIF-1α and VEGF protein levels in
control empty vector-transfected and
siRNA/Stat3 expressing MCF-7 tumor
cells. Nuclear protein was used for
detection of HIF-1α and cytoplasmic
proteins from the same cells were
analysed for VEGF expression levels.
Stat3
DNA-binding
activity
was
determined by EMSA, and Stat3 protein
level was assessed by Western blot
analysis. (b) Blocking Stat3 in v-Src
transformed Balb/c 3T3 cells inhibits
HIF-1α expression. 3T3 and v-Src/3T3
cells were infected with MSCV
containing either a control vector
encoding GFP or a dominant-negative
Stat3 mutant, Stat3D.
Western blot
analysis to detect protein levels and
EMSA to detect Stat3 DNA-binding
activity were shown.
SP-1 nuclear
protein was used here as an internal
loading control.
(c) Blocking Stat3
signaling by siRNA in the A2058 tumor
cells, which exhibit activated c-Src,
decreased the expression of both HIF-1α
and VEGF proteins. A decrease in
Stat3 DNA-binding and Stat3 protein
levels in the siRNA/Stat3 A2058 tumor
cells is shown by EMSA and Western blot
analysis, respectively. This figure worked
by Xu, Q

Stat3 is required for HIF-1α and VEGF induction by activated Src and Her-2/Neu
- Like IL-6R signaling, Src tyrosine kinase is known to activate both Jak/Stat3 and
PI3K/Akt pathways (23, 33).

Our previous work has demonstrated that Src tyrosine
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kinase activity-induced VEGF expression requires Stat3 in mouse 3T3 fibroblasts (21),
while other studies have shown that Src activity induces the protein synthesis of HIF-1α
(31).

The question remains whether Stat3 is also required for HIF-1α upregulation

induced by Src activity. Our published data demonstrated that blocking Stat3 in vSrc3T3 cells inhibits VEGF expression (21). Data in Figure 16b show that transforming
3T3 cells with v-Src leads to an increase in HIF-1α protein level, whereas blocking Stat3
signaling in v-Src/3T3 cells with Stat3D, a dominant-negative Stat3 mutant, abrogates vSrc-induced HIF-1α expression (Fig. 16b). We further tested whether blocking Stat3
would inhibit Src-induced HIF-1α expression in human A2056 melanoma cells, which
exhibit activated endogenous c-Src and is responsible for Stat3 activation (23).
Interrupting Stat3 signaling in A2058 tumor cells by siRNA/Stat3 also reduced HIF-1α
protein expression (Fig. 16c).

Moreover, VEGF expression and Stat3 DNA-binding

activity in A2058 melanoma cells were downregulated in the presence of siRNA/Stat3
(Fig. 16c). These data demonstrate that blocking Stat3 signaling inhibits expression of
both HIF-1α and VEGF induced by c-Src activity known to activate both Stat3 and
PI3K/Akt pathways.
In addition to Src tyrosine kinase, activation of Her-2/Neu has been shown to
induce HIF-1α expression through the PI3K/Akt pathway (8).

As shown in Figure 17a,

heregulin induces HIF-1α expression in MCF-7 cells. While MCF-7 breast cancer cells
displayed little endogenous activated Stat3, stimulation with heregulin at 100 ng/ml led to
detectable levels of activated Stat3 (Fig. 17a). This upregulation of Stat3 corresponded
to an increase in HIF-1α expression in control but not siRNA/Stat3 MCF-7 breast cancer
cells (Fig. 17b). Moreover, Her-2 activation by heregulin upregulates VEGF expression
in control but not Stat3/siRNA MCF-7 tumor cells, suggesting a critical requirement for
Stat3 in Her-2-induced HIF-1α and VEGF expression.

Like Her-2, EGFR

engagement/overactivity is known to activate Stat3 signaling (22).

Our results using

Stat3 antisense oligonucleotide indicate that Stat3 is also required for both HIF-1α and
VEGF upregulation by EGF stimulation in DU145 human prostate cancer cells (data not
shown).
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Stat3 regulates Akt gene expression - Our data thus far demonstrate that Stat3 is
required for HIF-1α induction by various growth signaling molecules.

The question

remains as to how Stat3 might regulate HIF-1α expression. Several reports have shown
that HIF-1α induction by Her2/neu and Src is mediated by the PI3K/Akt signaling
pathway (8, 9, 31, 34).

While the ability of Her2/neu to activate Akt has been

demonstrated (35, 36), whether Stat3 is involved in regulating Akt1 expression or activity
remains to be explored. IL-6 signaling-induced total Akt1 protein level was less in Stat3
knockdown MCF-7 breast cancer cells than control MCF-7 cells (Fig. 18a, left). To
eliminate the possibility that tumor cells might have unique mutations that
nonspecifically influence these findings, we performed the same experiments using
primary mouse embryonic fibroblasts (MEFs) with or without the Stat3 alleles (Fig. 18a,
right).
Figure 17. Her-2/Neu-induced HIF-1α
and VEGF expression is Stat3 dependent.
(a) Heregulin upregulates HIF-1α
expression in MCF-7 breast cancer cells
(Western blot). Increased Stat3 DNAbinding activity by heregulin in MCF-7 is
detected by EMSA. (b) HIF-1α and
VEGF upregulation by Her-2 activation
requires Stat3. Western blot analysis of
control
vector
and
siRNA/Stat3transfected MCF-7 cells showed a
requirement for Stat3 in both basal and
Her-2-induced HIF-1α and VEGF
upregulation. . This figure worked by Xu,
Q.

We next investigated whether Stat3 might regulate Akt gene expression.
Transcriptional regulation of the Akt1 gene by Stat3 was investigated by cloning a 2.2 kb
Akt1 promoter DNA fragment, beginning 2.2 kb upstream from the ATG translation start
site, into the luciferase reporter vector, pGL3.

Cotransfecting the pGL3/Akt1 promoter

construct with an expression plasmid encoding a constitutively activated Stat3 mutant,
Stat3C, into NIH 3T3 cells resulted in upregulation of Akt1 promoter activity (Fig. 18b).
The 2.2 kb Akt1 promoter region contains 13 consensus STAT DNA-binding
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sequences,TT(N)4-6AA.

We identified Stat3 binding to the Akt1 promoter region by

chromatin immunoprecipitation (ChIP) assays, followed by PCR using two pairs of Akt1
promoter specific primers.

For the ChIP assays, expression vectors encoding v-Src and

wild-type Stat3 were transfected into HEK293 cells.

Results from ChIP assays indicate

that Stat3 protein binds to both fragments of the 2.2 kb Akt1 promoter region (Fig. 18c).
This together with Western blot analyses data demonstrate that Stat3 participates in
regulating Akt1 expression, suggesting that Stat3 increases HIF-1α levels through Akt1.
Figure 18. Stat3 signaling is required and
sufficient for Akt1 expression.
(a)
Western blot analysis of protein samples
prepared from MCF-7 cancer cells
transfected with either a control vector or
the siRNA/Stat3 expression vector in the
presence or absence of IL-6 (left panel).
MEFs with or without the Stat3 alleles
treated with vehicle or IL-6 were also
subjected to Western blot analysis (right
panel).
(b) Stat3 increases Akt1
promoter activity.
Luciferase activity
after cotransfecting the Akt promoter/luc
reporter construct and an activated Stat3
(Stat3C) expression vector at indicated
DNA concentrations. (c) Stat3 binds to
the Akt1 promoter.
ChIP assays of
HEK293 cells transfected with expression
vectors encoding v-Src and wild-type
Stat3, followed by PCR using two pairs of
primers recognizing two fragments of the
2.2 Akt-1 promoter (Pro). This figure
worked by Park, S.

Effects of small-molecule Stat3 inhibitors on HIF-1α and VEGF expression - To
date, several Stat3-selective small molecule inhibitors – phosphopeptide (37) and
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peptidomimetics (38) as well as platinum (IV) complexes (38) – have been shown to
inhibit Stat3 signaling with IC50 values in the range of 5–250 µM.

We therefore

determined whether interrupting Stat3 signaling by some of the new small-molecule Stat3
inhibitors could block HIF-1 and VEGF expression.

Of the three tumor cell lines used

in this study, A2058 and DU145 display constitutively activated Stat3 (23, 39), whereas
MCF-7 tumor cells do not (Figure 16).

Treating DU145 and A2058 tumor cells with a

Stat3 inhibitor CPA-7 led to a reduction in Stat3 DNA-binding activity and expression of
both HIF-1α and VEGF (Fig. 19a, b).

Figure 19. Targeting Stat3 by a smallmolecule Stat3 inhibitor reduces HIF-1α
and VEGF expression in tumor cells. (a)
Treatment of DU145 prostate cancer cells
with CPA-7 (20 µM) resulted in lowered
Stat3 DNA-binding activity (bottom,
EMSA) and expression of both HIF-1α and
VEGF proteins (Western blot). (b) CPA-7
treatment (20 µM) of A2058 melanoma
tumor cells resulted in inhibition of Stat3
activity and HIF-1α and VEGF expression.
This figure worked by Xu, Q.
Targeting Stat3 inhibits tumor angiogenesis induced by both Jak/STAT and
PI3K/Akt pathways - Our data thus far identify Stat3 as an effective target for blocking
VEGF expression induced by several major activators of VEGF. We next determined
whether blocking Stat3 would result in inhibition of tumor angiogenesis in vivo. A2058
human melanoma tumors, which display activated Stat3 due to activation of endogenous
c-Src, were allowed to reach approximately 5 mm in diameter before mice were treated
with the Stat3 inhibitor, CPA-7.

Although in vivo Stat3 inhibition by CPA-7 in tumors

lasted only one day, treating mice with CPA-7 twice a week (i.v.) significantly inhibited
tumor growth (Fig. 20a).

To assess whether antiangiogenesis effects might contribute to

CPA-7-induced tumor growth inhibition, we harvested three tumors from mice treated
with both vehicle and CPA-7 on day 8 to compare their vascular density. Since tumor
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volumes of CPA-7-treated mice were smaller than control mice, which might potentially

Figure 20. Blocking Stat3 inhibits tumor growth and angiogenesis induced by both Stat3 and Akt.
(a) Targeting Stat3 in human tumors inhibits tumor growth, which is accompanied by a reduction
in tumor vessel density. Nude mice bearing subcutaneous A2058 tumors were treated with a
Stat3 inhibitor, CPA-7, at 5 mg/kg twice weekly. Top: in vivo tumor Stat3 activity after treating
with CPA-7 at indicated times. Bottom: tumor growth after CPA-7 treatment, DMSO=10%. n=8
for each group; *P<0.05. (b) CPA-7 inhibits tumor angiogenesis. Representative microscopic
photos of CD31 antibody-stained tumor sections ( 10). The bar graph shows the means of
neovascular densities s.d. The entire area of each tumor was photographed and included in
the analysis; three tumors from each group were analysed. Two additional DMSO-treated
small-sized tumors were also included, **P=0.004. (c) Tumor angiogenesis as determined by the
Matrigel assays. Top: proliferation rates of MCF-7 cells stably transfected with either a control
vector or Stat3siRNA expression vector. Bottom: microphotos of indicated Matrigel plugs
harvested from mice 5 days after implantation. Control and Stat3 knockdown (siRNA) MCF-7
tumor cells were treated with IL-6 to activate both Stat3 and PI3K/Akt pathways. For each
group, n=4 This figure worked by Briggs, J.

influence tumor vessel density and therefore complicate interpretation of data, we
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included an additional control group that was given vehicle treatment when tumor
volumes were considerably smaller. Thus, several vehicle-treated tumors of comparable
sizes to CPA-7-treated tumors were obtained for measuring microvessel density.
Microvessel density was significantly reduced in tumors from CPA-7-treated mice when
compared to vehicle-treated groups (no difference was detected between the two vehicletreated groups) (Fig. 20b).
Data from the above experiments indicate that targeting Stat3 inhibits tumor
growth involving antiangiogenesis effect.

Since blocking Stat3 is known to induce

tumor cell death and/or growth inhibition, we used an independent system, which does
not involve tumor cell apoptosis, to verify Stat3 as an effective target for antiangiogenesis.
Our results indicate that siRNA/Stat3 transfected MCF-7 tumor cells, having minimal
endogenous Stat3 activity, survive well in short-term culture.

While MCF-7 tumor cells

failed to form tumors beyond 1–2 mm, which prevents us from analyzing microvessel
density within tumors, control and siRNA/Stat3 MCF-7 tumor cells offer a unique
opportunity to use Matrigel assays to determine Stat3's role in tumor angiogenesis
independent of tumor cell survival/apoptosis. For the duration of the Matrigel assay, we
monitored proliferation rates of control and siRNA/Stat3 MCF-7 cells in culture. No
obvious differences in their growth rates were noted during the 5 days – time needed for
completing the Matrigel assay in vivo (Fig. 20c, left panel). As our results demonstrate
that Stat3 is required for HIF-1α and VEGF upregulation mediated by both Jak/STAT and
PI3K/Akt pathways, Stat3 knockdown tumor cells might have reduced tumor
angiogenesis even when both signaling pathways are activated. To test this hypothesis,
control and siRNA/Stat3 MCF-7 tumor cells were serum-starved for 4 h, followed by IL6 stimulation to activate both Jak/STAT and PI3K/Akt pathways. The MCF-7 tumor
cells were then mixed with Matrigel and implanted in vivo. Angiogenesis was
considerably reduced in the Matrigel containing siRNA/Stat3 MCF-7 tumor cells
compared to that of control MCF-7 cells (Fig. 20c).

Moreover, when stimulated by IL-6,

the control MCF-7 tumor cells were able to induce substantially more angiogenesis than
their siRNA/Stat3 counterpart (Fig. 20c).

These results demonstrate that blocking Stat3

in tumor cells abrogates tumor angiogenesis induced by activation of both PI3K/Akt and
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Jak/Stat3 pathways.

Discussion
Our data demonstrate that Stat3 is a key regulator of VEGF induced by multiple
oncogenic growth signaling pathways commonly activated in cancer (19, 22).

The

ability of Stat3 to activate the VEGF gene as a direct transcriptional activator has
previously been demonstrated (14, 15).

The data presented here show that Stat3 is also

required for growth signaling-induced expression of HIF-1, the only other known
inducible transcription factor of the VEGF promoter.

A requirement of Akt1 signaling

for growth signal-induced HIF-1α protein synthesis has been previously established (9).
Our results also identify Akt1 as a target gene of Stat3.

Moreover, our data show that

blocking Stat3 signaling inhibits tumor growth, reduces angiogenesis and abrogates
tumor angiogenesis induced by simultaneous activation of Jak/Stat3 and PI3K/Akt
signaling pathways.

However, whether Stat3 contributes to HIF-1 expression/activity

independent of Akt remains to be determined.
Our data substantiate how targeting a single transcription factor potentially
neutralizes the oncogenic potential of a multitude of upstream genetic aberrations (20,
22).

As proposed by Darnell, transcription factors pose ideal targets for cancer therapy

because a large array of diverse oncogenic/angiogenic proteins feed into a relativelysmall
number of signaling pathways (20).

Oncogenic signaling pathways in turn converge

upon a limited set of nuclear transcription factors, the final 'switches' determining gene
expression patterns and ultimately leading to malignancy (20).

Recent work by Gray et

al. also demonstrates that binding of both Stat3 and HIF to the VEGF promoter is
required for optimal VEGF expression under hypoxia (40). Together with our findings,
these results add a new dimension to the importance of targeting key transcription factors
for cancer therapy.
Although direct inhibition of specific transcription factors with small molecules
has been perceived to be a major challenge, Stat3 peptide inhibitors based upon rational
design have been obtained (37).

Moreover, combinatorial chemical libraries are being
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used to systematically convert these short peptides to peptidomimetics.

The

phosphopeptide sequence, PY*LKTK, and its peptidomimetic derivatives disrupt Stat3
dimerization with biological implications (38). In addition to structure-based rational
approaches, the availability of constructs in which luciferase expression is under the
control of a Stat3-dependent responsive element allows cell-based, high-throughput
screens of random chemical libraries for identifying specific inhibitors of Stat3.

Our

results here demonstrate that Stat3 inhibitors identified from such screens (38) also block
the expression of HIF-1α and VEGF.

Furthermore, inhibiting Stat3 by CPA-7 in vivo

can inhibit tumor growth and tumor angiogenesis.

The success of generating the first

lead compounds inhibiting Stat3 activity and angiogenesis raises the possibility that
targeting Stat3 with potent small-molecule drugs, actively being developed and/or
modified, may provide an exciting novel approach for clinical antiangiogenesis therapy.
This work demonstrates that Stat3 is required for both HIF-1 and VEGF
expression induced by oncoproteins commonly activated in cancer.
angiogenesis at another critical level:

Stat3 also regulates

Stat3 signaling is necessary for endothelial cell

proliferation, migration and microvascular tube formation (41-43).

It has been

demonstrated that VEGFR signals through Stat3 in endothelial cells (42).

Blocking

Stat3 in endothelial cells has been demonstrated to completely inhibit their migration and
vessel formation (43).

Moreover, Stat3 in endothelial cells is obligatory for the

signaling of bFGF receptor (41).

Our present study provides proof-of-concept that

targeting Stat3 effectively blocks production of VEGF and tumor angiogenesis. Based
upon these findings, Stat3 emerges as a molecular target whose inhibition not only
prevents tumor cell production of angiogenic factor(s) but also endothelial cells' response
to these factors.

Interestingly, a similar relationship between tumor Stat3 activity and

dendritic cell Stat3 signaling has been recently described (44). These studies show that
Stat3 activity promotes the production of tumor factors, including VEGF, that activate
Stat3 signaling in dendritic cells, leading to inhibition of dendritic cell maturation.
Conversely, blocking Stat3 signaling in either tumor or dendritic cells abrogates tumorinduced inhibition of dendritic cell maturation (44).

Thus, Stat3 plays a central role in

propagating oncogenic signals from tumor cells to effector cells involved in tumor
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angiogenesis and immune evasion. It has been well established that blocking Stat3
signaling in tumor cells with constitutively activated Stat3 inhibits tumor cell
proliferation and induces apoptosis (20, 22). In diverse human cancers displaying
dependence on persistently activated Stat3 for survival/proliferation (20, 22), targeting
Stat3 is expected to evoke potent antitumor effects through direct tumor cell death,
antitumor immune responses and antiangiogenesis.
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Chapter 4
Identification of 24p3 as a direct target of FOXO3a that is regulated by IL3 through
PI3K/Akt pathway

Abstract
Pro-apoptotic protein 24p3, a member of lipocalins, is induced upon interleukin
(IL)-3 deprivation and plays a pivotal role in induction of apoptosis in hematopoietic
cells (1). However, the molecular mechanism by which IL3 regulates 24p3 expression
is currently unknown.

Here, we show that 24p3 is a direct target gene of FOXO3a and

that PI3K/Akt mediates IL3 action on 24p3 through regulation of FOXO3a.

Inhibition

of PI3K/Akt but not MAPK pathway in FL5.12 cells induced 24p3 expression and
programmed cell death in the presence of IL3. Further, constitutively active Akt largely
attenuated the 24p3 expression and apoptosis in response to IL3 withdrawal. FOXO3a
directly binds to 24p3 promoter and induces the promoter activity.

Akt abrogates wild-

type FOXO3a, but not Akt nonphosphorylatable FOXO3a-3A function toward 24p3
expression and promoter activity. Therefore, these data indicate for the first time that
24p3 is a direct target gene of FOXO3a and that PI3K/Akt but not MAPK mediates IL3regulated 24p3 expression in hematopoietic cells.

Introduction
Apoptosis is a genetically controlled cell suicide program that has been implicated
in diverse biological processes such as the development, homeostasis of multicellular
organisms and defense mechanism against pathogens (2, 3, 4).

Apoptosis in

hematopoietic cells can be induced by withdrawal of cytokines such as IL3 (5).
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The IL3

exerts its survival and proliferative functions through a common signaling subunit, the βc
receptor. Signal transduction events that regulate survival by IL3 are in part mediated
by cytosolic tyrosine kinases (6).

In the absence of IL3, IL3-dependent progenitor cells

undergo apoptosis (7, 8).
Another signaling molecule that is activated by IL3 is phosphoinositide 3-kinase
(PI3K) (9, 10).

PI3K has been implicated in the regulation of survival in various cell

types (11). Akt is a downstream target of PI3K and is able to support the survival of a
number of cell types after survival factor deprivation (4, 12, 13).

Previous study has

also examined the ability of activated forms of Akt to protect cells from death induced by
withdrawal of IL-2 in BAF/3 cells (14).

Akt activity is induced rapidly by IL3 and the

activation of Akt by IL3 depends upon the activity of PI3K.

Previous studies

demonstrated that Akt prevents IL3-dependent FL5.12 cells from IL3 depletion-induced
apoptosis through phosphorylation of BAD (15, 16).
Proapoptotic protein 24p3, however, has been shown to be significantly elevated
at mRNA and protein levels in FL5.12 cells after IL3 withdrawal, which was
demonstrated to be essential for IL3 deprivation-induced apoptosis (1). The conditioned
medium from IL3-deprived cells, which contains secreted 24p3, induced apoptosis in
naïve cells, even when IL3 was present. The 24p3 also induces apoptosis in a wide
variety of leukocytes, indicating that IL3 deprivation enhances 24p3 transcription and
leads to synthesis and secretes 24p3, which induces apoptosis through an autocrine
manner (1).

In addition to murine FL5.12 pro-B cells, many other cell types were

susceptible to 24p3-mediated apoptosis, which include murine primary thymocytes,
murine primary splenocytes, murine primary bone marrow cells, human primary
neutrophils and human peripheral blood lymphocytes.

In contrast, human primary

macrophages, HeLa cells, and Jurkat cells were not susceptible to 24p3-mediated
apoptosis (1).

In addition, 24p3 receptor (24p3R) was recently identified in the FL5.12

cells and found to bind to iron-bound and iron-free forms of 24p3 (17). However, their
effects on cell survival are different.

Iron-bound 24p3 increases intracellular iron

concentration without promoting apoptosis; iron-free 24p3 decreases intracellular iron
levels, which induces expression of the proapoptotic protein Bim, resulting in apoptosis.
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Recent studies also showed that BCR-ABL oncoprotein activates expression of
24p3 but inhibits 24p3R transcription in BCR-ABL positive cells.
leads neighboring cells to apoptosis (17, 18).

The secreted 24p3

By inhibiting BCR-ABL,

imatinib/Gleevec inhibits 24p3 transcription and induces 24p3R expression. As a result,
BCR-ABL positive chronic myeloid leukemia cells undergo the programmed cell death
(18).
Members of forkhead transcription factor family play a proapoptotic role in
neurons or hematopoietic cells subjected to growth factor or cytokine withdrawal. Akt
antagonizes FOXO proapoptotic function through phosphorylation of serine/threonine
residues leading to FOXO translocation from the nucleus to the cytoplasm (19).

In this

report, we show that FOXO3a, a major member of the FOXO family, directly binds to
24p3 promoter and induces 24p3 transcription in response to IL3 withdrawal. Inhibition
of PI3K/Akt but not MAPK pathway antagonizes IL3 down-regulation of 24p3.
Activation of Akt inhibits 24p3 expression and apoptosis that are induced by IL3
deprivation in FL5.12 cells through phosphorylation of FOXO3a.

Material and methods
Cell Culture, Reagents and Transfection – IL3-dependent FL5.12 murine pro-B
cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum
and 10% WEHI-3B-conditioned medium (a source of IL3) (20). PD98059, Wortmannin,
and LY294002 were obtained from Calbiochem.
purchased from Invitrogen.

Human recombinant IGF-1 was

Electroporation was used for transfection of FL5.12 cells.

Cells were electroporated in 1 X 106 cells/400 µl at 275 V, 960 µF with with 25 µg of
plasmid DNA.

Stable clonal cell lines were established after selection with G418 (600

µg/ml).
Plasmids – Human 24P3 gene is amplified with nested PCR using a human
leukemia myeloid cDNA library (Stratagene).

The primers were 5-1: 5’-

AGCAGCCACCACAGCGCCTG-3’, 5-2: CCGGAATTCGGATCCATGCCCCTAGGT
CTCCTGTG-3’, 3-1: 5’-TCAATGGTGTTCGGGCTGGTG-3’, 3-2: 5’TGCTCTAGACT
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CGAGGCCGTCGATACACTGGTCGATTG-3’.

Amplified DNA fragments were

subcloned into the FLAG-tagged mammalian expression vector pcDNA3.5-GW-FLAG
and Glutathione S-Transferase fused vector pGEX-4T-1.

For cloning of human 24p3

promoter, a DNA fragment containing 24p3 promoter sequences were amplified from
human

genomic

DNA

using

the

nested

PCR

and

primers

(5’-1:

5’-

AAGACAGAATATCGCTCTGTTCCAGGC-3’, 5’-2: TTCAGATCTCCAGGCTAAAG
TGCAAAGGGG-3’, 3-1: 5’-CTGCTGGGCCTGGCAGGGGTGGAAG-3’, 3-2: 5’CCCAAGCTTAGGAGGTGGCGAGTGAGAGG-3’).

Amplified DNA fragments were

subcloned into the luciferase reporter vector pGL3 (Promega).

The integrity of all

constructs was confirmed by DNA sequencing. HA-FOXO3a and Flag-FOXO3a-3A
were kindly provided by Dr. B M T Burgering and Akt plasmids have previously been
described (21).
Luciferase Reporter Assay – FL5.12 or HEK293 cells were cultured in 12-well
plates and transiently transfected with pGL3/24p3-Luc, Foxo3a and/or Akt. The amount
of DNA in each transfection was kept constant by the addition of empty vector. After
36 h of transfection, luciferase activity was measured using a luciferase assay reagent
(Promega).

Transfection efficiency was normalized by co-transfection with

galactosidase expressing vector.

The

-

-galactosidase activity was measured by using

Galato-Light (Tropix). Luciferase activity was expressed as relative luciferase activity.
Northern and Western Blot Analysis – Northern blot analysis of total cellular RNA
was performed according to standard procedure.

Briefly, total RNA was

electrophoresed in 1.0% formaldehyde-agarose gels, transferred to Duralon-UVTM
membrane (Srtatagene), and then hybridized with [32p]-labeled 24p3 cDNA probe.
Membrane was exposed to X-ray film and the mRNA levels were visualized and
quantitated using PhosphorImager analysis (Molecular Dynamics).

Western blot

analysis was performed according to standard procedure. Briefly, the cells were lysed
with NP-40 lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 1% Sodium
deoxycholate, 1 mM EDTA, 1 mM PMSF, 5 µg/ml aprotinin and 5 µg/ml leupeptin),
separated in a SDS-PAGE and immunoblotted with appropriate antibodies as indicated in
the figure legends.
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Cell Viability – Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium
assay measuring mitochondrial respiratory function (22).

(MTS)

dye-reduction

FL5.12 cells (104 cells/well)

were plated in 96-well plate and treated with various conditional media and inhibitors as
indicated in the figure legends. Cells were incubated with MTS dye (20 µl/well) for 2 h
and solubilized with 25 µl/well of 10% sodium dodecyl sulphate (SDS) at room
temperature for 4 h.

Absorbance was determined in a Titertek plate reader at 490 nm.

ChIP Assay – ChIP assay was performed essentially as previously described (23).
Briefly, solubilized chromatin was prepared from a total of 2 X 107 asynchronously
growing FL5.12 cells that were electrophorated with HA-Foxo3a.

The chromatin

solution was diluted 10-fold with ChIP dilution buffer (1.1% Triton –100, 1.2 mM EDTA,
167 mM NaCl, 16.7 mM Tris•HCl, pH 8.1, 0.01% SDS, protease inhibitors), and
precleared with protein-A beads. The precleared chromatin solution was divided and
utilized in immunoprecipitation assay with either an anti-Foxo3a antibody (Upstate) or
anti-actin antibody.

Following wash, the antibody-protein-DNA complex was eluted

from the beads by resuspending the pellets in a buffer (1% SDS and 0.1 M NaHCO3) at
room temperature for 20 min.

After reverse-crosslink, protein and RNA were removed

by incubation with 10 µg of proteinase K and 10 µg of RNase A at 42 °C for 3 h.
Purified DNA was subjected to PCR with primers specific for 3 putative Foxo3a-binding
sites within the 24p3 promoter.

The sequences of the PCR primers used are as follows:

region 1 forward (-): 5’-CAGGAGCAGCAAACAGGTAAATCAATGGCC-3’, reverse (): 5’-CATCCCTCTGTCCCTGGCCATAACCTTG-3’; region 2 forward (-): 5’- TACCT
TTGAAAGCAGCCACAAGGGCGTGG-3’, reverse (-): 5’-AACAGACCCTGTGCAGC
TTCCTTGTCTGG-3’; region 3 forward (-): 5’- TTGCTCAACCTTGCACAGTTCCGA
CCTGG-3’,

reverse

(-):

5’-GGCCATGGTTTCCACAGCTACATGGTCTG-3’.

Amplified PCR products were resolved in 1.2% of agarose gel and visualized by
BioImage.
DNA Fragmentation and Caspase Activity –Approximately 2

g DNA obtained

from cells treated with different reagents was separated on 1.5% agarose gel and
visualized. Caspase activity was measured with the Caspase-Glo® 3/7 Assay system
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according to manufacture’s procedure (Promega).

Figure 21. PI3K/Akt, but not MAPK, pathway mediates IL3 regulation of 24p3 and cell
survival. (A) FL5.12 cells were treated with indicated agents and immunoblottted with
indicated antibodies. (B and C) FL5.12 cells were treated with indicated agents and cell
death was measured by MTS and DNA fragmentation. (D and E) FL5.12 cells were
stably transfected with constitutively active Akt or DN-Akt and treated with indicated
agents. Cell death was examined as panels B and C.
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Results

PI3K/Akt but not MAPK pathway inhibits 24p3 expression induced by IL3deprivation and mediates IL3 survival signal in FL5.12 cells. Previous studies have
demonstrated that IL3 activates Akt that leads to phosphorylation of BAD and cell
survival in IL3-dependent FL5.12 cells.

Deprivation of IL3 reduces Akt activation and

BAD phosphorylation that results in programmed cell death (15, 16).

Transcription

induction of 24p3, however, has been shown to play a pivotal role in induction of
apoptosis in response to IL3 withdrawal (1). To determine if PI3K/Akt pathway is
involved in IL3 regulation of 24p3, FL5.12 cells were cultured in IL3 free medium for 12
h and switched into the medium containing IL3, PI3K inhibitor LY294002 or MEK
inhibitor PD98059.

Immunoblotting analysis revealed that upon IL3 withdrawal, 24p3

was increased approximately three fold.
reduced the 24p3 expression.

Addition of IL3 into the medium significantly

However, inhibition of PI3K/Akt pathway with either

LY294002 or dominant negative Akt largely abrogated the IL3-repressed 24p3 whereas
MEK inhibitor PD98059 had no effect on 24p3 expression.

Furthermore, stable

expression of constitutively active Akt inhibited 24p3 induced by IL3 deprivation (Fig.
21A).
Figure 22.
PI3K/Akt
pathway regulates 24p3
at transcriptional level.
(A and B) Northern blot
analysis. FL5.12 cells
were transfected and
treated with indicated
plasmids and agents.
Total RNA was isolated
and subjected to Northern
blot analysis using [32P]dCTP labeled 24p3 cDNA
as probe (upper panels).
The 28S and/or 18S were
used as a loading control
(bottom panels).
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We further examined the role of PI3K/Akt and MAPK pathways in IL3-dependent
cell survival.

FL5.12 cells were treated with or without LY294002 or PD98059 in the

presence or the absence of IL3.

As shown in figure 21B and 21C, inhibition of PI3K

induced more significant cell death than inhibition of MAPK pathway.

Moreover,

ectopic expression of constitutively active Akt largely rescued the programmed cell death
induced by IL3 deprivation (Figs. 21D and 21E), whereas expression of dominant
negative Akt inhibited IL3-protected apoptosis (Fig. 21E). These data indicate that
PI3K/Akt pathway, but not MAPK, mediates IL3 action toward 24p3 and cell survival.

PI3K/Akt inhibits 24p3 expression at transcriptional level.

Having observed

PI3K/Akt pathway mediating IL3-regulated 24p3 protein expression, we next examined
if 24p3 is regulated by PI3K/Akt at transcriptional level. Following culture of FL5.12
cells in the absence or the presence of IL3 and treatment with LY294002, Akt inhibitor
API-2 or PD98059, Northern blot analysis shows that mRNA level of 24p3 is elevated
upon IL3 withdrawal. Addition of IL3 repressed 24p3 mRNA expression. Inhibition
of PI3K or Akt but not of MEK inhibits IL3 stimulation-reduced 24p3 mRNA (Fig. 21A
and data not shown). Further, expression of constitutively active Akt inhibited IL3
withdrawal-induced 24p3 whereas dominant negative Akt partially abrogated IL3repressed 24p3 mRNA expression (Figs. 22A and 22B).

Isolation of human 24p3 promoter and IL3 inhibition of 24p3 promoter activity
through PI3K/Akt pathway.

To further analyze the transcriptional regulation of 24p3

gene by Akt, we defined transcription start site using 5’ race and cloned the 5’ flanking
region of the human 24p3 gene (Fig. 23A).

Sequence analysis revealed 3 putative

binding sites (TTGTTTAC) for Foxo3a (–1178/-1163, -903/-892, and –69/-52), and one
site for NF-κB, CREB and C/EBP in the 24p3 promoter.

To examine if the 24p3

promoter is regulated by IL3, FL5.12 cells were transfected with pGL3-24p3-Luc and βgalactosidase, and then cultured in a medium supplement with or without IL3.

Figure

23C shows that 24p3 promoter activity was induced about 22 fold upon IL3 withdrawal,
whereas addition of IL3 reduced the promoter activity.
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However, inhibition of PI3K

Figure 23. Cloning of
human 24p3 promoter
and IL3 regulation of
24p3 promoter activity
through
PI3K/Akt
pathway. (A) DNA
sequence of human
24p3 promoter. TATA
box is labeled by bold.
Putative
FOXO3a
binding sites are boxed,
C/EBP
sites
are
underlined and NFκB
site
is
double
underlined.
(B)
A
diagram displays the
location of putative
FOXO3a-binding sites
indicated
by
blue
column within the 1.5kb 24p3 promoter. (C
and D) IL3 regulates
24p3 promoter via
PI3K/Akt
pathway.
Luciferase
reporter
assay was performed by
transfection of FL5.12
cells with indicated
plasmids and treated
with indicated agents.
Following
a
36-h
culture,
luciferase
activity was measured
and normalized to βgalactosidase. Results
are the mean ±S.E. of
three
independent
experiments performed
in triplicate.

but not of MAKP largely abrogated IL3-represssed 24p3 promoter activity.
Furthermore, IL3 deprivation-induced 24p3 promoter activity was reduced by expression
of constitutively active Akt in a dose-dependent manner (Fig. 23C).
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These findings

suggest that IL3 controls 24p3 transcription by regulation of transcriptional factor(s)
through a PI3K/Akt-dependent pathway.

Figure 24. FOXO3a induces
24p3 promoter activity that is
inhibited by IL3/Akt signaling.
(A) FOXO3a induces 24p3
promoter activity.
HEK293
cells were transfected with
pGL3-24p3-Luc,
galatosidase and increasing
amounts
of
FOXO3a.
Following incubation for 36 h,
luciferase activity was measured
and
normalized
to
βgalactosidase. (B) Akt inhibits
FOXO3a-induced
24p3
promoter activity.
HEK293
cells were transfected with
indicated plasmids and reporter
assay was performed as
described above. (C) IL3
regulates 24p3 promoter through
Akt phosphorylation FOXO3a.
FL5.12 cells were stably
transfected
with
wild-type
FOXO3a
and
Aktnonphosphorylatable FOXO3aA3 as well as 24p3-Luc and then
cultured in the presence or the
absence of IL3. The reporter
assay was performed as
described above.

FOXO3a mediates IL3 signals to regulate 24p3 promoter.

Previous studies

have shown that expression of FOXO transcription factor induces cell death and cell
growth arrest through transactivation of a number of molecules such as Bim, FasL and
Gadd45 (23, 24, 25).

Because 24p3 promoter contains 3 putative FOXO binding sites

and FOXO is a major target of Akt (25), we next examined if 24p3 promoter is directly
regulated by FOXO.

HEK293 cells were transfected with pGL3-24p3-Luc,
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β-galatosidase and increasing amounts of FOXO3a, one of the mostly studied FOXO
family members.

Figure 24A shows that 24p3 promoter activity was induced by

FOXO3a in a dose-dependent manner. Co-expression of constitutively active Akt
repressed the promoter activity induced by FOXO3a but not FOXO3a-A3, a mutant form
which can not be phosphorylated by Akt (Fig. 24B).

Moreover, FOXO3a-induced 24p3

promoter activity was largely inhibited by stimulation of F5.12 cells with IL3.

In

contrast, IL3 treatment had no effect on FOXO3a-A3-stimulated 24p3 promoter activity
(Fig. 24C).

Figure 25.
FOXO3a regulates
24p3
expression
through
a
phosphorylation-dependent manner.
(A) Phosphorylation of FOXO3a
correlates with expression of 24p3 in
response to IL3.
FL5.12 cells were
transfected with pcDNA3 or Myr-Akt,
cultured in the presence or the
absence of IL3 and immunoblotted
with indicated antibodies. (B and C)
IL3 failed to inhibit 24p3 expression
induced by constitutively active (Aktnonphosphorylatable) FOXO3a-A3.
FL5.12 cells were transfected/treated
with indicated plasmid and agent and
subjected immunoblotting (B) and
Northern blot (C) analyses.
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To further demonstrate that IL3 regulates 24p3 through Akt-FOXO3a axis, we
examined the levels of FOXO3a phosphorylation and 24p3 expression in response to IL3
treatment.

FL5.12 cells were transfected with constitutively active Akt (Myr-Akt) or

pcDNA3 vector and treated with or without IL3. Immunoblotting analysis shows that
IL3 deprivation reduced phosporylation levels of FOXO3a and Akt and increased 24p3
expression in pcDNA3- but not myr-Akt-transfected cells (Fig. 25A).

Further,

expression of non-phosphorylatable FOXO3a-A3 abrogated IL3-inhibited 24p3
expression (Figs. 25B and 25C).

Taken collectively, these data indicate that 24p3 is a

direct downstream target of FOXO3a and that FOXO3a-regulated 24p3 is controlled by
IL3-Akt pathway.

Figure 26. Define the FOXO3a response elements in 24p3 promoter. (A) -1309/-304 of 24p3
promoter is a FOXO3a response region. Reporter assay was performed as described above
except using different deletion mutants of 24p3 promoter-driven luciferase as reporters. (B)
FOXO3a directly binds to two putative FOXO sites within the response region in vivo. FL5.12
cells were transfected with HA-FOXO3a and subjected into chromatin immunoprecipitation
assay. (C) Mutation of the FOXO3a binding sites reduces 24p3 promoter activity. The F5.12
cells were transfected with indicated plasmids and reporter assay was performed as described
above.

Define the FOXO3a response element(s) in the 24p3 promoter. 24p3
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promoter contains 3 putative FOXO binding sites, and thus we next defined which
binding site(s) is required for the promoter to respond to FOXO3a transcription factor.
A series of deletion mutants of 24p3 promoter were created and used for reporter assay.
As seen in Fig. 26A, a mutant with deletion of -340/+18 considerably enhanced the
promoter activity induced by FOXO3a, whereas the mutant with deletion of a region (1309/-304) containing the second and/or the third binding site reduced FOXO3astimulated promoter activity, suggesting that major response elements to FOXO3a are
located in last two FOXO binding sites and that a repression element(s) may reside within
a region between -304bp and +18bp.

Furthermore, ChIP assay revealed that FOXO3a

bound to the second and third sites in vivo (Fig. 26B). In addition, luciferase reporter
assay using point mutation of each FOXO3a binding site demonstrated that these two
binding sites are required for the 24p3 promoter to respond to FOXO3a (Fig. 26C).

Figure 27. Activation of Akt not
only represses 24p3 expression
induced by IL3 withdrawal but also
inhibits 24p3-induced cell death.
(A) Conditioned medium from FL5.12
but not Myr-Akt-FL5.12 cells induces
death of naïve FL5.12 but not of MyrAkt-FL5.12 cells.
Insert shows
immunoblot
of
medium
from
pcDNA3-, Myr-Akt-transfected and
parental FL5.12 cells cultured with or
without IL3 for 36 h. Cell viability
was examined by MTT assay.
(B)
IGF1 inhibits apoptosis after IL3
withdrawal but not 24p3-containing
CM addition in naïve FL5.12. CMs
prepared from indicated cells
cultured in the medium with or
without IL3 and/or IGF1 were added
to naïve and Myr-Akt-transfected
FL5.12 cells.
Cell viability was
quantitated by MTT assay.
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Conditioned Medium (CM) from Myr-Akt-FL5.12 Cells Fail to Induce
Apoptosis; Myr-Akt-FL5.12 Cells Resist to the Apoptosis Induced by CM
Expressing 24p3.

Previous studies have shown that CM from IL-3 deprived FL5.12

cells expresses 24p3 and induces apoptosis in a number of hematopoietic cell lines (1).
Since Akt/FOXO3a mediates IL3 action on 24p3 and constantly active Akt inhibits 24p3
expression induced by IL3 withdrawal, we further examined the cell viability of naïve
FL5.12 cells following treatment with different CMs.

We collected medium from

pcDNA3-, Myr-Akt-transfected and parental FL5.12 cells cultured with or without IL3,
added the medium to naïve FL5.12 cells, and analyzed cell viability by MTT assay.
Conditioned medium from pcDNA3-transfected and parental FL5.12 cells cultured
without IL3 induced cell death.

However, the medium from constitutively active Akt-

transfected FL5.12 cultured in the absence of IL3 had no significantly effect on cell
viability, which is comparable to naïve FL5.12 cells treated with the medium from
FL5.12 cultured in the presence of IL3.

In addition, conditioned medium from FL5.12

and pcDNA3-FL5.12 cultured in the absence of IL3 failed to induce cell death in
constitutively active Akt-transfected F5.12 cells (Fig. 27A).

Further, the medium from

FL5.12 cells cultured in the absence of IL3 and presence of IGF1, a growth factor
primarily activating PI3K/Akt pathway, had no significant effect on cell survival (Fig.
27B).

These results further support our findings that 24p3 is regulated by IL3 through

PI3K/Akt/FOXO pathway and that activation of Akt not only inhibits 24p3 expression
induced by IL3 deprivation but also reduces 24p3-induced cell death.

Discussion
Previous studies have shown that Akt mediates IL3 cell survival signal through
phosphorylation of Bad, which leads to the switching of Bad from Bcl-2 and Bcl-XL
complex into 14-3-3 and the loss of its proapoptotic function (15).
24p3 has recently been identified as a key molecule for IL3 withdrawal-induced
apoptosis in IL3-dependent cells (1).

Neutralization of 24p3 using anti-24p3 antibody

largely reduces cell death induced by IL3 deprivation (1). 24p3 is transcriptionally
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regulated by IL3 signaling, i.e., withdrawal IL3 induces whereas additional IL3 represses
24p3 expression.

We demonstrated in this study that IL3 regulation of 24p3 is mediated

by Akt/FOXO3a axis. Transcription factor FOXO3a directly binds to and transactivates
24p3 promoter.

The regulation of 24p3 by FOXO3a is modulated by IL3 through

PI3K/Akt but not MAPK pathway.

IL3 activates Akt and leads to phosphorylation and

inhibition of FOXO3a action on 24p3, whereas IL3 deprivation resulted in
dephosphorylation and activation FOXO3a and increased expression of 24p3. Moreover,
constitutively active Akt inhibits death of FL5.12 cells after deprivation of IL3, which is
due to suppression of 24p3 transcription through phosphorylation of FOXO3a.
FOXO transcription factors are crucial regulators of cell fate.

It has been shown

that FOXO transcription factors control cell survival by regulation of the expression of
genes.

Common FOXO target genes that are involved in apoptosis include bNIP3 and

BCL2L11, which encode the pro-apoptotic Bcl-2 family members, bNIP3 and Bim,
respectively (23, 24).

In addition to direct targets, FOXO also indirectly down-regulate

the expression of the pro-survival Bcl-XL by inducing the expression of the
transcriptional repressor Bcl-6 (26). In neurons, FOXO3a triggers cell death circuitously
by inducing the expression of Fas ligand, which triggers programmed cell death through
the death receptor pathway (25). In hematopoietic cells, we showed in this report that
24p3 is a direct target of FOXO3a and provokes cell death after IL3 deprivation.
FOXO3a up-regulates 24p3 transcription through directly binding to 24p3 promoter.
In addition, a previous study demonstrated that 24p3 induces apoptosis in FL5.12
cells even the culture medium containing IL3 (1). However, our data showed that
constitutively active Akt-transfected FL5.12 cells resist to apoptosis induced by CM
expressing 24p3 (Fig. 27).

Since IL3 induces Akt activation, it is hard to understand

why constitutively active Akt could override 24p3-induced cell death.

A possible

explanation is that constitutively active Akt inhibits 24p3 receptor cascade and/or other
proapoptotic molecules prior to 24p3 treatment.

Further investigations are required for

the underlying mechanism.
In summary, we demonstrated that FOXO3a directly regulates 24p3 expression
and mediates IL3 signaling in hematopoietic cells. Deprivation of IL3 decreases Akt
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phosphorylation of FOXO3a, which leads to activation of 24p3 transcription and cell
death.

Inhibition of Akt but not MAPK increases 24p3 expression, whereas activation

of Akt reduces mRNA and protein levels of 24p3 and inhibits 24p3-induced apoptosis.
These findings indicate that 24p3 is a direct target of FOXO3a and that PI3K/Akt but not
the MAPK pathway mediates IL-3 action on 24p3 in hematopoietic cells.
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CHAPTER 5
Identification and characterization of a transcription factor TZP that interacts with
p53 and Akt
ABSTRACT
Akt regulates a diverse array of cellular functions, including apoptosis, cellular
proliferation, differentiation, and metabolism. While a number of molecules have been
identified as upstream regulators, such as PI3K, PDK1 and PTEN, or downstream targets,
such as MDM2, Bad, and FOXO, of Akt, the mechanisms by which Akt regulates the
cellular processes remain elusive. Here, we identify a novel transcription factor, dubbed
TZP (referring to Tudor and Zinc finger domain containing Protein), which binds to Akt
and p53.

TZP is an evolutionarily conserved nuclear protein. Overexpression of TZP

inhibits cell growth and DNA synthesis as well as cell survival. TZP not only directly
regulates p53 at the transcription level but also binds to and stabilizes p53 protein, which
leads to increase of expression of p53 downstream target genes, such as p21, BAX, and
GADD45.

Knockdown of TZP significantly reduces p53 expression.

Akt

phosphorylates TZP in vitro and in vivo which results in its translocation from the nucleus
to the cytoplasm and attenuation of its function toward p53.

These data suggest that

TZP plays an important role in maintaining normal p53 function and that Akt induces cell
growth and survival through inhibition of TZP/p53 axis.

Introduction
Akt was originally discovered as an oncogene transduced by the acute
transforming retrovirus (Akt-8), which was isolated from an AKR thymoma (1, 2), and
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subsequently found to encode a serine/threonine protein kinase (3).
as protein kinase B (4, 5).

Akt is also known

Viral akt is highly activated and oncogenic due to the fact

that v-akt is associated with the cell membrane through a myristylated Gag protein
sequence fused to the N-terminus of Akt (3).

The important role of Akt in

transformation and cancer was shortly thereafter strengthened by the cloning of the AKT2
gene (6) and the discovery that AKT2 is frequently amplified and overexpressed in human
cancers (6-8).
Akt3.

In mammals, there are three isoforms of Akt, termed Akt1, Akt2, and

These isoforms are products of distinct genes but are highly related, exhibiting

>80% protein sequence identity and sharing the same structural organization.

The

members of Akt family are activated by various stimuli in a phosphatidylinositol 3-kinase
(PI3K)-dependent manner (9-12). Activation of Akt depends on the integrity of the
pleckstrin homology (PH) domain, which mediates its membrane translocation, and on
the

phosphorylation

of

Thr308

in

the

activation

loop

and

Ser473

(13-16).

Phosphoinositides, PtdIns-3,4-P2 and PtdIns-3,4,5-P3, produced by PI3K bind directly to
the PH domain of Akt, driving a conformational change in the molecule, which enables
the activation loop of Akt to be phosphorylated by PDK1 at Thr308 (17). Full activation
of AKT1 is also associated with phosphorylation of Ser473 (18) within a C-terminal
hydrophobic motif characteristic of kinases in the AGC kinase family. Although the
role of PDK1 in Thr308 phosphorylation is well established, the mechanism of Ser473
phosphorylation is controversial. A number of candidate enzymes responsible for this
modification have been put forward, including integrin-linked kinase (19), PDK1 when in
a complex with the kinase PRK2 (20), Akt itself, through autophosphorylation (21),
PKCα (22), PKCβII (23), DNA-dependent kinase (24), and the rictor-mTOR complex
(25).

The activity of Akt is negatively regulated by tumor suppressor PTEN, which is

frequently mutated in human malignancy (26-29). Akt phosphorylates and/or interacts
with a number of molecules to exert its normal cellular functions, which include roles in
cell proliferation, survival, differentiation and metabolism (30).
The p53 gene represents one of the most studied tumor suppressor genes in
biology.

It is frequently mutated in a wide range of tumors and plays an essential role in
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maintaining genomic integrity (31–35).

Exposure of a normal cell to genotoxic stress

leads to an increase in p53 protein levels.

The increase in p53 protein results in an

increase in p53-dependent transcription of p53 target genes, which subsequently leads to
cell cycle arrest or apoptosis (36–39).

The practical implication of these facts is that

when a cell undergoes alterations that predispose it to become cancerous, p53 is activated
to trigger checkpoints that either take care of the damage through its DNA repair function
or eliminate the affected cells through induction of apoptosis, thereby preventing the
development of tumors (34, 40).

Therefore, regulation of p53 activity is critical to allow

both normal cell growth and tumor suppression.

The current dogma is that p53

regulation in DNA damage-activated cell cycle checkpoints occurs at the level of protein
degradation and protein stability.

This includes regulation of p53 protein stability,

posttranslational modifications, protein-protein interactions, and subcellular localization.
These mechanisms keep a strong check on p53 in normal circumstances but allow rapid
activation in response to cellular stress that might be caused by or contribute to oncogenic
progression (33, 34). However, little is known about the transcriptional regulation of
the p53 gene and the contribution of this transcriptional control of p53 itself to DNA
damage–induced cell cycle checkpoints.

Previous studies have shown that p53 is

transcriptionally up-regulated by the homeobox protein HOXA5 (41, 42). Recently, the
Bcl6 oncoprotein was found to suppress p53 expression through binding to p53 and
inhibiting p53 promoter activity (43). Several studies have raised the possibility that
p53 may also be regulated at the transcriptional level in response to genotoxic stress (44,
45).

However, the underlying mechanism and functional consequences remain unclear.

A link between Akt and p53 pathway was established by identification of Akt
phosphorylation of MDM2 (46).

MDM2 is an E3 ubiquitin ligase that negatively

regulates p53 transcriptional activity (47).

Phosphorylation of MDM2 on serine166 and

serine186 by Akt stimulates translocation of MDM2 to the nucleus, where it binds to p53
and targets p53 degradation by proteasome (48-50).

Here, we identified a novel

transcription factor TZP that interacts with both p53 and Akt. TZP directly binds to p53
promoter and upregulates p53 at mRNA level. Notably, TZP also forms a complex with
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p53 and enhances p53 stability.

As a result, TZP inhibits cell growth, cell cycle

progression and DNA synthesis as well as cell survival. Akt phosphorylates TZP on
serine-291 within TZP nuclear localization signal, which leads to the translocation of TZP
from the nucleus to the cytoplasm and loss of its function toward p53.

Material and methods
Yeast Two-hybrid Screening and Expression Constructs—Yeast two-hybrid system
was employed to identify Akt interaction protein(s) using the C-terminal regulatory
region of Akt as bait following the manufacturer's procedure (Clontech).

A human fetal

brain library (Clontech) was screened. Full-length cDNA of TZP, amplified from a
human Marathon-ready skeletal muscle cDNA (Clontech) by PCR, was subcloned into
3X Flag-pcDNA3, pEGFP-C1 and pTRE-tight vectors. TZP mutants were created with
the

QuikChange

multiple

site-directed

mutagenesis

kit

(Stratagene).

The

cytomegalovirus-based expression constructs encoding HA-tagged, p53, MDM2, and
ubiquitin as well as pGL3-p21-Luc and -p53-Luc have previously been described (51,
52).
Cell Culture and Transfection - HEK293, MCF7, HeLa, HCT116, and A-T cell
lines GM9067 and GM9067-AT were obtained from ATCC and cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal bovine serum.

Lipofectamine

plus (Invitrgen) was used for transfection.
Glutathione S-transferase (GST) Fusion Protein and Generation of Anti-TZP
Antibody - Different portions of TZP, including AT-hook region, C2H2 zinc finger domain,
C-terminal motif, and the regions containing each Akt phosphorylation site, were
subcloned into pGEX-4T1.

Expression and purification of the GST fusion protein were

carried out as previously described (53). Polyclonal anti-TZP antibody was raised in
New Zealand White rabbit. Approximately 300 µg of GST fusion protein (GST-TZP/AThook and GST-TZP/C-terminal) was used to immunize rabbit every 2 weeks; rabbits were
bled 10 days after each booster injection.

The anti-TZP antibodies were affinity purified

with Affi-Gel protein A (Bio-Rad).
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Northern Blot Analysis – Northern blot analysis of total cellular RNA was
performed according to standard procedures. RNA was extracted using the RNeasy
purification kits (QIAGEN Inc.).

Total RNA was electrophoresed in 1.0%

formaldehyde-agarose gels, transferred to Duralon-UVTM membrane (Srtatagene), and
then hybridized with randomly primed

α-32P-labeled cDNA probes for TZP or p53.

Membranes were exposed to autoradiography and the mRNA levels were visualized and
quantified using PhosphorImager analysis (Molecular Dynamics).
Immunoprecipitation and Immunoblotting Analysis - Cells were lysed in a lysis
buffer containing 20 mM Tris-HCl (pH 7.5), 137 mM NaCl, 15% (v/v) glycerol, 1%
Nonidet P-40, 2 mM phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin and leupeptin, 2
mM benzamidine, 20 mM NaF, 10 mM NaPPi, 1 mM sodium vanadate, and 25 mM βglycerolphosphate. Lysates were subjected to immunoprecipitation and immunoblotting
analysis as previously described (54).
protein G (2:1)-agarose beads.

Briefly, lysates were precleared with protein A-

Following the removal of the beads by centrifugation,

lysates were incubated with appropriate antibodies in the presence of protein A-protein G
(2:1)-agarose beads for 2 hours.

After wash, the immunoprecipitates were subjected to

SDS-PAGE and in vitro kinase assay. Protein expression was determined by probing
Western blot of the immunoprecipitates or total cell lysates with the appropriate
antibodies as noted in the figure legends.
GST Pull-down Assay - Glutathione-agarose beads coupled to GST alone, GSTp53, and GST-deletion mutants of p53 were incubated with whole cell lysate ( 800 µg of
protein) for 2 h at 4 °C. After wash four times with lysis buffer, the beads were
subjected to Western blot analysis with appropriate antibodies.
In vitro Kinase Assay—Akt kinase assay was performed as previously described
(55, 56).

Briefly, reactions were carried out in the presence of 10 µCi of [γ-32P] ATP and

3 µM cold ATP in 30 µl of buffer containing 20 mM Hepes (pH 7.4), 10 mM MgCl2, 2
mM MnCl2, and 1 mM dithiothreitol. GST-TZPs were used as exogenous substrate.
After incubation at room temperature for 30 min, the reactions were stopped by adding
protein loading buffer and separated in SDS-PAGE gels. Each experiment was repeated
three times.

The relative amounts of incorporated radioactivity were determined by
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autoradiography and quantified with a Phosphorimager (Amersham Biosciences).
In Vivo [32P]-orthophosphate Cell Labeling – HEK293 cells were co-transfected
with FLAG-TZP and constitutively active Akt or pcDNA3 and labeled with [32P]orthophosphate (0.5 mCi/ml) in phosphate- and serum-free minimum essential medium
for 4 hours.

Cell lysates were subjected to immunoprecipitation with anti-FLAG

antibody (Sigma).

The immunoprecipitates were separated by SDS-PAGE and

transferred to membrane. The phosphorylated TZP was examined by autoradiography
(57).
Cell proliferation, Viability and DNA Synthesis Assays - TZP-, TAP/Akt and
pcDNA3-transfected cells were plated in 35-mm dishes at a density of 1.0 x 105 cells/dish.
Cell numbers were measured with a Coulter Counter (Coulter Electronics, FL) daily for
up to 3 days following seeding.

MTS assays were performed according to the

manufacturer’s recommendations (Promega, Madison, WI).

The cells were plated in

96-well microtiter plates at a density of 1.0 x 103 cells/well in Dulbecco's modified
Eagle's medium with 10% FBS.

The number of cells at 1, 2, and 3 days was determined

using cell counter and the colorimetric CellTiter96 Aqueous (MTS) assay (Promega).
Results were depicted as absorbance at 490 nm as a function of time. Cell viability was
examined with Trypan blue staining following treatment of cells with doxorubicin (1 M)
for 12 h.
Thymidine incorporation was used to investigate the effect of TZP on DNA
synthesis. The cells were grown to 80% confluence in 6-well plates, and during the last
16 h of growth they were subjected to 5

Ci/ml of [3H] thymidine.

After rinsing twice

with ice-cold serum-free medium, the cells were incubated twice with 5ml of 10% TCA
for 10 min on ice and lysed in 500 ul 1% SDS in 0.3N NaOH for 30 min at 37°C.
Incorporated radioactivity was quantitated with a spectrometer.
Luciferase Reporter Assay – NIH3T3 or HEK293 cells were cultured in 12-well
plates and transiently transfected with pGL3/p53-Luc, p21-Luc, TZP and/or Akt as well
as pSV2-β-galactosidase.

The amount of DNA in each transfection was kept constant

by the addition of empty vector. After 36 h of transfection, luciferase activity was
measured using a luciferase assay reagent (Promega). Transfection efficiency was
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normalized by co-transfection with

β-galactosidase expressing vector.

galactosidase activity was measured by using Galato-Light (Tropix).

The

β-

Luciferase activity

was expressed as relative luciferase activity.
Cyclic Amplification and Selection of Targets (CASTing) - A 76-bp
oligonucleotide containing 26 random nucleotides in the center flanked by sequences
complementary to primers A and B was synthesized (Invitrogen).

The sequences of the

oligonucleotides are as follows: 76-base oligonucleotide, 5’- CAGGTCAGTTCAGCGG
ATCCTGTC(N)26GAGGCGAATTCAGTGCAACTGCAGC-3’; primer A, 5’-GCTGCA
GTTGCACTGAATTCGCCTC-3’; primer B, 5’- CAGGTCAGTTCAGCGGATCCTGT
CG-3’.

A random sequence library of double-stranded radiolabeled oligonucleotides

was prepared by annealing the oligonucleotide to 5-fold excess of primer B followed by
extension with Klenow enzyme.

EMSAs (electrophoretic mobility-shift assays) were

performed by adding 5 µg of Flag-TZP containing nuclear extract to radiolabeled DNA in
DNA binding buffer (5% glycerol, 10 mM Hepes, pH 7.9, 75 mM KCl, 1 mM DTT, 2.5
mM MgCl2, 1 mM EDTA) in the presence of 0.5 µg of poly (dA.dT) and 1 µg of bovine
serum albumin.

The reaction was incubated at room temperature for 30 min and

subsequently the DNA-protein complexes were resolved by electrophoresis.

The

complexes formed specifically in the presence of Flag-TZP proteins were detected by
autoradiography, excised from gels, and eluted overnight at 37 °C in DNA-elution buffer
containing 0.3 M NaCl, 1 mM EDTA, and 0.1% SDS.

The eluted DNA was extracted

once in phenol-chloroform, and then precipitated with ethanol.

Purified DNA was

subjected to re-amplification by PCR in the presence of [α-32P] dCTP.

The amplified

radiolabeled DNA was purified using G-50 Nick columns (Amersham) and was used in
subsequent EMSA experiments.

After four cycles of CASTing, the final amplified DNA

was cloned directly using pGEM-T Cloning kit (Promega).
independent clones were determined.

Nucleotide sequences of 34

The degenerate portion of the sequences was

compiled and analyzed for shared sequence patterns by visual inspection and by weblogo
software (http://weblogo.berkeley.edu).
ChIP and EMSA Assay - ChIP assay was performed essentially as previously
described (58).

Solubilized chromatin was prepared from a total of 2 X 107
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asynchronously growing HEK293 or HCT116 cells that were transfected with wild type
TZP or mutant TZP. The chromatin solution was diluted 10-fold with ChIP dilution
buffer (1.1% Triton –100, 1.2 mM EDTA, 167 mM NaCl, 16.7 mM Tris•HCl, pH 8.1,
0.01% SDS, protease inhibitors), and precleared with protein-A beads blocked with 2 µg
sheared salmon sperm DNA and pre-immune serum.

The precleared chromatin solution

was divided and utilized in immunoprecipitation assay with either anti-Flag, or -TZP
antibody. Following wash, the antibody-protein-DNA complex was eluted from the
beads by resuspending the pellets in 1% SDS, 0.1 M NaHCO3 at room temperature for 20
min.

After crosslink, protein and RNA were removed by incubation with 10 µg

proteinase K and 10 µg RNase A at 42 °C for 3 hour. Purified DNA was subjected to
PCR with primers specific for putative TZP-binding site within the p53 promoter.
Amplified PCR products were resolved by 1.2% of agarose gel electrophoresis and
visualized by BioImage.

EMSA was performed as described above. The sequences of

oligonucleotides used for EMSA and ChIP assays are: p53 EMSA primer: 5’-GTCCAGC
TTTGTGCCAGGAGCCTC-3’, 5’-CCCCTCCCATGTGCTCTCAAGACTGG-3’, 5’-G
GATTGGGGTTTTCCCCTCCCATGTG-3’; p53 ChIP primer: 5’-CAATTCTGCCCTC
ACAGCTCTGGCTTGC-3’, 5’-CTCAAAACTTTTAGCGCCAGTCTTGAGC-3’ and
p21 ChIP primer: 5’-GGGGAGGGAGGTCCCGGGCGGCGTCGG-3’, 5’-GACATGGC
GCCTCCTCTGAGTGCCTCG-3’.
RNA Interference (RNAi) - The RNAi duplexes were synthesized by Dharmacon
Research Inc.

The cDNA-targeted region and the sequence of TZP RNAi duplexes are:

AAGAGGAUGGAUCUUCUGAAU and AAAGCAUUGGAGGAGGAUAAU.
RNAi duplexes were reconstituted to 20 µM in sterile RNase-free water.

The

Transfection

of RNAi for targeting endogenous genes was performed using oligofectamine reagent
(Invitrogen) according to the manufacturer’s instruction.
Chromatin Association - Chromatin was isolated as described previously with
small modifications (59).

Briefly, Flag-TZP stably transfected HeLa cells were

resuspended in buffer A (10 mM HEPES, [pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.34 M
sucrose, 10% glycerol, 1 mM DTT, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 0.1 mM
phenylmethylsulfonyl fluoride).

NP-40 (0.1%) was added, and the cells were incubated
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for 5 min on ice.

Nuclei (P1) were collected by low-speed centrifugation (5 min, 1,300

g, 4 °C). The supernatant (S1) was further clarified by high-speed centrifugation (15
min, 20,000 g, 4 °C). Nuclei were washed once in buffer A, and then lysed in buffer B
(3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, protease inhibitors as described above).
Insoluble chromatin was collected by centrifugation (5 min, 1,700 g, 4 °C) and washed
once in buffer B.

The final chromatin pellet (P3) was resuspended in sonication buffer

(50 mM Tris, [pH 8.1], 10 mM EDTA, 1%SDS) and sonicated 2 x 10s in a Branson
sonicator using a microtip at 10% amplitude. Chromatin was diluted 1:10 with dilution
buffer (0.01 % SDS, 1.1 % Triton, 1.2 mM EDTA, 16.7 mM Tris-Cl pH 8.2, 167 mM
NaCl, 10µg/ml PMSF, 10µg/ml leupeptin, 10µg/ml aprotinin) and Flag-TZP was
immunoblotted with α-Flag antiserum.

To release chromatin-bound proteins by

nuclease treatment, cell nuclei (P1) were resuspended in prewarmed buffer A plus 1 mM
CaCl2 and 0.3 U of micrococcal nuclease (Sigma). After incubation at 37°C for 1 min,
the nuclease reaction was stopped by the addition of 1 mM EGTA.

Nuclei were

collected by low-speed centrifugation and lysed according to the chromatin isolation
protocol described above.
Flow Cytometry and Cell Cycle Analysis - For flow cytometry, TZP HeLa/Tet-on
cells were treated with or without 1 µg/ml doxycycline for 12 h and then incubated with
40 ng/ml nocodazole for additional 12 h to synchronize cells at G2/M phase.

The cells

were washed and further cultured in fresh medium without nocodazole for different time
points.

Cells were fixed in prechilled 70% ethanol for 2 h. Following wash with PBS,

cells were resuspended in propidium iodide (PI) staining solution (0.1% Triton X-100/0.2
mg/ml DNase-free RNase A/20 µg/ml PI prepared in PBS) for 15 min at 37 °C and then
analyzed by flow cytometry. DNA content histograms and FACS data were analyzed
using FLOWJO software.
In vivo Ubiquitination Assay - H1299 cells were co-transfected with wild type p53,
TZP, and ubiquitin together with or without MDM2, and then treated with 50 μM of
proteasome inhibitor MG132 (Sigma) for 2 hours prior to harvest. Following wash
twice with ice-cold PBS, harvested cells were lysed in a lysis buffer [50 mM Tris HCl,
pH 7.4, 150 mM NaCl, 1 mM EDTA, (1% w/v) Triton X-100, Glycerol (10% w/v) and
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protease inhibitor mixture].

Cell lysates were immunoprecipitated with anti-p53

antibody and then blotted with an anti-ubiquitin antibody.

Results
Identification of Akt binding protein, TZP. In an attempt to identify protein(s)
that interacts with Akt, the C-terminal regulatory domain of Akt (amino acids 410-480)
was used as bait in a yeast two-hybrid screening.

A human fetal brain cDNA library

was used in this screen, because Akt is highly expressed in brain (60, 61).
32 clones that specifically interacted with the bait were identified.

Altogether,

Sequence analysis

revealed that three of the clones contained overlapping sequences of a cDNA. The
largest clone contained a 262-amino acid open reading frame with a conserved tudor
domain and a A-T hook motif.

Additional cDNA clones were isolated from a human

skeletal cDNA library by plaque hybridization using the largest clone as radiolabeled
probe.

Sequence analysis revealed that the full-length open reading frame of cDNA
Figure 28. Identification of
TZP that interacts with Akt.
(A) Schematic structure of
TZP.
TZP contains two
tudor, an AT-hook, a C2H2
Zinc finger, and a PHD
finger domain and three
nuclear localization signals
(NLS). (B) Northern blot
analysis
shows
the
expression of TZP in
multiple human tissues.
(C) TZP binds to Akt.
HEK293 cells were cotransfected with Flag-TZP
and
HA-Akt.
After
incubation for 48 h, cells
were
lysed
and
immunoprecipitated,
and
immunoblotted
with
indicated antibodies.
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encodes an 1,012-amino acid protein, which is composed of two tudor domains, a A-T
hook motif, a zinc-finger domain and a PHD finger motif (Fig. 28A). Therefore, we
named it as TZP (accession number AY027523).

In addition, TZP contains three

nuclear localization signals and two putative Akt phosphorylation consensus sites (Fig.
28A).

The expression pattern of TZP is similar to that of Akt1, being abundant in

skeletal muscle, brain, pancreas, and heart (Fig. 28B).

To confirm the association Akt

with TZP identified by yeast two-hybrid screening, HEK293 cells were cotransfected
with Flag-TZP and HA-Akt.

Immunoprecipitation was performed with anti-Flag and

detected with anti-HA antibody or vice versa. As shown in Figure 28C, HA-Akt was
detected in the Flag-TZP immunoprecipitates and TZP was coimmunoprecipitated with
anti-HA antibody.

These data suggest that TZP could be a transcription factor, which

may be regulated by Akt.

Expression of TZP inhibits cell proliferation, DNA synthesis and cell survival,
and induces G1 and G2/M cell cycle arrest.
changes of cells expressing ectopic TZP.

We next examined the phenotypic

Since HeLa (wild type p53 degraded by

HPV18-E6 oncoprotein; ref. 62) and MCF7 (wild type p53; ref. 63) cells express low
levels of endogenous TZP, we stably transfected the pCMV-3xFlag-TZP and pTREFLAG-TZP into HeLa/MCF7 and HeLa-Tet-on/MCF7-Tet-off cells, respectively. As
controls, pCMV-3xFlag vector was also introduced into the cells.
from each transfectant were established after selection.
confirmed by Western blot analyses (Fig. 29A).

Eight clonal cell lines

Expression of TZP was

Cell growth, DNA synthesis, cell

survival and cell cycle progression were evaluated in these clonal cell lines.

As shown

in Fig. 29B, cell growth was significantly inhibited by ectopic expression of TZP.
Furthermore, [3H]-thymidine incorporation experiments revealed that TZP
represses DNA synthesis (Fig. 29C).

In addition, expression of TZP enhanced cell death

(~40%) induced by doxorubicin (Fig. 29D). Nocodazole cell synchronization analyses
and doxycyclin induction of TZP revealed that overexpression TZP delayed cell cycle
transition both from G1 to S and from M to G1 phase (Fig. 29E and 29F). These
findings were further confirmed in TZP-stably transfected HCT116 and A2780S cell lines
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(data not shown).

Thus, we conclude that the TZP is a growth inhibition gene and its
Figure 29. TZP inhibits cell
growth, DNA synthesis and
survival and induces cell cycle
arrest. (A) Western blot analysis
shows expression of TZP in an
inducible TZP HeLa/Tet-on cell
line.
(B) TZP inhibits cell
growth. TZP stably transfected
HeLa and pcDNA3-HeLa (mock)
cells were seeded into 12-well
tissue culture plate. The cell
number was counted at indicated
time points.
(C) TZP inhibits
DNA synthesis. Indicated cells
were labeled with
[3H]
thymidine.
The thymidine
incorporation was count by
liquid scintillation. (D) TZP
sensitizes cells to DNA damageinduced death. Inducible TZP
HeLa cells were seeded in 96well plate and treated with
doxorubicin for indicated time.
Cell survival was evaluated with
MTS. (E) TZP induces cell
cycle arrest. MCF7/Tet-off/TZP
inducible cells were treated with
or without doxycyclin and
synchronized at G2/M phase.
After wash, cells were further
cultured in fresh medium without
nocodazole for another 1–4 h
and then fixed and analyzed by
flow cytometry. (F) HeLa/Teton/TZP inducible cells were
treated with and without 1 µg/ml
doxycycline for 48 h and
examined
for
cell
cycle
distribution.
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protein product regulates cell proliferation, survival, and G1/S and G2/M cell cycle
checkpoints.

Figure 30. TZP binds to
DNA. (A and B) Association
of TZP with chromatin. (C)
Schematic
procedure
of
CASTing
analysis.
(D)
Sequence alignment of TZP
binding consensus sequence.
(E) Electrophoretic mobility
shift assay were performed as
described in experimental
procedures. (F) Luciferase
assay.
TZP consensus
binding sequence was cloned
to
pGL3-basic
vector.
HEK293
cells
were
transfected with indicated
plasmids. Following 36-h
culture, luciferase activity
was measured and normalized
to β-galactosidase. Results
are the mean ± S.E. of three
independent
experiments
performed in triplicate.

TZP associates with chromatin and binds to a DNA consensus motif.

It has

been demonstrated that AT-hook binds to the A/T rich DNA sequence and enhances
accessibility of the promoter to transcription factor (64). C2H2 zinc-finger and PHD
finger domains are known to involve DNA binding and protein-protein interaction (65).
Since TZP has three putative DNA binding motifs, i.e., an AT-hook, a C2H2 zinc finger,
and a PHD finger domain, we examined whether TZP associated with DNA in the form
of chromatin.

We used a small-scale biochemical fractionation scheme illustrated in Fig.
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30A.

HEK293-Flag-TZP cell lysates prepared with a nonionic detergent were divided

by sequential centrifugation into soluble cytosolic components called S2 and nuclear
fraction. The nuclear fraction was divided into two aliquots, treated with (+) or without
(-) micrococcal nuclease and further fractionated into soluble nuclear components called
S3 and insoluble nuclear pellets called P3.

Immunoblotting analysis showed that TZP

protein was not in S2 cytoplasmic fraction and that the majority of the TZP in the P3
fraction becomes soluble (S3) after MNase treatment (Fig. 30B).
Figure
31.
TZP
transcriptionally upregulates
p53. (A) HCT116 p53+/+
cells were transfected with
TZP and immunoblotted with
indicated antibodies. (B and
C) TZP inducible HeLa/Tet-on
and MCF7/Tet-off cells were
treated with or without
doxycyclin for indicated time
and then immunoblotted with
indicated antibodies. (D)
Northern blot analysis of TZP
inducible MCF7/Tet-off cells
with [32p]dCTP-labeled p53
and actin cDNA as probes.
(E) Knockdown of TZP
reduces
p53
expression.
HCT116 p53+/+ cells were
seeded into 6-well plate and
treated with TZP/RNAi or
scramble RNAi and subjected
into Western (left panels) and
Northern (right panels) blot
analysis.

Next, we searched the TZP-DNA binding consensus sequence using cyclic
amplification and selection of target (CASTing) assay (Fig. 30C). The oligonucleotide
library selected after four rounds of TZP binding was cloned into pGEM-T, and the
isolated clones were sequenced. Of 60 sequenced clones, all contained at least one
RGTGNR (R = A or G and N = A, G, C or T; Fig. 30D). To confirm this result, EMSA
was carried out with the [32p]-ATP labeled TZP consensus sequence containing
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oligonucleotide.

As shown in Fig. 30E, TZP bound to the oligonucleotide that was

competed by excess of cold probe while the supershift was not observed. Further, we
cloned three repeats of TZP binding consensus sequence (TBCS) into pGL3 luciferase
vector (pGL3-3xTBCS-Luc).

Reporter assay was performed with HEK293 cells

transfected with pGL3-3xTBCS-Luc and increasing amounts of TZP.

Fig. 30F shows

that the promoter activity was induced by TZP in a dose dependent manner.

Taken

collectively, these data indicate that TZP associates with DNA in the form of chromatin
and induces transcription by binding to a specific DNA element.
TZP transcriptionally upregulates p53. Since TZP inhibits cell growth and
survival and regulates both G1 and G2/M cell cycle checkpoints, we examined the effects
of TZP on expression of a dozen molecules involving both cell survival and cell cycle
progression.

Immunoblotting analysis revealed that p53 was upregulated by TZP in

different cell lines, including HCT116, HeLa and MCF7 examined (Figs. 31 A-C).
However, TZP was unable to induce p53 expression in HCT116-p53 null cell line(data
not shown).

Accordingly, downstream targets of p53, such as p21, Bax and GADD45,

were also upregulated (Fig. 31C).

Furthermore, mRNA level of p53 was increased after

inducing TZP expression (Fig. 31D).

In addition, knockdown of TZP significantly

reduced p53 expression at both mRNA and protein levels (Fig. 31E).

Thus, we

conclude that TZP transcriptionally regulates p53 and is essential for maintaining basal
expression level of p53.
TZP binds to p53 promoter and induces the promoter activity. We next
examined if TZP induces p53 promoter activity.

HeLa cells were transfected with

pGL2-p53/-2.4 or its deletion mutants (pGL2-p53/-110, pGL2-p53/-240, and pGL2-p53/460) and increasing amounts of TZP.

Following 36 h incubation, luciferase reporter

assay was performed and showed that TZP considerably induced p53/-110 promoter
activity, but to much lesser extent in other p53 promoter fragment-driven luciferase
reporters (Fig. 32B).

This suggests that repression element(s) resides in a region

between -110bp and -2.4kb of the promoter. Further, sequence analysis revealed two
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putative TZP-binding consensus sites in the p53 promoter at -29/-34 and -79/-84 (Fig.
32A).

Mutations of these 2 sites by converting the core sequence GTG to AAA largely

abrogated pGL2-p53/-110 promoter activity induced by TZP (Fig. 32C).
To determine if TZP directly binds to the TZP-binding site of p53 promoter in
vivo, we carried out chromatin immunoprecipitation (ChIP) assay, which detects specific
genomic DNA sequences that are associated with a particular transcription factor in intact
cells. HEK293 cells were transfected with Flag-TZP and immunoprecipitated with antiFlag antibody.

The TZP bound chromatin was subjected to PCR using oligonucleotide

primers that amplify region spanning TZP-binding site within the p53 promoter.

As

show in Fig. 32D, the anti-Flag antibody pulled down TZP binding site (-268/-4). In
contrast, immunoprecipitation with an irrelevant antibody (anti-IgG) resulted in the
absence of band in this site.

Since the two TZP binding sites (-29/-34 and -79/-84) are

very close to each other in the p53 promoter, ChIP assay is unable to distinguish which
site directly binds to TZP. However, mutation analysis of the promoter showed that the
both TZP-binding sites are required for p53 promoter to respond to TZP (Fig. 32C).
Furthermore, EMSA assay revealed that TZP is capable of binding to the DNA
oligonucleotides corresponding to the two TZP-binding sites while supershift was not
detected (Fig. 32E). Nevertheless, these data indicate that p53 is a direct target of TZP.

Akt phosphorylates TZP and induces TZP translocation from the nucleus
into the cytoplasm where they interact.

Since TZP contains two putative Akt

phosphorylation consensus sites (Fig. 33A), we next determined whether TZP is
phosphorylated by Akt.

HEK293 cells were co-transfected with Flag-TZP and

constitutively active Akt or pcDNA3 vector and then labeled with [32P]-orthophosphate.
The labeled TZP was immunoprecipitated with anti-Flag antibody, separated and blotted
on a membrane.

PhosphoImager quantification analysis revealed that the incorporation

of 32p into TZP was 8-fold higher in Akt/TZP transfected cells as compared to the cells
transfected with pcDNA3/TZP (Fig. 33B). Further, in vitro kinase assay showed that
Akt phosphorylation of TZP on serine-291 but not serine-265 (Figs. 33C and 33D).
These results indicate that Akt phosphorylates TZP in vitro and in vivo. We further
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Figure 32. TZP binds to and induces p53 promoter. (A) p53 promoter contains two
putative TZP binding regions highlighted by underlines. Primers used for Chip
analysis are highlighted. (B and C) Luciferase assay. MCF7 cells were seeded
into 12-well plate and transfected with indicated plasmids and then subjected into
luciferase assay. (D) ChIP assay shows that TZP binds to p53 promoter in vivo.
HEK293 cells were transfected with Flag-TZP and assayed with chromatin
immunoprecipitation as described in experimental procedures. (E) TZP binds
p53 promoter in vitro. EMSA was performed as described in experimental
procedures.
examined if Akt phosphorylation of TZP affects their interaction.

Phosphomimic and

nonphosphorylatable TZP were created by mutation of serine-291 into aspartic acid
(TZP-D) and alanine (TZP-A), respectively.
that

wild

type

TZP

and

Co-immunoprecipitation analysis revealed

phosphomimic

TZP-D

bound

to

Akt

nonphosphorylatable TZP-A failed to interact with Akt (Fig. 33E), implying that
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whereas

phosphorylation of TZP by Akt is important for their interaction.
Since serine-291 of TZP locates at a nuclear localization signal, we next tested
whether Akt phosphorylation of TZP affects its subcellular localization.
were transfected with Red-Myr-Akt and/or GFP-TZP.

MCF7 cells

GFP-TZP was exclusively

localized in the nucleus in the cells transfected with GFP-TZP alone.

Figure 33. Akt phosphorylates TZP in vitro and in vivo. (A) TZP contains two putative
Akt phosphorylation sites. (B) TZP is phosphorylated by Akt in vivo. HEK293 cells
were co-transfected with Flag-TZP and constitutively active Akt or pcDNA3 and labeled
with [32P]-orthophosphate (0.5 mCi/ml) for 4 h. Cell lysates were immunoprecipitated
with anti-Flag antibody, separated by SDS-PAGE and transferred to a membrane. The
phosphorylated TZP band was examined by autoradiography. (C and D) Akt
phosphorylates TZP on Ser291. In vitro Akt kinase assay was performed using fulllength TZP (c), GST-fused wild-type and mutant TZP (d) as substrates. (E) Coimmunoprecipitation. HEK293 cells were co-transfected with Flag-tagged wild type and
the phosphorylation site mutated TZP and HA-Akt. After 48 h incubation, cells were
lysed, immunoprecipitated and immunoblotted with indicated antibodies.
However, co-transfection of constitutively active Akt resulted in TZP redistribution from
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the nucleus to the cytoplasm.
cytoplasm (Fig. 34A).

Interestingly, Akt was colocalized with TZP in the

Further, coimmunoprecipitation revealed the interaction between

TZP and 14-3-3 in normal culture condition and the interaction was slightly increased by
serum stimulation (Fig. 34B).

Collectively, these results suggest that TZP is

phophorylated by Akt which leads to TZP translocation from the nucleus into the
cytoplasm where TZP interacts with Akt and 14-3-3.

Figure 34. Akt phosphorylation to TZP results in TZP nuclear exclusion and
slightly increases TZP interaction with 14-3-3 protein. (A) MCF7 cells were
cotransfected with GFP-TZP and Red-active Akt. Nucleus was stained with DAPI.
(B) TZP binds to 14-3-3. HEK293 cells were transfected with Flag-TZP. After
48 h culture, immunoprecipitation was performed with anti-14-3-3 antibody and the
immunoprecipitates were immunoblotted with ant-Flag antibody.
Akt phosphorylation of TZP inhibits TZP transactivation activity.

To

determine role of Akt phosphorylation of TZP in TZP function, Gal4 fused TZP construct
was created and used for the reporter assay.

As shown in Figs. 35A and 35B, Gal4-TZP

but not TZP considerably induced the activity of pTK-Luc, a luciferase gene under the
control of the thymidine kinase minimal promoter.

Expression of constitutively active

Akt inhibited the promoter activity induced by Gal4-TZP.

Further, p53 promoter

activity induced by TZP was also inhibited by Akt in a dose-dependent manner (Fig. 35C).
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Accordingly, TZP-induced p53 expression was reduced when cells were co-transfected
with constitutively active Akt (Fig. 35D).

To examine if TZP regulation of p53

dependson phosphorylation of serine-291, HCT116 cells were transfected with TZPS291A or TZP-S291D together with or without constitutively active Akt.

As shown in

Fig. 35D, expression of TZP-S291A but not TZP-S291D increased p53 expression and
Akt had no effect on p53 expression in both TZP-S291A and TZP-S291D-transfected
cells.

These findings suggest that TZP transactivation activity and TZP-regulated p53

are inhibited by Akt through a phosphorylation-dependent manner.
Figure 35. Akt inhibits
TZP
transcriptional
activity. (A-C) Reporter
assay. HeLa cells were
seeded into 12-well plate
and transfected indicated
plasmids Following 36 h
incubation,
luciferase
activity was measured and
normalized
to
βgalactosidase.
Results
are the mean ± S.E. of
three
independent
experiments performed in
triplicate.
(D) Western
blot analysis.
HCT116
p53+/+ cells were cotransfected with indicated
plasmids. After culture
for 36 h, cells were lysed
and immunoblotted with
indicated antibodies.
Increase of TZP expression at mRNA and protein levels in response DNA
damage. While p53 is upregulated primarily through stabilization in response to DNA
damage, several studies have shown that p53 is also regulated at the transcriptional level
in response to genotoxic stress (44, 45).

Thus, we next asked if TZP is regulated by

DNA damage and mediates stress-induced p53.
doxorubicin or etoposide for different time points.
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HCT116 cells were treated with
Northern and Western blotting

analyses revealed upregulation of TZP at mRNA and protein levels after the treatment for
30 min.

Accordingly, elevated protein and mRNA levels of p53 were detected in

response to the treatment (Fig. 36A-D).

These findings were further confirmed in HeLa

and MCF7 cell lines (Fig. 36E and 36F and data not shown).

These results indicate that

TZP is a DNA damage-response gene and could mediate transcriptional upregulation of
p53 by genotoxic stress.

TZP mediates the upregulation of p53 by DNA damage.

To demonstrate

whether TZP is responsible for stress-induced p53 expression, we knocked-down TZP
with RNA interference (RNAi) prior to challenging HCT116 cells with doxorubicin or
etoposide. Immunoblotting analysis showed that the knockdown of TZP significantly
reduced p53 levels induced by doxorubicin or etoposide in wild-type p53 but not p53-null
HCT116 cells (Figs. 37A and 37B).
Bax were decreased (Fig. 37A).

Accordingly, p53 downstream target genes p21 and

Moreover, chromatin immunoprecipitation showed that

the ability of p53 to bind to p21 promoter was considerably reduced by knockdown of
TZP (Fig. 37C).
Figure 36. TZP is induced
by DNA damage. (A and
B) Northern blot analysis.
HCT116 p53+/+ cells
were seeded into 6-well
plate and challenged with
100 µM etoposide (A) and
10 µM doxorubicin (B) for
indicated time.
Total
RNA was extracted and
assayed by Northern blot
analysis.
(C-F)
Immunoblotting analysis.
HCT116 p53+/+ (C, D),
HeLa (E), and MCF7 (F)
cells were treated with 100
µM etoposide (C, E) and
10 µM doxorubicin (D, F)
for indicated time and then
immunoblotted
with
indicated antibodies.
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Accumulated evidences demonstrate that upregulation of p53 by DNA damage is
largely due to its protein stabilization through phosphorylation by stress kinases such as
Chk1/2, ATM/ATR, DNA-PK and JNK (66). Thus, we further examined if TZP also
regulates p53 stability.
transfected HCT116.

Pulse-chase assay was performed in pcDNA- and TZP-

Fig. 38A shows that the degradation rate of p53 was significantly

decreased in TZP-HCT116 cells.

Further, the possible effect of TZP on p53

ubiquitination was examined in p53-null H1299 cells.

After transfection with p53,

Figure 37. Knockdown of TZP reduces p53 expression induced by DNA damage. (A and
B) Western blot analysis. HCT116 p53+/+ and p53-/- cells were transfected with
scramble and TZP SiRNA. After 68 h of the transfection, cells were treated with 10 µM
doxorubicin or 100 µM etoposide for 4 h and then immunoblotted with indicated
antibodies for p53. (C) Knockdown of TZP decreases p53 binding to p21 promoter.
HCT116 p53+/+ cells were transfected with scramble and TZP SiRNA. Following
treatment with doxorubicin, p53 DNA binding activity was examined with ChIP assay
using the primers derived from p21 promoter.
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Mdm2, and ubiquitin together with or without TZP, immunoblotting of p53
immunoprecipitates with anti-Myc (ubiquitin) antibody revealed that ubiquitination of
p53 induced by Mdm2 was considerably reduced by TZP (Fig. 38B).

Figure 38. TZP stabilizes and interacts with p53. (A) Western blot analysis. HCT116
p53+/+ cells were transfected with pcDNA3 (left) and TZP (right). After 36 h of the
transfection, cells were treated with cycloheximide (CHX) for indicated time and then
immunoblotted with indicated antibodies. (B) TZP inhibits mdm2-mediated p53
ubiquitination. P53-null H1299 cells were transfected with HA-p53, mdm2, Flag-TZP,
and Myc-ubiquitin. Following 48 h incubation, cells were immunoprecipitated with
anti-HA antibody and immunoblotted anti-myc antibody (top panel).
Panels 2-4 show
expression of transfected plasmids. (C) Co-immunoprecipitation. HEK293 was
cotransfected with Flag-TZP and GFP-p53. After 48 h of the transfection, cells were,
lysed, immunoprecipitated and immunoblotted with indicated antibodies. (D) TZP
directly binds to p53. GST pull down assay was performed as described in experimental
procedures.
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To explore underlying mechanism, co-immunoprecipitation showed that TZP
physically interacts with p53 (Fig. 38C). GST-pull down assay revealed that GST-p53
directly bound to TZP (Fig. 38D).

These data indicate that TZP not only

transcriptionally upregulates p53 but also binds to and stabilizes p53 protein and that TZP
plays an important role in regulation of p53 at both physiological and DNA-damage
conditions.
Figure 39. Akt inhibits the
interaction between TZP and p53.
(A) HEK293 cells were transfected
with TZP, p53, active Akt (Ac) and
dominant negative Akt. After 48 h
of the transfection, cells were lysed,
immunoprecipitated
and
immunoblotted
with
indicated
antibodies. (B) H1299 cells were
transfected with Flag-tagged wild
type TZP, nonphosphorylatable TZPA, phospho-mimic TZP-D and Redp53. After 48 h incubation, cells
were lysed, immunoprecipitated and
immunoblotted
with
indicated
antibodies.

Akt inhibits the interaction between TZP and p53.

Akt was shown to

phosphorylate TZP and reduce its transactivation activity (Figs. 33-35). Since TZP also
binds to p53, we further asked if Akt phosphorylation of TZP affects TZP/p53 complex
formation.

Immunoprecipitation revealed that expression of constitutively active

Aktreduced the ability of TZP to associate with p53 while dominant negative Akt had no
detectable effect on the complex (Fig. 39A).

Consistent with these findings,

phosphomimic TZP-D reduced its capability of binding to p53 and nonphosphorylatable
TZP-A exhibited no significant change of interacting with p53 as compared to wild type
TZP (Fig. 39B). In combination with the findings in Figs. 33-35, our data suggest that
Akt inhibits TZP transcriptional activity toward p53 and reduces the TZP association with
p53 through phosphorylation of serine-291.
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Discussion
Akt was shown to regulate p53 through phosphorylation of Mdm2.
Phosphorylated Mdm2 leads to its retention in the nucleus where Mdm2 inhibits p53
transactivation function and targets p53 degradation (46, 50).

In this report, we

identified TZP as a transcription factor that interacts with Akt and p53. TZP binds to
and transactivates p53 promoter resulting in induction of p53 mRNA. Further, TZP also
interacts with p53 protein and inhibits Mdm2-mediated p53 ubiquitination and
degradation.

Akt phosphorylates TZP and promotes TZP translocation from the nucleus

to the cytoplasm, which lead to downregulation of p53 at mRNA and protein levels.
Importantly, we showed that TZP is required to maintain of basal level of p53 as well as
genotoxic stress-induced p53. These findings indicate that TZP plays a pivotal role in
both Akt and p53 signaling and establish additional connection between Akt and p53
cascades.
TZP contains multiple functional domains including tudor motif, AT-hook region,
C2H2 zinc finger and PHD finger domains.

The tudor domain was thought to act as an

adaptor mediating intramolecular as well as intermolecular protein-protein interactions
and protein-nucleic acid associations (67).

AT-hook binds to the A/T rich DNA

sequence and enhances accessibility of the promoter to transcription factor (64). C2H2
zinc finger and PHD finger domains are known to involve in DNA binding and proteinprotein interaction (65).

We showed in this study that TZP directly associates with

chromatin and transactivates p53 promoter through binding to DNA motif (RGTGNR).
Recent reports suggest that tudor and PHD-finger domains bind to methylated lysine
residue of histone (68, 69).

Further studies are required to examine if TZP binds to

methylated histone and involves in chromatin modification.
In addition to p53 gene mutation, frequent downregulation of p53 messenger
RNA has been detected in human cancer (70, 71).
transcription factors that regulate p53 synthesis.

However, little is known about the
HOXA5 was shown to be co-

downregulated with p53 in some of breast tumors and to transcriptionally activate p53
(72).

Our data showed that expression of TZP inhibits cell proliferation and induces cell
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death and cell cycle arrest (Fig. 23).

TZP localizes at chromosome 20q11 where is

frequently deleted in human cancer (73, 74), suggesting that TZP could be a putative
tumor suppressor gene, which needs to be further investigated.
Akt mediates extra- and intra-cellular signals to regulate a variety of cellular
processes (14).

However, the role and mechanism of Akt in DNA-damage response has

not been well documented.

Several studies suggest that Akt overcomes DNA damage-

induced G2/M arrest by inhibition of Chk1 and Chk2 kinase activity (75). However,
only Chk1 was found to be directly phosphorylated by Akt (76). Activated Chk1 and
Chk2 were known to phosphorylate and stabilize p53.

Our data showed that TZP

upregulates p53 at both transcriptional and posttranslational levels.

In response to

genotoxic stress, both TZP and p53 were induced and knockdown of TZP decreased p53
level.

Akt phosphorylates and abrogates TZP function.

Thus, these findings provided

another direct link between Akt and p53 in the stress pathway, while the mechanism of
induction of TZP by genotoxic stress remains to be investigated.
In summary, TZP is a transcriptional factor and a binding partner of p53 and Akt.
It exhibits tumor suppressor activity and plays a critical role in maintaining basal level of
p53 and stress-induced p53.

TZP not only transcriptionally regulates p53 but also

stabilizes p53 protein. Akt phosphorylates TZP leading to its translocation from the
nucleus to the cytoplasm and attenuation of its growth inhibition function.

Further

investigations are required for the ability of TZP to bind to methylated histone and the
role of TZP in histone modification. Importantly, tumor suppressor activity of TZP and
its possible involvement in human malignancy need to be further studied. In addition,
the genome wide TZP target genes need to be identified in order to illustrate normal
cellular function of TZP.
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Chapter 6
Discussion and Conclusion
During cancer development, tumor cells acquire a number of phenotypic changes
that allow them to proliferate both rapidly and limitlessly, invade the surrounding tissue,
survive lacking their normal microenvironment, and finally, metastasize to other sites.
These features are usually accompanied with up-regulation of oncogenic and/or downregulation of tumor suppressor signaling.

As a result of concentrated worldwide

research activity in the last several years, PI3K/Akt signal transduction pathway has been
shown to play an essential role in tumor development-related cellular processes,
including cell survival, apoptosis, proliferation, angiogenesis and migration.

It has been

demonstrated that three isoforms of Akt are frequently altered in a various types of
human tumor. Increasing evidences have shown that expression of constitutively active
Akt in many cell types promotes cellular transformation by two distinct mechanisms:
inducing cell proliferation under conditions in which cells should normally be growth
arrested and promoting cell survival under conditions in which they should die. While a
number of downstream targets of Akt have been identified, the mechanism of Akt in
human oncogenesis remains elusive.
The central hypothesis of this thesis is that Akt contributes to human oncogenesis
by mediating oncogenic signals and regulating downstream molecules which are
associated with cell survival, growth and angiogenesis. To test this hypothesis, I have
carried out three projects during last five years: 1) Cloning of Akt1 promoter and
identification of Akt1 as direct target gene of Stat3; 2) Downregulation of pro-apoptotic
protein 24p3 by Akt through phosphorylation of FOXO3a and 3) Identification and
characterization of a transcription factor TZP that interacts with p53 and Akt.
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Alterations of the AKT1 at the DNA level have been reported in a single gastric
cancer.

However, a number of tumors exhibit elevated levels of mRNA, protein and/or

kinase of AKT1, implicating that the AKT1 is regulated at transcriptional, translational
and/or posttranslational levels.
documented.

Posttranslational regulation of AKT1 has well been

To examine transcription regulation of AKT1, I have cloned the human

AKT1 promoter and demonstrated that AKT1 is a direct target gene of Stat3.

The AKT1

promoter activity is significantly induced by constitutively active Src and Stat3.
Knockdown of Stat3 or dominant-negative Sat3 reduced AKT1 expression induced by
constitutively active Src.

AKT1 level is low in Stat3-null MEFs and reintroduction of

the AKT1 rescued the Stat3-null MEF cell death resulted from serum starvation.

In

addition, we have recently reported that constitutively active Stat3 induces hypoxia
inducible factor (HIF)-1α and knockdown AKT1 largely abrogates the HIF-1α
expression stimulated by Stat3 (1, 2).

All these findings indicate that the AKT1 gene is a

direct downstream target of Stat3 and mediates Src/Stat3 cell survival and angiogenesis
function. In addition, elevated levels of AKT1 mRNA and protein could be resulted
from activation of Stat3 in the same subset of human malignancy.
Previous studies have shown that Akt overcomes IL3 deprivation-induced
apoptosis through phosphorylation of Bad in hematopoietic cells.
level of endogenous Bad is low in these cell lines.

However, expression

A proapoptotic protein 24p3 has

been demonstrated to play a key role in induction of apoptosis upon IL3 withdrawal. I
have shown that Akt inhibits IL3 deprivation-induced 24p3 expression and cell death.
Forkhead transcription factor FOXO3a binds to and activates 24p3 promoter leading to
expression of 24p3 in response to IL3 withdrawal. Akt phosphorylates FOXO3a and
inhibits its action toward 24p3.

Therefore, these findings indicate for the first time that

24p3 is a direct target gene of FOXO3a and that Akt mediates IL3-regulated 24p3
expression in hematopoietic cells. In addition, 24p3, but not Bad, could be a major
target of Akt protection cells from apoptosis induced by IL3 withdrawal.
Finally, I have identified a novel transcription factor TZP that interacts with Akt
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and p53.

Expression of TZP inhibits cell growth and survival and induces both G1 and

G2/M cell cycle arrest.
transcription.

TZP directly binds to p53 promoter and induces p53

In addition, TZP interacts with p53 and prevents p53 from Mdm2-

mediated degradation. In response genotoxic stress, both TZP and p53 were upregulated
and knockdown of TZP reduced p53 expression. Akt phosphorylates TZP resulting in
its translocation from the nucleus into the cytoplasm, and thus inhibits TZP function.
Therefore, I conclude that TZP is a key transcription factor that regulates p53. In
addition to Mdm2 that is positively regulated by Akt, Akt reduces p53 function through
negative regulation of TZP.
These data suggested that Akt contributes to human oncogenesis by mediating
oncogenic protein, Src and STAT3, which are associated with cell survival, growth, and
angiogenesis. Furthermore, I showed that Akt regulates downstream transcription factor
Foxo3a and TZP which are associated with cell cycle and cell death. These imply that akt
is a good candidate as a therapeutic target of human cancer.
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